徳島大学 / 教育研究者総覧 --- 中村信元

個人のホームページ

https://researchmap.jp/zxcvbnm-2 (researchmap)

専門分野

研究テーマ

著書・論文

著書:

1.	賀川久美子, 前田悠作, 大浦雅博, 曽我部公子, 藤野ひかる, 髙橋真美子, 丸橋朋子, 岩佐昌美, 宇高憲吾, 原田武志, 伊勢孝之, 藤井志朗, 中村信元, 三木浩和, 八木秀介, 竹内恭子, 尾崎修治, 安倍正博, 藤野ひかる : 治療後長期生存が得られた心不全合併ALアミロイドーシス症例の検討, 臨床血液, 2017年10月. (要約) <p>ALアミロイドーシスは，多発性骨髄腫やMGUS(monoclonal gammopathy of undetermined significance)などのモノクローナルな形質細胞が産生する免疫グロブリン軽鎖および重鎖が，アミロイド線維として組織に沈着し，臓器障害を惹起する難治性疾患である．なかでも心アミロイドーシス(以下CA)は，心不全症状が出現してからは，無治療の場合極めて予後不良であるため，その管理・治療が重要である<sup>1)</sup>．ALアミロイドーシスに対しては，自家末梢血幹細胞移植併用メルファラン大量療法(以下ASCT)の有効性が報告されているが，CAにおいては治療関連毒性が強く，その適応を慎重に検討する必要がある<sup>2, 3)</sup>．近年，多発性骨髄腫において，ボルテゾミブ(Bor)や，免疫調節薬であるサリドマイド(Thal)やレナリドミド(Len)などの新規薬を用いた治療により，治療成績が向上している．ALアミロイドーシス症例においてもこれらの新規薬の有効性が示され，CAに対しても，重篤な有害事象の発生率が低く，有効であったとの報告がある<sup>4∼6)</sup>．しかしながら，その長期の治療成績や予後については，十分な情報がない．そこで我々は，当科において治療し，長期生存が得られた心不全合併CA例について，後方視的に検討した．</p> (キーワード) Cardiac AL amyloidosis / Autologous hematopoietic stem cell transplantation / Long-term survival (出版サイトへのリンク) ● Publication site (DOI): 10.11406/rinketsu.58.2197 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390282680011466240 ● Search Scopus @ Elsevier (DOI): 10.11406/rinketsu.58.2197 (DOI: 10.11406/rinketsu.58.2197, CiNii: 1390282680011466240)
2.	安倍正博, 三木浩和, 中村信元 : 「骨髄腫∼いつ治療するのか?∼初発，再発，そして早期介入」骨髄腫骨病変の管理:ゾレドロン酸かデノスマブか, 臨床血液, 2015年. (要約) 新規薬が臨床応用され骨髄腫の治療成績が向上しているが，骨破壊病変は依然として生活の質(QoL)の低下の最も多い原因である．初回化学療法を受ける症候性骨髄腫患者すべてに骨病変の有無にかかわらずゾレドロン酸の点滴静注を反復することが骨病変の進行防止と予後の改善の点から推奨されている．デノスマブはゾレドロン酸と同等の治療効果を発揮する．デノスマブは即効性で皮下投与という利便性があり，腎機能にも影響を与えにくいが，低カルシウム血症を来しやすく，ゾレドロン酸と同程度に顎骨壊死の発生がみられる．ゾレドロン酸は骨に長期間蓄積するが，デノスマブは骨への蓄積性がない．したがって，長期投与後の骨質への影響などに両者の違いがある可能性がある．また，治療奏効後の強力な骨吸収抑制薬継続投与の有用性および新規薬との併用下での骨病変治療薬の至適な投与開始時期，投与方法や投与期間，予後に及ぼす影響が今後の検討課題である． (キーワード) Zoledronic acid / Denosumab / Multiple myeloma / RANKL (出版サイトへのリンク) ● Publication site (DOI): 10.11406/rinketsu.56.997 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390001205035009152 ● Search Scopus @ Elsevier (DOI): 10.11406/rinketsu.56.997 (DOI: 10.11406/rinketsu.56.997, CiNii: 1390001205035009152)
3.	中村信元, 安倍正博 : 臓器移植．ALアミロイドーシス，多発性骨髄腫の類縁疾患, 医薬ジャーナル社, 2014年8月.
4.	中村信元, 安倍正博 : アミロイドーシス効果判定基準効果判定基準 2005コンセンサスクライテリア，2011新基準．ALアミロイドーシス，多発性骨髄腫の類縁疾患, 医薬ジャーナル社, 2014年8月.
5.	中村信元 : (chapter6), 2014年1月.
6.	中村信元, 安倍正博, 松本俊夫 : 新規治療薬の開発と臨床応用の可能性を探る (抗RANKL抗体などを中心に), 2012年3月.

学術論文(審査論文):

1.	Taiki Hori, Ken-ichi Aihara, Takeshi Watanabe, Kaori Inaba, Keisuke Inaba, Yousuke Kaneko, Saki Kawata, Keisuke Kawahito, Hiroki Kita, Kazuma Shimizu, Minae Hosoki, Kensuke Mori, Teruyoshi Kageji, Hideyuki Uraoka and Shingen Nakamura : The Respiratory Adjusted Shock Index at Admission Is a Valuable Predictor of In-Hospital Outcomes for Elderly Emergency Patients with Medical Diseases at a Japanese Community General Hospital., Journal of Clinical Medicine, Vol.13, No.16, 2024. (要約) : The RASI is a simple indicator that can be used for predicting in-hospital outcomes in elderly emergency patients with medical diseases. Larger prospective studies based on this study are needed. (徳島大学機関リポジトリ) ● Metadata: 119610 (出版サイトへのリンク) ● Publication site (DOI): 10.3390/jcm13164866 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39201007 ● Search Scopus @ Elsevier (PMID): 39201007 ● Search Scopus @ Elsevier (DOI): 10.3390/jcm13164866 (徳島大学機関リポジトリ: 119610, DOI: 10.3390/jcm13164866, PubMed: 39201007)
2.	Mamiko Takahashi, Shin Kondo, Kumiko Kagawa, Masafumi Nakamura, Yusaku Maeda, Ryohei Sumitani, Hikaru Yagi, Masahiro Oura, Kimiko Sogabe, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Itsuro Endo, Masahiro Abe and Shingen Nakamura : Skeletal muscle mass during chemotherapy for haematological malignancies: a retrospective study., BMJ Supportive & Palliative Care, Vol.14, No.2, 195-199, 2024. (要約) This study investigated whether baseline or alteration in muscle mass affects complications during chemotherapy or overall survival (OS) in haematological malignancies. Skeletal Muscle Index (SMI) was evaluated by bioimpedance analysis before and after chemotherapy in patients with haematological malignancies, and the association between muscle mass and clinical data was retrospectively analysed. Exactly 104 patients were enrolled, with a mean age of 62.2 years. SMI was 7.85 and 6.08 in male and female patients under 65 years and 7.10 and 5.92 over 65 years, before chemotherapy, respectively. Lower baseline SMI was not correlated with worse OS in total patients (p=0.915). After a median measurement interval of 30 days after chemotherapy (n=67), body weight and SMI decreased by 2.73% and 2.87% (mean), respectively. The decrease in body weight correlated with the loss of trunk muscle mass (R=0.2107) but was more strongly associated with the loss of lower limbs muscle mass (R=0.3985). The muscle mass of lower limbs significantly decreased in lymphoma patients who experienced febrile neutropenia (-0.42% vs -6.04%, p=0.040). OS significantly decreased in lymphoma patients with loss of lower limbs muscle ≥2.8% (p=0.0327). Muscle loss occurred following anticancer treatments, significantly contributing to worse outcomes. Body composition assessment and relevant multimodal prevention of muscle loss may be vital for patients receiving chemotherapy for haematological malignancies. (キーワード) Humans / Male / Female / Retrospective Studies / Middle Aged / Hematologic Neoplasms / Muscle, Skeletal / Aged / Adult / Antineoplastic Agents / Aged, 80 and over / Body Composition / Sarcopenia (徳島大学機関リポジトリ) ● Metadata: 119635 (出版サイトへのリンク) ● Publication site (DOI): 10.1136/spcare-2024-004870 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38569748 ● Search Scopus @ Elsevier (PMID): 38569748 ● Search Scopus @ Elsevier (DOI): 10.1136/spcare-2024-004870 (徳島大学機関リポジトリ: 119635, DOI: 10.1136/spcare-2024-004870, PubMed: 38569748)
3.	Taiki Hori, Taro Shimizu, Hidenori ANDO, Naoto Okada, Hiroki Yamagami, Saya Yasui, Minae Hosoki, Akihiro Tojima, Toshiki Otoda, Tomoyuki Yuasa, Ken-ichi Aihara, Makoto Takishita, Sumiko Yoshida, Masahiro Abe, Tatsuhiro Ishida and Shingen Nakamura : Humoral immune response against SARS-CoV-2 and polyethylene glycol elicited by anti-SARS-CoV-2 mRNA vaccine, and effect of pre-existing anti-polyethylene glycol antibody in patients with hematological and autoimmune diseases., Heliyon, Vol.10, No.10, e31489, 2024. (要約) The effects of vaccination are modified by hematological and autoimmune diseases and/or treatment. Anti-SARS-CoV-2 mRNA vaccine contains polyethylene glycol (PEG), it is largely unknown whether PEG influences the effects of vaccination or induces a humoral response. This study examined whether anti-PEG antibodies before vaccination (pre-existing) influenced the acquisition of SARS-CoV-2 antibodies and evaluated the relationship between the development of anti-SARS-CoV-2 antibodies and anti-PEG antibodies after SARS-CoV-2 vaccination in hematological and autoimmune diseases. Anti-SARS-CoV-2 antibody IgG, anti-PEG IgG, and IgM titers were evaluated in patients with hematological and autoimmune diseases after the second dose of BNT162B2. Anti-PEG IgG and IgM titers were also measured before vaccination to examine changes after vaccination and the relationship with vaccine efficacy. In patients with hematological (n = 182) and autoimmune diseases (n = 96), anti-SARS-CoV-2 and anti-PEG antibody titers were evaluated after a median of 33 days from 2nd vaccination. The median anti-SARS-CoV-2 antibody titers were 1901 AU/mL and 3832 AU/mL in patients with hematological and autoimmune disease, respectively. Multiple regression analysis showed that age and days from 2nd vaccination were negatively associated with anti-SARS-CoV-2 antibody titers. Anti-CD20 antibody treatment was negatively correlated with anti-SARS-CoV-2 antibody titers in hematological disease, and C-reactive protein (CRP) was positively correlated with anti-SARS-CoV-2 antibody titers in autoimmune disease. Baseline anti-PEG antibody titers were significantly higher in patients with autoimmune disease but were not correlated with anti-SARS-CoV-2 antibody titers. Patients with increased anti-PEG IgG acquired higher anti-SARS-CoV-2 antibody titers in patients with autoimmune disease. Anti-SARS-CoV-2 antibody acquisition was suboptimal in patients with hematological disease, but both anti-SARS-CoV-2 antibody and anti-PEG IgG were acquired in patients with autoimmune disease, reflecting robust humoral immune response. Pre-existing anti-PEG antibody titers did not affect anti-SARS-CoV-2 antibody acquisition. (徳島大学機関リポジトリ) ● Metadata: 119625 (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.heliyon.2024.e31489 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38813140 ● Search Scopus @ Elsevier (PMID): 38813140 ● Search Scopus @ Elsevier (DOI): 10.1016/j.heliyon.2024.e31489 (徳島大学機関リポジトリ: 119625, DOI: 10.1016/j.heliyon.2024.e31489, PubMed: 38813140)
4.	Shingen Nakamura, Keijiro Hara, Tomoko Kobayashi, Ryohei Sumitani, Masahiro Oura, Yusaku Maeda, Kimiko Sogabe, Hikaru Yagi, Mamiko Takahashi, Shiroh Fujii, Takeshi Harada, Yoshimi Bando, Masahiro Abe and Hirokazu Miki : Tl uptake and retention mimicking malignant lymphoma in a patient with human immunodeficiency virus infection., Parasitology International, Vol.101, 102895, 2024. (要約) Various opportunistic infections develop during immunodeficiency due to human immunodeficiency virus (HIV) infection. The treatment options for malignant lymphoma (ML) and toxoplasmic encephalitis (TE) are completely different; therefore, their discrimination is critical. A 25-year-old female of foreign nationality had been experiencing headaches for several weeks and suddenly developed convulsions. Brain computed tomography revealed multiple intracranial lesions; therefore, the patient was referred to the neurosurgery department. Brain magnetic resonance imaging (MRI) revealed multiple masses with surrounding edema, accompanied by enhanced contrast. The largest mass (2 cm) in the left occipital lobe exhibited ringed contrast enhancement. Her blood test results showed a CD4 count of 40/μL, positive HIV Ag/Ab, HIV-RNA level of 56 × 10 copies/mL, positive anti-Toxoplasma IgG (63 IU/mL), and negative anti-Toxoplasma IgM. Tl- single photon emission computed tomography (Tl-SPECT) revealed abnormal accumulation only in the tumor in the left occipital lobe (early T/N ratio, 3.034; delayed T/N ratio, 2.738; retention index, 0.9), which was suspected to be a ML. Both tumors, with or without high accumulation of Tl, were subjected to craniotomy biopsy. Pathological examination revealed infiltration of small lymphocytes with a necrotic background. The patient was diagnosed with TE based on a positive result of a tissue polymerase chain reaction test for Toxoplasma gondii. Two weeks after sulfamethoxazole and trimethoprim combination therapy, MRI imaging showed dramatic improvement in multiple brain tumors. This case is atypical because ML was ruled out despite high Tl-SPECT uptake and retention. Careful diagnosis through pathological examination and DNA testing is important. (キーワード) Humans / Female / Adult / Toxoplasmosis, Cerebral / Lymphoma / HIV Infections / Magnetic Resonance Imaging / Diagnosis, Differential / Tomography, Emission-Computed, Single-Photon / Toxoplasma (徳島大学機関リポジトリ) ● Metadata: 119634 (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.parint.2024.102895 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38614255 ● Search Scopus @ Elsevier (PMID): 38614255 ● Search Scopus @ Elsevier (DOI): 10.1016/j.parint.2024.102895 (徳島大学機関リポジトリ: 119634, DOI: 10.1016/j.parint.2024.102895, PubMed: 38614255)
5.	Taiki Hori, Ken-ichi Aihara, Koki Ishida, Kaori Inaba, Keisuke Inaba, Yousuke Kaneko, Keisuke Kawahito, Shoki Bekku, Minae Hosoki, Kensuke Mori, Kanako Itami, Masayo Katsuse, Yoshimi Hanaoka, Teruyoshi Kageji, Hideyuki Uraoka and Shingen Nakamura : Usefulness of Palliative Prognostic Index, Objective Prognostic Score, and Neutrophil-Lymphocyte Ratio/Albumin Ratio As Prognostic Indicators for Patients Without Cancer Receiving Home-Visit Palliative Care: A Pilot Study at a Community General Hospital., Palliative Medicine Reports, Vol.5, No.1, 142-149, 2024. (要約) < 0.001). The survival curves of the groups classified according to PPI, OPS, and NLR/Alb were significantly stratified. The predictive capacities of PPI, OPS, and NLR/Alb for death within 21 days were as follows: PPI (area under the curve [AUC]: 0.71; sensitivity: 59%; specificity: 68%), OPS (AUC: 0.73; sensitivity: 88%; specificity: 47%), and NLR/Alb (AUC: 0.72; sensitivity: 72%; specificity: 73%). (徳島大学機関リポジトリ) ● Metadata: 119250 (出版サイトへのリンク) ● Publication site (DOI): 10.1089/pmr.2023.0096 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38596695 ● Search Scopus @ Elsevier (PMID): 38596695 ● Search Scopus @ Elsevier (DOI): 10.1089/pmr.2023.0096 (徳島大学機関リポジトリ: 119250, DOI: 10.1089/pmr.2023.0096, PubMed: 38596695)
6.	Minae Hosoki, HORI Taiki, KANEKO Yohsuke, Kensuke Mori, Saya Yasui, Seijiro Tsuji, Hiroki Yamagami, Saki Kawata, Tomoyo Hara, Shiho Masuda, Yukari Mitsui, Kiyoe Kurahashi, Takeshi Harada, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : Causes of In-Hospital Death and Pharmaceutical Associations with Age of Death during a 10-Year Period (2011-2020) in Individuals with and without Diabetes at a Japanese Community General Hospital., Journal of Clinical Medicine, Vol.13, No.5, 1283, 2024. (要約) Since diabetes and its complications have been thought to exaggerate cardiorenal disease, resulting in a short lifespan, we investigated causes of death and lifespans in individuals with and without diabetes at a Japanese community general hospital during the period from 2011 to 2020. Causes of death and age of death in individuals with and those without diabetes were compared, and associations between medications used and age of death were statistically analyzed. A total of 2326 deaths were recorded during the 10-year period. There was no significant difference between the mean ages of death in individuals with and those without diabetes. Diabetic individuals had higher rates of hepato-pancreatic cancer and cardio-renal failure as causes of death. The prescription rates of antihypertensives, antiplatelets, and statins in diabetic individuals were larger than those in non-diabetic individuals. Furthermore, the use of sulfonyl urea or glinides and insulin was independently and inversely associated with the age of death. In conclusion, individuals with diabetes were treated with comprehensive pharmaceutical interventions and had life spans comparable to those of individuals without diabetes. This study's discovery of an inverse relationship between the use of insulin secretagogues or insulin and the age of death suggests that the prevention of life-threatening hypoglycemia is crucial for individuals with diabetes. (徳島大学機関リポジトリ) ● Metadata: 119252 (出版サイトへのリンク) ● Publication site (DOI): 10.3390/jcm13051283 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38592103 ● Search Scopus @ Elsevier (PMID): 38592103 ● Search Scopus @ Elsevier (DOI): 10.3390/jcm13051283 (徳島大学機関リポジトリ: 119252, DOI: 10.3390/jcm13051283, PubMed: 38592103)
7.	Shin-ichiro Yanagiya, Takeshi Honda, Hiroki Takanari, Kimiko Sogabe, Shingen Nakamura, Yoshimi Bando, Masahiro Abe and Hirokazu Miki : Raman Microspectroscopy for Label-Free Diagnosis of Amyloid Light-chain Amyloidosis in Various Organs, Journal of Raman Spectroscopy, 2024. (キーワード) ラマン顕微分光法 / 全身性アミロイドーシス / タンパク質 (protein) / 光学顕微鏡法 (徳島大学機関リポジトリ) ● Metadata: 119087 (出版サイトへのリンク) ● Publication site (DOI): 10.1002/jrs.6665 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1002/jrs.6665 (徳島大学機関リポジトリ: 119087, DOI: 10.1002/jrs.6665)
8.	Tomoko Maruhashi, Hirokazu Miki, Kimiko Sogabe, Asuka Oda, Ryohei Sumitani, Masahiro Oura, Mamiko Takahashi, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Kiyoe Kurahashi, Itsuro Endo and Masahiro Abe : Acute suppression of translation by hyperthermia enhances anti-myeloma activity of carfilzomib, International Journal of Hematology, Vol.119, No.3, 291-302, 2024. (要約) Hyperthermia is a unique treatment option for cancers. Multiple myeloma (MM) remains incurable and innovative therapeutic options are needed. We investigated the efficacy of hyperthermia and carfilzomib in combination against MM cells. Although MM cell lines exhibited different susceptibilities to pulsatile carfilzomib treatment, mild hyperthermia at 43℃ induced MM cell death in all cell lines in a time-dependent manner. Hyperthermia and carfilzomib cooperatively induced MM cell death even under suboptimal conditions. The pro-survival mediators PIM2 and NRF2 accumulated in MM cells due to inhibition of their proteasomal degradation by carfilzomib; however, hyperthermia acutely suppressed translation in parallel with phosphorylation of eIF2α to reduce these proteins in MM cells. Recovery of β5 subunit enzymatic activity from its immediate inhibition by carfilzomib was observed at 24 h in carfilzomib-insusceptible KMS-11, OPM-2, and RPMI8226 cells, but not in carfilzomib-sensitive MM.1S cells. However, heat treatment suppressed the recovery of β5 subunit activity in these carfilzomib-insusceptible cells. Therefore, hyperthermia re-sensitized MM cells to carfilzomib. Our results support the treatment of MM with hyperthermia in combination with carfilzomib. Further research is warranted on hyperthermia for drug-resistant extramedullary plasmacytoma. (キーワード) Humans / Multiple Myeloma / Oligopeptides / Hyperthermia, Induced (徳島大学機関リポジトリ) ● Metadata: 119321 (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s12185-023-03706-8 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38252236 ● Search Scopus @ Elsevier (PMID): 38252236 ● Search Scopus @ Elsevier (DOI): 10.1007/s12185-023-03706-8 (徳島大学機関リポジトリ: 119321, DOI: 10.1007/s12185-023-03706-8, PubMed: 38252236)
9.	Kimiko Sogabe, Shingen Nakamura, Yoshiki Higa, Hirokazu Miki, Asuka Oda, Tomoko Maruhashi, Ryohei Sumitani, Masahiro Oura, Mamiko Takahashi, Masafumi Nakamura, Yusaku Maeda, Tomoyo Hara, Hiroki Yamagami, Shiroh Fujii, Kumiko Kagawa, Shuji Ozaki, Kiyoe Kurahashi, Itsuro Endo, Ken-ichi Aihara, Emiko Nakaue, Masahiro Hiasa, Jumpei Teramachi, Takeshi Harada and Masahiro Abe : Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors., International Journal of Hematology, Vol.119, No.3, 303-315, 2024. (要約) Resistance to proteasome inhibitors (PIs) has emerged as an important clinical issue. We investigated the mechanisms underlying multiple myeloma (MM) cell resistance to PIs. To mimic their pharmacokinetic/pharmacodynamic (PK/PD) profiles, MM cells were treated with bortezomib and carfilzomib for 1 h at concentrations up to 400 and 1,000 nM, respectively. Susceptibility to these PIs markedly varied among MM cell lines. Pulsatile treatments with PIs suppressed translation, as demonstrated by incorporation of puromycin at 24 h in PI-susceptible MM.1S cells, but not PI-resistant KMS-11 cells. Inhibition of β5 subunit activity decreased at 24 h in KMS-11 cells, even with the irreversible PI carfilzomib, but not under suppression of protein synthesis with cycloheximide. Furthermore, the proteasome-degradable pro-survival factors PIM2 and NRF2 acutely accumulated in MM cells subjected to pulsatile PI treatments. Accumulated NRF2 was trans-localized into the nucleus to induce the expression of its target gene, HMOX1, in MM cells. PIM and Akt inhibition restored the anti-MM effects of PIs, even against PI-resistant KMS-11 cells. Collectively, these results suggest that increased synthesis of β5 proteasome subunit and acute accumulation of PIM2 and NRF2 reduce the anti-MM effects of PIs. (キーワード) Humans / Proteasome Inhibitors / NF-E2-Related Factor 2 / Multiple Myeloma / Proteasome Endopeptidase Complex / Drug Resistance, Neoplasm / Cell Line, Tumor / Bortezomib / Antineoplastic Agents / Proto-Oncogene Proteins / Protein Serine-Threonine Kinases (徳島大学機関リポジトリ) ● Metadata: 119384 (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s12185-023-03705-9 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38245883 ● Search Scopus @ Elsevier (PMID): 38245883 ● Search Scopus @ Elsevier (DOI): 10.1007/s12185-023-03705-9 (徳島大学機関リポジトリ: 119384, DOI: 10.1007/s12185-023-03705-9, PubMed: 38245883)
10.	堀太貴, 中村信元, 粟飯原賢一 : Clinical Significance of Phase Angle and Extracellular Water-to-Total Body Water Ratio Measured by Bioelectrical Impedance Analysis, Journal of leukemia, Vol.12, 368, 2024年. (徳島大学機関リポジトリ) ● Metadata: 119624 (徳島大学機関リポジトリ: 119624)
11.	Shingen Nakamura and Hirokazu Miki : Discrimination between Toxoplasmic Encephalitis and Central Nervous System Lymphoma: An Updated Review, Journal of Hematology & Thromboembolic Diseases, Vol.14, No.12, 602, 2024. (徳島大学機関リポジトリ) ● Metadata: 119611 (徳島大学機関リポジトリ: 119611)
12.	Hiroki Yamagami, Tomoyo Hara, Saya Yasui, Minae Hosoki, Taiki Hori, Yousuke Kaneko, Yukari Mitsui, Kiyoe Kurahashi, Takeshi Harada, Sumiko Yoshida, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Cross-Sectional and Longitudinal Associations between Skin Autofluorescence and Tubular Injury Defined by Urinary Excretion of Liver-Type Fatty Acid-Binding Protein in People with Type 2 Diabetes., Biomedicines, Vol.11, No.11, 3020, 2023. (要約) = 0.026). In conclusion, SAF is positively correlated with uL-FABP but not with uACR in people with T2D. Thus, there is a possibility that SAF can serve as a novel predictor for the development of diabetic tubular injury. (キーワード) skin autofluorescence / type 2 diabetes / diabetic kidney disease / albuminuria / tubular injury / L-FABP (徳島大学機関リポジトリ) ● Metadata: 119108 (出版サイトへのリンク) ● Publication site (DOI): 10.3390/biomedicines11113020 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38002020 ● CiNii @ 国立情報学研究所 (CRID): 1870302167614368000 ● Summary page in Scopus @ Elsevier: 2-s2.0-85178346619 (徳島大学機関リポジトリ: 119108, DOI: 10.3390/biomedicines11113020, PubMed: 38002020, CiNii: 1870302167614368000, Elsevier: Scopus)
13.	Saya Yasui, Yousuke Kaneko, Hiroki Yamagami, Minae Hosoki, Taiki Hori, Akihiro Tani, Tomoyo Hara, Kiyoe Kurahashi, Takeshi Harada, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Hiroyasu Mori, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Takeshi Soeki and Ken-ichi Aihara : Dehydroepiandrosterone Sulfate, an Adrenal Androgen, Is Inversely Associated with Prevalence of Dynapenia in Male Individuals with Type 2 Diabetes., Metabolites, Vol.13, No.11, 1129, 2023. (要約) Dehydroepiandrosterone sulfate (DHEAS) is thought to be associated with life expectancy and anti-aging. Although skeletal muscle disorders are often found in diabetic people, the clinical significance of DHEAS in skeletal muscle remains unclear. Therefore, we aimed to determine whether DHEAS is associated with the development of skeletal muscle disorders in individuals with type 2 diabetes (T2D). A cross-sectional study was conducted in 361 individuals with T2D. Serum DHEAS levels, skeletal muscle mass index (SMI), handgrip strength (HS), and gait speed (GS) were measured in the participants. Pre-sarcopenia, sarcopenia, and dynapenia were defined according to the definitions of the AWGS 2019 criteria. DHEAS level was positively associated with HS but not with SMI or GS after adjustment of confounding factors. Multiple logistic regression analyses in total subjects showed that DHEAS level had an inverse association with the prevalence of dynapenia but not with the prevalence of pre-sarcopenia or sarcopenia. Furthermore, a significant association between DHEAS level and dynapenia was found in males but not in females. ROC curve analysis indicated that cutoff values of serum DHEAS for risk of dynapenia in males was 92.0 μg/dL. Therefore, in male individuals with T2D who have low serum levels of DHEAS, adequate exercise might be needed to prevent dynapenia. (徳島大学機関リポジトリ) ● Metadata: 119107 (出版サイトへのリンク) ● Publication site (DOI): 10.3390/metabo13111129 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37999225 ● CiNii @ 国立情報学研究所 (CRID): 1870583643033891840 ● Summary page in Scopus @ Elsevier: 2-s2.0-85178271509 (徳島大学機関リポジトリ: 119107, DOI: 10.3390/metabo13111129, PubMed: 37999225, CiNii: 1870583643033891840, Elsevier: Scopus)
14.	Masahiro Oura, Takeshi Harada, Asuka Oda, Jumpei Teramachi, Atsushi Nakayama, Ryohei Sumitani, Yusuke Inoue, Yusaku Maeda, Kimiko Sogabe, Maruhashi Tomoko, Mamiko Takahashi, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Shingen Nakamura, Tomoyo Hara, Hiroki Yamagami, Kiyoe Kurahashi, Itsuro Endo, Hiroo Hasegawa, Hiroshi Fujiwara and Masahiro Abe : Therapeutic efficacy of the resorcylic acid lactone LL-Z1640-2 for adult T-cell leukaemia/lymphoma, eJHaem, Vol.4, No.3, 667-678, 2023. (要約) Adult T-cell leukaemia/lymphoma (ATL) remains incurable. The NF-κB and interferon regulatory factor 4 (IRF4) signalling pathways are among the critical survival pathways for the progression of ATL. TGF-β-activated kinase 1 (TAK1), an IκB kinase-activating kinase, triggers the activation of NF-κB. The resorcylic acid lactone LL-Z1640-2 is a potent irreversible inhibitor of TAK1/extracellular signal-regulated kinase 2 (ERK2). We herein examined the therapeutic efficacy of LL-Z1640-2 against ATL. LL-Z1640-2 effectively suppressed the in vivo growth of ATL cells. It induced in vitro apoptosis and inhibited the nuclear translocation of p65/RelA in ATL cells. The knockdown of strongly induced ATL cell death while downregulating MYC. LL-Z1640-2 as well as the NF-κB inhibitor BAY11-7082 decreased the expression of IRF4 and MYC at the protein and mRNA levels, indicating the suppression of the NF-κB-IRF4-MYC axis. The treatment with LL-Z1640-2 also mitigated the phosphorylation of p38 MAPK along with the expression of CC chemokine receptor 4. Furthermore, the inhibition of STAT3/5 potentiated the cytotoxic activity of LL-Z1640-2 against IL-2-responsive ATL cells in the presence of IL-2. Therefore, LL-Z1640-2 appears to be an effective treatment for ATL. Further studies are needed to develop more potent compounds that retain the active motifs of LL-Z1640-2. (出版サイトへのリンク) ● Publication site (DOI): 10.1002/jha2.758 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37601887 ● Search Scopus @ Elsevier (PMID): 37601887 ● Search Scopus @ Elsevier (DOI): 10.1002/jha2.758 (DOI: 10.1002/jha2.758, PubMed: 37601887)
15.	Shiho Masuda, Tomoyo Hara, Hiroki Yamagami, Yukari Mitsui, Kiyoe Kurahashi, Sumiko Yoshida, Takeshi Harada, Toshiki Otoda, Tomoyuki Yuasa, Shingen Nakamura, Akio Kuroda, Itsuro Endo, Toshio Matsumoto, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Vascular Endothelial Function Is Associated with eGFR Slope in Female and Non-Smoking Male Individuals with Cardiovascular Risk Factors: A Pilot Study on the Predictive Value of FMD for Renal Prognosis., Journal of Atherosclerosis and Thrombosis, 2023. (要約) In individuals with cardiovascular risk factors, evaluation of vascular endothelial function enables prediction of renal prognosis in females and non-smoking males. (徳島大学機関リポジトリ) ● Metadata: 118250 (出版サイトへのリンク) ● Publication site (DOI): 10.5551/jat.63987 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37081616 ● Search Scopus @ Elsevier (PMID): 37081616 ● Search Scopus @ Elsevier (DOI): 10.5551/jat.63987 (徳島大学機関リポジトリ: 118250, DOI: 10.5551/jat.63987, PubMed: 37081616)
16.	Takeshi Harada, Hiroto Ohguchi, Asuka Oda, Michiyasu Nakao, Jumpei Teramachi, Masahiro Hiasa, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Tomoko Maruhashi, Mamiko Takahashi, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Shigeki Sano, Teru Hideshima and Masahiro Abe : Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase, Blood Advances, Vol.7, No.6, 1019-1032, 2023. (要約) Multiple myeloma (MM) preferentially expands and acquires drug resistance in the bone marrow (BM). We herein examined the role of histone deacetylase 1 (HDAC1) in the constitutive activation of the master transcription factor IRF4 and the prosurvival mediator PIM2 kinase in MM cells. The knockdown or inhibition of HDAC1 by the class I HDAC inhibitor MS-275 reduced the basal expression of IRF4 and PIM2 in MM cells. Mechanistically, the inhibition of HDAC1 decreased IRF4 transcription through histone hyperacetylation and inhibiting the recruitment of RNA polymerase II at the IRF4 locus, thereby reducing IRF4-targeting genes, including PIM2. In addition to the transcriptional regulation of PIM2 by the HDAC1-IRF4 axis, PIM2 was markedly upregulated by external stimuli from BM stromal cells and interleukin-6 (IL-6). Upregulated PIM2 contributed to the attenuation of the cytotoxic effects of MS-275. Class I HDAC and PIM kinase inhibitors cooperatively suppressed MM cell growth in the presence of IL-6 and in vivo. Therefore, the present results demonstrate the potential of the simultaneous targeting of the intrinsic HDAC1-IRF4 axis plus externally activated PIM2 as an efficient therapeutic option for MM fostered in the BM. (キーワード) Histone Deacetylase 1 / Interleukin-6 / Benzamides / Pyridines (徳島大学機関リポジトリ) ● Metadata: 118211 (出版サイトへのリンク) ● Publication site (DOI): 10.1182/bloodadvances.2022007155 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36129197 ● Search Scopus @ Elsevier (PMID): 36129197 ● Search Scopus @ Elsevier (DOI): 10.1182/bloodadvances.2022007155 (徳島大学機関リポジトリ: 118211, DOI: 10.1182/bloodadvances.2022007155, PubMed: 36129197)
17.	Taiki Hori, Shingen Nakamura, Hiroki Yamagami, Saya Yasui, Minae Hosoki, Tomoyo Hara, Yukari Mitsui, Shiho Masuda, Kiyoe Kurahashi, Sumiko Yoshida, Takeshi Harada, Akio Kuroda, Toshiki Otoda, Tomoyuki Yuasa, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Phase angle and extracellular water-to-total body water ratio estimated by bioelectrical impedance analysis are associated with levels of hemoglobin and hematocrit in patients with diabetes., Heliyon, Vol.9, No.4, 2023. (要約) PhA and ECW/TBW but not SMI were associated with levels of Hgb and Hct in patients with diabetes. Therefore, aberrant values of PhA and ECW/TBW suggest a risk of anemia in diabetic patients. (徳島大学機関リポジトリ) ● Metadata: 118251 (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.heliyon.2023.e14724 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37057050 ● Search Scopus @ Elsevier (PMID): 37057050 ● Search Scopus @ Elsevier (DOI): 10.1016/j.heliyon.2023.e14724 (徳島大学機関リポジトリ: 118251, DOI: 10.1016/j.heliyon.2023.e14724, PubMed: 37057050)
18.	Jumpei Teramachi, Hirokazu Miki, Shingen Nakamura, Masahiro Hiasa, Takeshi Harada and Masahiro Abe : Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents., Journal of Bone and Mineral Metabolism, 1-16, 2023. (要約) MM cells produce a variety of cytokines to stimulate receptor activator of nuclear factor-κB ligand-mediated osteoclastogenesis and suppress osteoblastic differentiation from bone marrow stromal cells, leading to extensive bone destruction with rapid loss of bone. MM cells alter the microenvironment through bone destruction where they colonize, which in turn favors tumor growth and survival, thereby forming a vicious cycle between tumor progression and bone destruction. Denosumab or zoledronic acid is currently recommended to be administered at the start of treatment in newly diagnosed patients with MM with bone disease. Proteasome inhibitors and the anti-CD38 monoclonal antibody daratumumab have been demonstrated to exert bone-modifying activity in responders. Besides their anti-tumor activity, the effects of new anti-MM agents on bone metabolism should be more precisely analyzed in patients with MM. Because prognosis in patients with MM has been significantly improved owing to the implementation of new agents, the therapeutic impact of bone-modifying agents should be re-estimated in the era of these new agents. (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s00774-023-01403-4 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36856824 ● Search Scopus @ Elsevier (PMID): 36856824 ● Search Scopus @ Elsevier (DOI): 10.1007/s00774-023-01403-4 (DOI: 10.1007/s00774-023-01403-4, PubMed: 36856824)
19.	Taiki Hori, Saya Yasui, Minae Hosoki, Hiroki Yamagami, Toshiki Otoda, Tomoyuki Yuasa, Kenichi Aihara, Makoto Takishita, Akihiko Yokohama, Mitusharu Ueda, Masahiro Abe and Shingen Nakamura : Systemic amyloidosis associated with non-IgM type paraprotein with lymphoplasmacytic lymphoma, International Journal of Myeloma, Vol.13, No.2, 7-12, 2023. (徳島大学機関リポジトリ) ● Metadata: 118610 (出版サイトへのリンク) ● Publication site (DOI): 10.57352/ijm.13.2_7 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.57352/ijm.13.2_7 (徳島大学機関リポジトリ: 118610, DOI: 10.57352/ijm.13.2_7)
20.	高原由実子, 三木浩和, 中村信元, 林成樹, 住谷龍平, 大浦雅博, 曽我部公子, 髙橋真美子, 丸橋朋子, 富永誠記, 岡本秀樹, 岡田直人, 矢野由美子, 高橋真理, 大坂朱美, 原田武志, 藤井志朗, 菅俊行, 青田桂子, 尾崎修治, 安倍正博 : 徳島県におけるHIV感染症および後天性免疫不全症候群患者の臨床的特徴と今後の課題, 四国医学雑誌, Vol.78, No.5-6, 193-198, 2022年. (要約) 【Introduction】The survival rate in patients with HIV infection and acquired immunodeficiency syndrome (AIDS) has been improved dramatically due to the advances in anti-HIV drug therapy, while aging-associated complications become a critical issue. The incidence of sudden occurrence of AIDS without prior detection of HIV infection, so called ``Ikinari AIDS'', still remains high. 【Objective】We retrospectively analyzed the incidence and clinical characteristics of HIV/AIDS patients in both Tokushima University Hospital and Tokushima Prefectural Central Hospital. 【Results】Eighty four patients (74 males and 10 females) with a median age of 39 years old (range 16 - 85) were enrolled. Thirty-four patients (40.5%) were diagnosed with ``Ikinari AIDS'' from 2001 to 2020. All 4 patients were diagnosed with ``Ikinari AIDS'' after 2020. AIDS-defining illnesses were diagnosed as follows ; pneumocystis pneumonia in 21 cases, CMV infection in 8 cases and candidiasis in 6 cases. All patients over 60 years old were suffered from AIDS. Other complications included syphilis in 17 cases, hepatitis B infection in 12 and herpes zoster in 7. 【Discussion/Conclusion】In Tokushima, the incidence rate of ``Ikinari AIDS'' appeared to be higher than that of national average. COVID - 19 pandemic hampered the public health care services of awareness-raising activity for HIV infection and telephone consultations about HIV, which may become more lease asymptomatic HIV patients without diagnosis. For early diagnosis of HIV/AIDS, it is becoming more important to share information to make early screening of HIV infection among medical staffs, such as medical doctors, dentists, nurses, pharmacists and MSWs. (キーワード) HIV / AIDS / Ikinari AIDS (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1520013962706680448 (CiNii: 1520013962706680448)
21.	Shingen Nakamura, Motoki Sugasaki, Masayoshi Souri, Hirohito Akazawa, Maiko Sogawa, Taiki Hori, Hiroki Yamagami, Makoto Takishita, Ken-ichi Aihara, Masahiro Abe, Atsushi Yasumoto, Eriko Morishita and Akitada Ichinose : Autoimmune Acquired Factor XIII/13 Deficiency after SARS-CoV-2 mRNA Vaccination., Thrombosis and Haemostasis, 2022. (徳島大学機関リポジトリ) ● Metadata: 118345 (出版サイトへのリンク) ● Publication site (DOI): 10.1055/a-1863-7265 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35636450 ● Search Scopus @ Elsevier (PMID): 35636450 ● Search Scopus @ Elsevier (DOI): 10.1055/a-1863-7265 (徳島大学機関リポジトリ: 118345, DOI: 10.1055/a-1863-7265, PubMed: 35636450)
22.	Naoto Okada, Akikazu Murakami, Masami Satou, Shingen Nakamura, Shiroh Fujii, Kimiko Sogabe, Mamiko Takahashi, Asami Okada, Akane Abe, Hideki Fujii, Masahiro Abe, Momoyo Azuma and Keisuke Ishizawa : First reported case of Lachnoanaerobaculum gingivalis bacteremia in an acute myeloid leukemia patient with oral mucositis during high dose chemotherapy., Anaerobe, Vol.76, 2022. (要約) During chemotherapy in patients with oral mucositis, we should consider the possibility of L. gingivalis bacteremia. (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.anaerobe.2022.102610 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35811059 ● Search Scopus @ Elsevier (PMID): 35811059 ● Search Scopus @ Elsevier (DOI): 10.1016/j.anaerobe.2022.102610 (DOI: 10.1016/j.anaerobe.2022.102610, PubMed: 35811059)
23.	Hiroki Yamada, Rio Ohmori, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato : A machine learning model using SNPs obtained from a genome-wide association study predicts the onset of vincristine-induced peripheral neuropathy, The Pharmacogenomics Journal, 2022. (要約) Vincristine treatment may cause peripheral neuropathy. In this study, we identified the genes associated with the development of peripheral neuropathy due to vincristine therapy using a genome-wide association study (GWAS) and constructed a predictive model for the development of peripheral neuropathy using genetic information-based machine learning. The study included 72 patients admitted to the Department of Hematology, Tokushima University Hospital, who received vincristine. Of these, 56 were genotyped using the Illumina Asian Screening Array-24 Kit, and a GWAS for the onset of peripheral neuropathy caused by vincristine was conducted. Using Sanger sequencing for 16 validation samples, the top three single nucleotide polymorphisms (SNPs) associated with the onset of peripheral neuropathy were determined. Machine learning was performed using the statistical software R package "caret". The 56 GWAS and 16 validation samples were used as the training and test sets, respectively. Predictive models were constructed using random forest, support vector machine, naive Bayes, and neural network algorithms. According to the GWAS, rs2110179, rs7126100, and rs2076549 were associated with the development of peripheral neuropathy on vincristine administration. Machine learning was performed using these three SNPs to construct a prediction model. A high accuracy of 93.8% was obtained with the support vector machine and neural network using rs2110179 and rs2076549. Thus, peripheral neuropathy development due to vincristine therapy can be effectively predicted by a machine learning prediction model using SNPs associated with it. (徳島大学機関リポジトリ) ● Metadata: 117583 (出版サイトへのリンク) ● Publication site (DOI): 10.1038/s41397-022-00282-8 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35752658 ● Search Scopus @ Elsevier (PMID): 35752658 ● Search Scopus @ Elsevier (DOI): 10.1038/s41397-022-00282-8 (徳島大学機関リポジトリ: 117583, DOI: 10.1038/s41397-022-00282-8, PubMed: 35752658)
24.	Shin Kondo, Tatsuro Inoue, Takashi Saito, Yuka Kawamura, Ayane Katayama, Masafumi Nakamura, Ryohei Sumitani, Mamiko Takahashi, Masahiro Oura, Kimiko Sogabe, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Nori Sato, Rei Ono, Masahiro Abe and Shinsuke Katoh : Allogeneic haematopoietic stem cell transplantation and patient falls: impact of lower extremity muscle strength., BMJ Supportive & Palliative Care, 2022. (要約) Pretransplant LEMS was a significant predictor of post-transplant falls. The results of this study may help to prevent falls in patients undergoing allo-HSCT. (出版サイトへのリンク) ● Publication site (DOI): 10.1136/bmjspcare-2022-003582 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35534187 ● Search Scopus @ Elsevier (PMID): 35534187 ● Search Scopus @ Elsevier (DOI): 10.1136/bmjspcare-2022-003582 (DOI: 10.1136/bmjspcare-2022-003582, PubMed: 35534187)
25.	Minori Takei, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato : A genome-wide association study predicts the onset of dysgeusia due to anti-cancer drug treatment, Biological & Pharmaceutical Bulletin, Vol.45, No.1, 114-117, 2022. (要約) Dysgeusia is a major side effect of anti-cancer drug treatment. Since dysgeusia significantly lowers the patient's QOL, predicting and avoiding its onset in advance is desirable. Accordingly, aims of the present study were to use a genome-wide association study (GWAS) to identify genes associated with the development of dysgeusia in patients taking anti-cancer drugs and to predict the development of dysgeusia using associated single nucleotide polymorphisms (SNPs). GWAS was conducted on 76 patients admitted to the Department of Hematology, Tokushima University Hospital. Using Sanger sequencing for 23 separately collected validation samples, the top two SNPs associated with the development of dysgeusia were determined. GWAS identified rs73049478 and rs41396146 SNPs on the retinoic acid receptor beta (RARB) gene associated with dysgeusia development due to the administration of anti-cancer drugs. Evaluation of the two SNPs using 23 validation samples indicated that the accuracy rate of rs73049478 was relatively high (87.0%). Thus, the findings of the present study suggest that the rs73049478 SNP of RARB can be used to predict the onset of dysgeusia caused by the administration of anti-cancer drugs. (キーワード) Antineoplastic Agents / Dysgeusia / Genetic Predisposition to Disease / Genome-Wide Association Study / Humans / Pharmaceutical Preparations / Polymorphism, Single Nucleotide / Quality of Life (徳島大学機関リポジトリ) ● Metadata: 117584 (出版サイトへのリンク) ● Publication site (DOI): 10.1248/bpb.b21-00745 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34657909 ● CiNii @ 国立情報学研究所 (CRID): 1390290617368322560 ● Summary page in Scopus @ Elsevier: 2-s2.0-85123201593 (徳島大学機関リポジトリ: 117584, DOI: 10.1248/bpb.b21-00745, PubMed: 34657909, CiNii: 1390290617368322560, Elsevier: Scopus)
26.	西條早希, 中村信元, 三木浩和, 谷口早紀, 岡本秀樹, 富永誠記, 岡田直人, 矢野由美子, 髙橋真理, 青田桂子, 菅俊行, 渡邊浩良, 大坂朱美, 安倍正博 : 徳島大学病院における先天性血友病患者(成人例)の実態調査∼移行期医療の重要性∼, 四国医学雑誌, Vol.77, No.5-6, 261-268, 2021年. (要約) 【Introduction】Congenital hemophilia is a category of hemorrhagic disease caused by a genetic defect in the production of coagulation factors. It is treated by administering regular coagulation factor injections on an ongoing basis. Hemophilia is a hereditary illness, often causing social and psychological problems as a result of the disease. To analyze the objective effects of hemophilia, we conducted a retrospective analysis in Tokushima University Hospital. 【Result】All 23 cases were men between the ages of20and72. Hemophilia A was present in17cases, and hemophilia B was present in six. Nineteen out of 23 cases were severe, and the others were intermediate. Medical assessments were conducted at pediatrics in seven cases and hematology in 16 cases. Adoption of the self-injection technique was not realized in five cases. Seventeen cases were complicated by hemophilic arthropathy, seven with human immunodeficiency virus(HIV), and 12 with hepatitis C virus. Eight participants were unemployed, and17were unmarried. 【Discussion】 Many adult hemophilia patients still visit pediatrics in our hospital. Hemophilia in the period of growth between adolescence and young adulthood is often accompanied by life-altering events such as entering higher education, marriage, and work experience. Therefore, collaboration among professionals of multiple occupations, such as doctors, nurses, pharmacists, medical social workers, and clinical psychologists, is essential. Furthermore, there are many cases of HIV and hepatitis C virus infections complicating hemophilia study due to the stigma surrounding HIV-tainted blood. 【Conclusion】It is imperative that we establish a long-term, sustainable, and multi-disciplinary transitional care and medical support system for patients and their families. (キーワード) Congenital Hemophilia / Transitional Care (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1520855132284626560 (CiNii: 1520855132284626560)
27.	Shin Kondo, Kumiko Kagawa, Takashi Saito, Masahiro Oura, Kimiko Sogabe, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Nori Sato, Rei Ono, Masahiro Abe and Shinsuke Katoh : Allogeneic haematopoietic stem cell transplantation-clinical outcomes: impact of leg muscle strength., BMJ Supportive & Palliative Care, 2021. (要約) Pre-transplant LEMS was a significant factor in predicting OS and NRM. (出版サイトへのリンク) ● Publication site (DOI): 10.1136/bmjspcare-2021-003256 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34949601 ● Search Scopus @ Elsevier (PMID): 34949601 ● Search Scopus @ Elsevier (DOI): 10.1136/bmjspcare-2021-003256 (DOI: 10.1136/bmjspcare-2021-003256, PubMed: 34949601)
28.	Yousuke Kaneko, Motoki Sugasaki, Naoto Okada, Mako Niimi, Saya Yasui, Taiki Hori, Ken-ichi Aihara, Makoto Takishita, Masahiro Abe and Shingen Nakamura : Artifactual prolongation of the activated partial thromboplastin time by amikacin or gentamicin with ellagic acid, but not silica activated reagent., International Journal of Laboratory Hematology, Vol.44, No.2, e72-e75, 2021. (キーワード) Amikacin / Anti-Bacterial Agents / Ellagic Acid / Gentamicins / Humans / Indicators and Reagents / Partial Thromboplastin Time / Silicon Dioxide (徳島大学機関リポジトリ) ● Metadata: 118369 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/ijlh.13718 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34585530 ● Search Scopus @ Elsevier (PMID): 34585530 ● Search Scopus @ Elsevier (DOI): 10.1111/ijlh.13718 (徳島大学機関リポジトリ: 118369, DOI: 10.1111/ijlh.13718, PubMed: 34585530)
29.	Naoki Hosen, Satoshi Yoshihara, Hiroyuki Takamatsu, Masaki Morishima, Yasuyuki Nagata, Hiroshi Kosugi, Yoshimitsu Shimomura, Ichiro Hanamura, Shigeo Fuji, Koichiro Minauchi, Junya Kuroda, Rikio Suzuki, Noriko Nishimura, Nobuhiko Uoshima, Hirohisa Nakamae, Yawara Kawano, Ishikazu Mizuno, Hiroshi Gomyo, Kenshi Suzuki, Shuji Ozaki, Shingen Nakamura, Yoichi Imai, Masahiro Kizaki, Eiju Negoro, Hiroshi Handa and Shinsuke Iida : Expression of activated integrin β7 in multiple myeloma patients., International Journal of Hematology, Vol.114, No.1, 3-7, 2021. (要約) Multiple myeloma (MM) is still extremely difficult to cure, and new therapeutic drugs are needed. We recently found that integrin β7 is constitutively activated in MM cells, and chimeric antigen receptor (CAR) T cells targeting activated integrin β7 have a significant anti-MM effect. In this study, we performed flow cytometry analysis of the expression of activated integrin β7 in bone marrow cells from 137 symptomatic MM patients. In 60/137 (44%) MM patients, activated integrin β7 was detected in most MM cells (> 80% of MM cells were in the positive gate). Activated integrin β7 was highly expressed in MM cells even in heavily treated patients. It also showed high expression in many CD38 (キーワード) Aged / Bone Marrow Cells / Female / Flow Cytometry / Humans / Immunotherapy, Adoptive / Integrin beta Chains / Male / Multiple Myeloma / Plasma Cells (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s12185-021-03162-2 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33999338 ● Search Scopus @ Elsevier (PMID): 33999338 ● Search Scopus @ Elsevier (DOI): 10.1007/s12185-021-03162-2 (DOI: 10.1007/s12185-021-03162-2, PubMed: 33999338)
30.	Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Shingen Nakamura, Mohannad Ashtar, Sou Shimizu, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Shiroh Fujii, Kumiko Kagawa, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe : TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma, Haematologica, Vol.106, No.5, 1401-1413, 2021. (要約) Along with the tumor progression, the bone marrow microenvironment is skewed in multiple myeloma (MM), which underlies the unique pathophysiology of MM and confers aggressiveness and drug resistance in MM cells. TGF-β-activated kinase-1 (TAK1) mediates a wide range of intracellular signaling pathways. We demonstrate here that TAK1 is constitutively overexpressed and phosphorylated in MM cells, and that TAK1 inhibition suppresses the activation of NF-κB, p38MAPK, ERK and STAT3 to decrease the expression of critical mediators for MM growth and survival, including PIM2, MYC, Mcl-1, IRF4, and Sp1, along with a substantial reduction in the angiogenic factor VEGF in MM cells. Intriguingly, TAK1 phosphorylation was also induced along with upregulation of vascular cell adhesion molecule-1 (VCAM-1) in bone marrow stromal cells (BMSCs) in cocultures with MM cells, which facilitated MM cell-BMSC adhesion while inducing IL-6 production and receptor activator of nuclear factor κ-Β ligand (RANKL) expression by BMSCs. TAK1 inhibition effectively impaired MM cell adhesion to BMSCs to disrupt the support of MM cell growth and survival by BMSCs. Furthermore, TAK1 inhibition suppressed osteoclastogenesis enhanced by RANKL in cocultures of bone marrow cells with MM cells, and restored osteoblastic differentiation suppressed by MM cells or inhibitory factors for osteoblastogenesis overproduced in MM. Finally, treatment with the TAK1 inhibitor LLZ1640-2 markedly suppressed MM tumor growth and prevented bone destruction and loss in mouse MM models. Therefore, TAK1 inhibition may be a promising therapeutic option targeting not only MM cells but also the skewed bone marrow microenvironment in MM. (キーワード) Animals / Bone Marrow Cells / MAP Kinase Kinase Kinases / Mice / Multiple Myeloma / NF-kappa B / Osteoclasts / Osteolysis / RANK Ligand / Tumor Microenvironment (徳島大学機関リポジトリ) ● Metadata: 116529 (出版サイトへのリンク) ● Publication site (DOI): 10.3324/haematol.2019.234476 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32273474 ● Search Scopus @ Elsevier (PMID): 32273474 ● Search Scopus @ Elsevier (DOI): 10.3324/haematol.2019.234476 (徳島大学機関リポジトリ: 116529, DOI: 10.3324/haematol.2019.234476, PubMed: 32273474)
31.	Ryohei Sumitani, Taiki Hori, Jumpei Murai, Shiyori Kawata, Masahiro Oura, Kimiko Sogabe, Mamiko Takahashi, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe and Shingen Nakamura : Acute Myeloid Leukemia Developing with Acute Pancreatitis Mimicking Autoimmune Pancreatitis., Internal Medicine, Vol.60, No.11, 1753-1757, 2021. (要約) A 33-year-old man was admitted to our hospital for fever and abdominal pain. A blood analysis revealed pancytopenia and increased serum pancreatic enzymes with disseminated intravascular coagulation. A detailed examination revealed acute pancreatitis, with diffuse swelling of the pancreas and diffuse beaded dilatation of the main pancreatic duct, which mimicked autoimmune pancreatitis complicated by acute myeloid leukemia. Systemic cytotoxic chemotherapy led to the remission of leukemia and pancreatitis. We hypothesized that the etiology of acute pancreatitis was invasion of leukemia cells. Acute pancreatitis is rare as a symptom of leukemia; however, we should consider the possibility of leukemia during the differential diagnosis of acute pancreatitis. (キーワード) Acute Disease / Adult / Autoimmune Diseases / Autoimmune Pancreatitis / Humans / Leukemia, Myeloid, Acute / Male / Pancreatitis (徳島大学機関リポジトリ) ● Metadata: 116536 (出版サイトへのリンク) ● Publication site (DOI): 10.2169/internalmedicine.4916-20 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33456032 ● Search Scopus @ Elsevier (PMID): 33456032 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.4916-20 (徳島大学機関リポジトリ: 116536, DOI: 10.2169/internalmedicine.4916-20, PubMed: 33456032)
32.	Tashima Hozumi, Endo Yuka, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato : Association analysis between adverse drug reactions to cytarabine therapy and single nucleotide polymorphisms in cytarabine metabolic genes in patients with hematopoietic tumor, Personalized Medicine Universe, Vol.10, 1-6, 2021. (徳島大学機関リポジトリ) ● Metadata: 117585 (出版サイトへのリンク) ● Publication site (DOI): 10.46459/pmu.2021002 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.46459/pmu.2021002 (徳島大学機関リポジトリ: 117585, DOI: 10.46459/pmu.2021002)
33.	Mamiko Takahashi, Ryohei Sumitani, Taiki Hori, Jumpei Murai, Shiyori Kawata, Masahiro Oura, Kimiko Sogabe, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe and Shingen Nakamura : Intravenous busulfan-based conditioning with autologous stem cell transplantation for refractory B-cell lymphoma with central nervous system involvement., The Journal of Medical Investigation : JMI, Vol.68, No.1.2, 196-201, 2021. (要約) The prognosis of relapsed or refractory lymphoma with central nervous system (CNS) involvement remains poor because of the lack of anticancer drugs with sufficient CNS penetration. [Case 1] A 65-year-old man was diagnosed with Stage IV mantle cell lymphoma. After two courses of chemotherapy and autologous hematopoietic stem cell (HSC) collection, urinary retention with fever developed. Cerebrospinal fluid analysis revealed leptomeningeal involvement, which was refractory to high-dose methotrexate therapy. Autologous peripheral blood stem cell transplantation (ASCT) was performed, followed by intravenous busulfan (ivBU), cyclophosphamide, and etoposide ; thereafter, no relapse has been detected for over six years. [Case 2] A 40-year-old woman with right lower hemiplegia was diagnosed with primary CNS lymphoma. Although four courses of high-dose methotrexate therapy were administered, the cerebral tumor increased in size. HSCs were collected after methotrexate therapy, and ASCT was performed in addition to conditioning using ivBU, cyclophosphamide, and etoposide, followed by whole-brain and local boost irradiation. She achieved complete remission, but relapsed two years after ASCT. High-dose ivBU-containing conditioning regimens with ASCT may be useful for refractory B-cell lymphoma with CNS involvement. J. Med. Invest. 68 : 196-201, February, 2021. (徳島大学機関リポジトリ) ● Metadata: 116021 (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.68.196 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33994471 ● Search Scopus @ Elsevier (PMID): 33994471 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.196 (徳島大学機関リポジトリ: 116021, DOI: 10.2152/jmi.68.196, PubMed: 33994471)
34.	Yuka Sogawa, Makoto Fukui, Shingen Nakamura, Kimiko Sogabe, Ryohei Sumitani, Masami Yoshioka, Masahiro Abe and Daisuke Hinode : Involvement of oral bacteria and oral immunity as risk factors for chemotherapy- induced fever with neutropenia in patients with hematological cancer, International Journal of Hematology, Vol.112, No.6, 851-859, 2020. (要約) The aim of this study is to investigate the association between chemotherapy-induced fever with neutropenia less than 1500/μL (FwN) and oral bacteria and/or oral immunity in patients with hematological cancer. Thirty-two patients with hematological cancer were enrolled in the study. Secretory immunoglobulin A (sIgA) in saliva and the anaerobic bacteria in tongue coating of each subject were assessed before the first chemotherapy. Eleven subjects had an onset of FwN and 21 subjects did not during the observation periods. It was revealed by the Cox-proportional hazard model analysis that the levels of sIgA were low (HR 0.98, p < 0.05) and the rate of Fusobacterium nucleatum [F. nucleatum count per total bacterial count (%)] was high (HR 1.65, p < 0.05) in patients with FwN onset. Using ROC curve analysis, the optimal cutoff point based on the AUC in the F. nucleatum/sIgA ratio was 0.023, and this model had a 78.4% probability (p < 0.01). The risk of FwN onset was also significantly higher among the group of ≥ 0.023 F. nucleatum/sIgA ratio (HR 66.06, p < 0.01). These results suggest that the rate of F. nucleatum and the levels of sIgA at baseline might be related to FwN onset as risk factors. (キーワード) Adult / Aged / Aged, 80 and over / Antineoplastic Agents / Bacterial Load / Febrile Neutropenia / 女性 (female) / Fusobacterium nucleatum / Hematologic Neoplasms / Humans / Immunoglobulin A, Secretory / 男性 (male) / Middle Aged / Mouth / Risk Factors / Young Adult (徳島大学機関リポジトリ) ● Metadata: 115932 (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s12185-020-02975-x (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32880823 ● Summary page in Scopus @ Elsevier: 2-s2.0-85090162636 (徳島大学機関リポジトリ: 115932, DOI: 10.1007/s12185-020-02975-x, PubMed: 32880823, Elsevier: Scopus)
35.	Shun-Ichi Kimura, Yoshinobu Kanda, Masaki Iino, Takahiro Fukuda, Emiko Sakaida, Tatsuo Oyake, Hiroki Yamaguchi, Shin-Ichiro Fujiwara, Yumi Jo, Akinao Okamoto, Hiroyuki Fujita, Yasushi Takamatsu, Yoshio Saburi, Itaru Matsumura, Jun Yamanouchi, Souichi Shiratori, Moritaka Gotoh, Shingen Nakamura and Kazuo Tamura : Efficacy and safety of micafungin in empiric and D-index-guided early antifungal therapy for febrile neutropenia; A subgroup analysis of the CEDMIC trial., International Journal of Infectious Diseases : IJID, Vol.100, 292-297, 2020. (要約) The efficacy of micafungin in patients undergoing high-risk treatment was not strongly impaired in DET compared to that in EAT. (キーワード) Adult / Aged / Antifungal Agents / Febrile Neutropenia / Female / Humans / Male / Micafungin / Middle Aged / Neutrophils / Treatment Outcome / Young Adult (徳島大学機関リポジトリ) ● Metadata: 116538 (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.ijid.2020.08.081 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32891738 ● Search Scopus @ Elsevier (PMID): 32891738 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijid.2020.08.081 (徳島大学機関リポジトリ: 116538, DOI: 10.1016/j.ijid.2020.08.081, PubMed: 32891738)
36.	Mohannad Ashtar, Hirofumi Tenshin, Jumpei Teramachi, Ariunzaya Bat-Erdene, Masahiro Hiasa, Asuka Oda, Kotaro Tanimoto, Sou Shimizu, Yoshiki Higa, Takeshi Harada, Masahiro Oura, Kimiko Sogabe, Shingen Nakamura, Shiroh Fujii, Ryohei Sumitani, Hirokazu Miki, Kengo Udaka, Mamiko Takahashi, Kumiko Kagawa, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe : The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat., Cancers, Vol.12, No.4, 2020. (要約) Receptor activator of NF-κB ligand (RANKL), a critical mediator of osteoclastogenesis, is upregulated in multiple myeloma (MM). The xanthine oxidase inhibitor febuxostat, clinically used for prevention of tumor lysis syndrome, has been demonstrated to effectively inhibit not only the generation of uric acid but also the formation of reactive oxygen species (ROS). ROS has been demonstrated to mediate RANKL-mediated osteoclastogenesis. In the present study, we therefore explored the role of cancer-treatment-induced ROS in RANKL-mediated osteoclastogenesis and the suppressive effects of febuxostat on ROS generation and osteoclastogenesis. RANKL dose-dependently induced ROS production in RAW264.7 preosteoclastic cells; however, febuxostat inhibited the RANKL-induced ROS production and osteoclast (OC) formation. Interestingly, doxorubicin (Dox) further enhanced RANKL-induced osteoclastogenesis through upregulation of ROS production, which was mostly abolished by addition of febuxostat. Febuxostat also inhibited osteoclastogenesis enhanced in cocultures of bone marrow cells with MM cells. Importantly, febuxostat rather suppressed MM cell viability and did not compromise Dox's anti-MM activity. In addition, febuxostat was able to alleviate pathological osteoclastic activity and bone loss in ovariectomized mice. Collectively, these results suggest that excessive ROS production by aberrant RANKL overexpression and/or anticancer treatment disadvantageously impacts bone, and that febuxostat can prevent the ROS-mediated osteoclastic bone damage. (徳島大学機関リポジトリ) ● Metadata: 115041 (出版サイトへのリンク) ● Publication site (DOI): 10.3390/cancers12040929 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32283857 ● Search Scopus @ Elsevier (PMID): 32283857 ● Search Scopus @ Elsevier (DOI): 10.3390/cancers12040929 (徳島大学機関リポジトリ: 115041, DOI: 10.3390/cancers12040929, PubMed: 32283857)
37.	Kengo Udaka, Shingen Nakamura, Shiroh Fujii, Ryosuke Miyamoto, Naoko Matsui, Shiyori Kawata, Taiki Hori, Junpei Murai, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Mamiko Takahashi, Takeshi Harada, Kumiko Kagawa, Yuishin Izumi, Masahiro Abe and Hirokazu Miki : Successful treatment of progressive multifocal leukoencephalopathy with mirtazapine and mefloquine in refractory myeloma, International Journal of Myeloma, Vol.10, No.1, 8-12, 2020.
38.	Shuji Ozaki, Takeshi Harada, Hikaru Yagi, Etsuko Sekimoto, Hironobu Shibata, Toshio Shigekiyo, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa and Masahiro Abe : Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma, Cancers, Vol.12, No.1, 12, 2019. (要約) We retrospectively analyzed multiple myeloma (MM) patients who underwent autologous stem cell transplantation (ASCT) without maintenance therapy to assess the impact of recovery of normal immunoglobulin (Ig) on clinical outcomes. The recovery of polyclonal Ig was defined as normalization of all values of serum IgG, IgA, and IgM 1 year after ASCT. Among 50 patients, 26 patients showed polyclonal Ig recovery; 14 patients were in ≥complete response (CR) and 12 remained in non-CR after ASCT. The patients with Ig recovery exhibited a significantly better progression-free survival (PFS, median, 46.8 vs 26.7 months, = 0.0071) and overall survival (OS, median, not reached vs 65.3 months, < 0.00001) compared with those without Ig recovery. The survival benefits of Ig recovery were similarly observed in ≥CR patients (median OS, not reached vs 80.5 months, = 0.061) and non-CR patients (median OS, not reached vs 53.2 months, = 0.00016). Multivariate analysis revealed that non-CR and not all Ig recovery were independent prognostic factors for PFS (HR, 4.284, 95%CI (1.868-9.826), = 0.00059; and HR, 2.804, 95%CI (1.334-5.896), = 0.0065, respectively) and also for OS (HR, 8.245, 95%CI (1.528-44.47), = 0.014; and HR, 36.55, 95%CI (3.942-338.8), = 0.0015, respectively). Therefore, in addition to the depth of response, the recovery of polyclonal Ig after ASCT is a useful indicator especially for long-term outcome and might be considered to prevent overtreatment with maintenance therapy in transplanted patients with MM. (徳島大学機関リポジトリ) ● Metadata: 115047 (出版サイトへのリンク) ● Publication site (DOI): 10.3390/cancers12010012 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31861479 ● Summary page in Scopus @ Elsevier: 2-s2.0-85077198248 (徳島大学機関リポジトリ: 115047, DOI: 10.3390/cancers12010012, PubMed: 31861479, Elsevier: Scopus)
39.	Naoto Okada, Masayuki Chuma, Momoyo Azuma, Shingen Nakamura, Hirokazu Miki, Hirofumi Hamano, Mitsuhiro Goda, Kenshi Takechi, Yoshito Zamami, Masahiro Abe and Keisuke Ishizawa : Effect of serum concentration and concomitant drugs on vancomycin-induced acute kidney injury in haematologic patients: a single-centre retrospective study., European Journal of Clinical Pharmacology, Vol.75, No.12, 1695-1704, 2019. (要約) The optimal initial VCM trough concentration was 10-15 mg/L in haematologic patients, considering safety and effectiveness. There were differences in the effect of VCM-induced AKI between nephrotoxic drugs. (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s00228-019-02756-4 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31511938 ● Search Scopus @ Elsevier (PMID): 31511938 ● Search Scopus @ Elsevier (DOI): 10.1007/s00228-019-02756-4 (DOI: 10.1007/s00228-019-02756-4, PubMed: 31511938)
40.	井上雄介, 池亀彰茂, 徳永尚樹, 井上千尋, 中尾隆之, 長井幸二郎, 高橋真美子, 藤井志朗, 中村信元, 安倍正博 : 芽球様の形態を示した肝脾型T細胞リンパ腫の一症例, 日本検査血液学会雑誌, Vol.20, No.2, 231-237, 2019年.
41.	Masami Iwasa, Takeshi Harada, Asuka Oda, Ariunzaya Bat-Erdene, Jumpei Teramachi, Hirofumi Tenshin, Mohannad Ashtar, Masahiro Oura, Kimiko Sogabe, Kengo Udaka, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki and Masahiro Abe : PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ., Oncotarget, Vol.10, No.20, 1903-1917, 2019. (要約) gene silencing abolished the PD-L1 upregulation by panobinostat and IFN-γ in combination, indicating a critical role for STAT1. These results suggest that panobinostat enhances PD-L1 expression by facilitating the IFN-γ-STAT1 pathway in a ligand-dependent manner in MM cells with ambient IFN-γ. PD-L1 upregulation should be taken into account when combining immunotherapies with panobinostat. (徳島大学機関リポジトリ) ● Metadata: 113359 (出版サイトへのリンク) ● Publication site (DOI): 10.18632/oncotarget.26726 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30956773 ● Summary page in Scopus @ Elsevier: 2-s2.0-85062760316 (徳島大学機関リポジトリ: 113359, DOI: 10.18632/oncotarget.26726, PubMed: 30956773, Elsevier: Scopus)
42.	宮上侑子, 中村信元, 大浦雅博, 岡本惠暢, 高橋真美子, 曽我部公子, 岩佐昌美, 原田武志, 藤井志朗, 三木浩和, 賀川久美子, 上原久典, 安倍正博 : 不明熱と著明な高CRP血症で発症したde novo CD20陰性びまん性大細胞型B細胞リンパ腫の1例, 四国医学雑誌, Vol.74, No.5-6, 193-200, 2018年. (要約) A 68-year-old woman presented with sustained fever for more than 1 month and admitted due to hematemesis and systemic edema. Computed tomography scan revealed swelling of the cervical, paraaortic lymph nodes. Blood test results showed severe anemia, elevation of white blood cell count, elevation of liver enzyme and coagulopathy with high C-reactive protein. Biopsy of the right cervical lymph node showed proliferation of abnormal lymphoid cells with necrosis and hemorrhage, which are positive for CD79α, CD30, MUM-1, and bcl-6 and negative for CD20, CD5, CD10, ALK, CD38, CD138, and EBER. Gene rearrangement of immunoglobulin heavy chain was detected in tumor cells. Bone marrow aspiration showed tumor involvement. The patient was diagnosed with de novo CD20-negative diffuse large B-cell lymphoma(DLBCL)stage IV B. Reduced CHOP therapy was performed under artificial respiration due to pulmonary edema and takotsubo cardiomyopathy. Although her general condition and high CRP levels temporarily improved, she died 47 days after admission due to rapid relapse. De novo CD20-negative DLBCL was rare and presented with high CRP levels and rapid progression, and was thought to be clinically different from the existing DLBCL. It is imperative to elucidate molecular pathophysiology and establish new treatment strategy for de novo CD20-negative DLBCL. (キーワード) CD20 / fever of unknown origin / diffuse large B-cell lymphoma / CRP (徳島大学機関リポジトリ) ● Metadata: 112987 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1050583647829887360 (徳島大学機関リポジトリ: 112987, CiNii: 1050583647829887360)
43.	Ariunzaya Bat-Erdene, Shingen Nakamura, Asuka Oda, Masami Iwasa, Jumpei Teramachi, Mohannad Ashtar, Takeshi Harada, Hirokazu Miki, Hirofumi Tenshin, Masahiro Hiasa, Shiroh Fujii, Kimiko Sogabe, Masahiro Oura, Kengo Udaka, Kumiko Kagawa, Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Itsuro Endo and Masahiro Abe : Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA., British Journal of Haematology, 2018. (徳島大学機関リポジトリ) ● Metadata: 113393 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/bjh.15673 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30474853 ● Summary page in Scopus @ Elsevier: 2-s2.0-85057280798 (徳島大学機関リポジトリ: 113393, DOI: 10.1111/bjh.15673, PubMed: 30474853, Elsevier: Scopus)
44.	Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Takeshi Harada, Shingen Nakamura, Ryota Amachi, Hirofumi Tenshin, Masami Iwasa, Shiroh Fujii, Kumiko Kagawa, Hirokazu Miki, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe : Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma., British Journal of Haematology, Vol.180, No.4, 581-585, 2018. (徳島大学機関リポジトリ) ● Metadata: 112935 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/bjh.14388 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27748523 ● Search Scopus @ Elsevier (PMID): 27748523 ● Search Scopus @ Elsevier (DOI): 10.1111/bjh.14388 (徳島大学機関リポジトリ: 112935, DOI: 10.1111/bjh.14388, PubMed: 27748523)
45.	Shingen Nakamura, Momoyo Azuma, Tomoko Maruhashi, Kimiko Sogabe, Ryohei Sumitani, Munenori Uemura, Masami Iwasa, Shiro Fujii, Hirokazu Miki, Kumiko Kagawa, Takashi Hiraga, Noriyasu Kondo, Hiromi Fujita, Fumihiko Mahara and Masahiro Abe : Steroid pulse therapy in patients with encephalopathy associated with severe fever with thrombocytopenia syndrome., Journal of Infection and Chemotherapy, Vol.24, No.5, 389-392, 2018. (要約) Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne infectious disease caused by the SFTS virus (SFTSV). Clinical symptoms of SFTS often involve encephalopathy and other central neurological symptoms, particularly in seriously ill patients; however, pathogenesis of encephalopathy by SFTSV is largely unknown. Herein, we present case reports of three patients with SFTS, complicated by encephalopathy, admitted to Tokushima University hospital: one patient was a 63-year-old man, while the other two were 83- and 86-year-old women. All of them developed disturbance of consciousness around the 7th day post onset of fever. After methylprednisolone pulse therapy of 500 mg/day, all of them recovered without any neurological sequelae. SFTSV genome was not detected in the cerebrospinal fluid of 2 out of the 3 patients that were available for examination. In these patients, disturbance of consciousness seemed to be an indirect effect of the cytokine storm triggered by SFTSV infection. We propose that short-term glucocorticoid therapy might be beneficial in the treatment of encephalopathy during early phase of SFTSV infection. (徳島大学機関リポジトリ) ● Metadata: 113012 (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.jiac.2017.11.004 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29428565 ● Search Scopus @ Elsevier (PMID): 29428565 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jiac.2017.11.004 (徳島大学機関リポジトリ: 113012, DOI: 10.1016/j.jiac.2017.11.004, PubMed: 29428565)
46.	Shiroh Fujii, Shingen Nakamura, Asuka Oda, Hirokazu Miki, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Ariunzaya Bat-Erdene, Yusaku Maeda, Masahiro Oura, Mamiko Takahashi, Masami Iwasa, Itsuro Endo, Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Takeshi Harada, Kumiko Kagawa, Michiyasu Nakao, Shigeki Sano and Masahiro Abe : Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity., British Journal of Haematology, Vol.180, No.2, 246-258, 2018. (要約) Proviral Integrations of Moloney virus 2 (PIM2) is overexpressed in multiple myeloma (MM) cells, and regarded as an important therapeutic target. Here, we aimed to validate the therapeutic efficacy of different types of PIM inhibitors against MM cells for their possible clinical application. Intriguingly, the thiazolidine-2,4-dione-family compounds SMI-16a and SMI-4a reduced PIM2 protein levels and impaired MM cell survival preferentially in acidic conditions, in contrast to other types of PIM inhibitors, including AZD1208, CX-6258 and PIM447. SMI-16a also suppressed the drug efflux function of breast cancer resistance protein, minimized the sizes of side populations and reduced in vitro colony-forming capacity and in vivo tumourigenic activity in MM cells, suggesting impairment of their clonogenic capacity. PIM2 is known to be subject to ubiquitination-independent proteasomal degradation. Consistent with this, the proteasome inhibitors bortezomib and carfilzomib increased PIM2 protein levels in MM cells without affecting its mRNA levels. However, SMI-16a mitigated the PIM2 protein increase and cooperatively enhanced anti-MM effects in combination with carfilzomib. Collectively, the thiazolidine-2,4-dione-family compounds SMI-16a and SMI-4a uniquely reduce PIM2 protein in MM cells, which may contribute to their profound efficacy in addition to their immediate kinase inhibition. Their combination with proteasome inhibitors is envisioned. (キーワード) Animals / Antineoplastic Agents / Cell Line, Tumor / Cell Survival / Cell Transformation, Neoplastic / Disease Models, Animal / Humans / Hydrogen-Ion Concentration / Mice / Multiple Myeloma / Proteasome Inhibitors / Protein-Serine-Threonine Kinases / Proteolysis / Proto-Oncogene Proteins / Thiazolidinediones (徳島大学機関リポジトリ) ● Metadata: 112752 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/bjh.15033 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29327347 ● Summary page in Scopus @ Elsevier: 2-s2.0-85040344893 (徳島大学機関リポジトリ: 112752, DOI: 10.1111/bjh.15033, PubMed: 29327347, Elsevier: Scopus)
47.	山口純代, 中村信元, 住田智志, 前田悠作, 大浦雅博, 高橋真美子, 岩佐昌美, 原田武志, 藤井志朗, 三木浩和, 賀川久美子, 岸潤, 安倍正博 : リウマチ様関節炎に対する免疫抑制療法中に発症した成人T細胞性白血病/リンパ腫の1例, 四国医学雑誌, Vol.73, No.5,6, 301-308, 2017年. (要約) A 64-year-old woman presented with lower leg edema, fever, and bilateral joint pain, involving the wrists, fingers, and knees, in April 201X. Serological test results were negative for rheumatoid factor, antinuclear antibody, and anti-cyclic citrullinated peptide antibody. A diagnosis of remitting seronegative symmetrical synovitis with pitting edema syndrome, a type of seronegative rheumatoid arthritis, was made and prednisolone was administered. The joint pain was refractory to prednisolone therapy. In February, 201X+2, the patient presented with right cervical lymphadenopathy. The CT scan revealed swelling of the cervical, axillary, and inguinal lymph nodes bilaterally and rapidly enlarged. In April, 18F-fluorodeoxyglucose PET/CT scan showed an abnormal collection in the enlarged lymph nodes. The patient subsequently developed hoarseness with dyspnea and attended our department. Blood test results showed high levels of lactate dehydrogenase (547U/L) and soluble interleukin‐2 receptor (34200 IU/L) and were positive for anti-human T-cell leukemia virus type1 (HTLV‐1) antibody. Biopsy of the right cervical lymph node showed proliferation of abnormal lymphoid cells positive for CD3, CD4, and CD25 and negative for CD7. Monoclonal integration of HTLV‐1 proviral DNA was detected in the lymph node. A diagnosis of adult T-cell leukemia/lymphoma (ATLL), lymphoma type was made. The pain involving multiple joints was attributed to HTLV‐1associated arthropathy. Immunosuppressive therapy for HTLV‐1 carrier status may have played a role in the development of ATLL. (キーワード) Adult T-cell leukemia/lymphoma / HTLV-1 / rheumatoid arthritis / immunosuppressive therapy (徳島大学機関リポジトリ) ● Metadata: 112059 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1050020697876757248 (徳島大学機関リポジトリ: 112059, CiNii: 1050020697876757248)
48.	Hirokazu Miki, Shingen Nakamura, Asuka Oda, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Ariunzaya Bat-Erdene, Yusaku Maeda, Masahiro Oura, Mamiko Takahashi, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kiyoe Kurahashi, Sumiko Yoshida, Kumiko Kagawa, Itsuro Endo, Aihara Kenichi, Mariko Ikuo, Kouji Itou, Koichiro Hayashi, Michihiro Nakamura and Masahiro Abe : Effective impairment of myeloma cells and their progenitors by hyperthermia., Oncotarget, Vol.9, No.12, 10307-10316, 2017. (要約) Multiple myeloma (MM) remains incurable, and MM-initiating cells or MM progenitors are considered to contribute to disease relapse through their drug-resistant nature. In order to improve the therapeutic efficacy for MM, we recently developed novel superparamagnetic nanoparticles which selectively accumulate in MM tumors and extirpate them by heat generated with magnetic resonance. We here aimed to clarify the therapeutic effects on MM cells and their progenitors by hyperthermia. Heat treatment at 43°C time-dependently induced MM cell death. The treatment upregulated endoplasmic reticulum (ER) stress mediators, ATF4 and CHOP, while reducing the protein levels of Pim-2, IRF4, c-Myc and Mcl-1. Combination with the proteasome inhibitor bortezomib further enhanced ER stress to potentiate MM cell death. The Pim inhibitor SMI-16a also enhanced the reduction of the Pim-2-driven survival factors, IRF4 and c-Myc, in combination with the heat treatment. The heat treatment almost completely eradicated "side population" fractions in RPMI8226 and KMS-11 cells and suppressed their clonogenic capacity as determined by colony formation and tumorigenic capacity in SCID mice. These results collectively demonstrated that hyperthermia is able to impair clonogenic drug-resistant fractions of MM cells and enhance their susceptibility to chemotherapeutic drugs. (徳島大学機関リポジトリ) ● Metadata: 113059 (出版サイトへのリンク) ● Publication site (DOI): 10.18632/oncotarget.23121 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29535808 ● Summary page in Scopus @ Elsevier: 2-s2.0-85041952629 (徳島大学機関リポジトリ: 113059, DOI: 10.18632/oncotarget.23121, PubMed: 29535808, Elsevier: Scopus)
49.	Hirofumi Tenshin, Jumpei Teramachi, Asuka Oda, Ryota Amachi, Masahiro Hiasa, Ariunzaya Bat-Erdene, Keiichiro Watanabe, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kumiko Kagawa, Kimiko Sogabe, Shingen Nakamura, Hirokazu Miki, Kiyoe Kurahashi, Sumiko Yoshida, Kenichi Aihara, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe : TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects., Blood Advances, Vol.1, No.24, 2124-2137, 2017. (要約) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) agonists induce tumor-specific apoptosis indicating that they may be an attractive therapeutic strategy against cancers, including multiple myeloma (MM). Osteoclastogenesis is highly induced in MM, which in turn enhances MM growth, thereby forming a vicious cycle between MM tumor expansion and bone destruction. However, the effects of TRAIL on MM-enhanced osteoclastogenesis remain largely unknown. Here, we show that TRAIL induced apoptosis in MM cells, but not in osteoclasts (OCs), and that it rather facilitated receptor activator of NF-B ligand-induced osteoclastogenesis along with upregulation of cellular FLICE inhibitory protein (c-FLIP). TRAIL did not induce death-inducing signaling complex formation in OCs, but formed secondary complex (complex II) with the phosphorylation of transforming growth factor -activated kinase-1 (TAK1), and thus activated NF-B signaling. c-FLIP knockdown abolished complex II formation, thus permitting TRAIL induction of OC cell death. The TAK1 inhibitor LLZ1640-2 abrogated the TRAIL-induced c-FLIP upregulation and NF-B activation, and triggered TRAIL-induced caspase-8 activation and cell death in OCs. Interestingly, the TRAIL-induced caspase-8 activation caused enzymatic degradation of the transcription factor Sp1 to noticeably reduce c-FLIP expression, which further sensitized OCs to TRAIL-induced apoptosis. Furthermore, the TAK1 inhibition induced antiosteoclastogenic activity by TRAIL even in cocultures with MM cells while potentiating TRAIL's anti-MM effects. These results demonstrated that osteoclastic lineage cells use TRAIL for their differentiation and activation through tilting caspase-8-dependent apoptosis toward NF-B activation, and that TAK1 inhibition subverts TRAIL-mediated NF-B activation to resume TRAIL-induced apoptosis in OCs while further enhancing MM cell death in combination with TRAIL. (徳島大学機関リポジトリ) ● Metadata: 111724 (出版サイトへのリンク) ● Publication site (DOI): 10.1182/bloodadvances.2017008813 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29296860 ● Search Scopus @ Elsevier (PMID): 29296860 ● Search Scopus @ Elsevier (DOI): 10.1182/bloodadvances.2017008813 (徳島大学機関リポジトリ: 111724, DOI: 10.1182/bloodadvances.2017008813, PubMed: 29296860)
50.	Shingen Nakamura : Multiple myeloma with high adenosine deaminase expression, International Journal of Myeloma, Vol.7, No.1, 1-5, 2017. (徳島大学機関リポジトリ) ● Metadata: 114702 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390292815268483584 (徳島大学機関リポジトリ: 114702, CiNii: 1390292815268483584)
51.	Ariunzaya Bat-Erdene, Hirokazu Miki, Asuko Oda, Shingen Nakamura, Jumpei Teramachi, Ryota Amachi, Hirofumi Tenshin, Masahiro Hiasa, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kimiko Sogabe, Kumiko Kagawa, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara and Masahiro Abe : Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors., Oncotarget, Vol.7, No.48, 79064-79075, 2016. (要約) Panobinostat, a pan-deacetylase inhibitor, synergistically elicits cytotoxic activity against myeloma (MM) cells in combination with the proteasome inhibitor bortezomib. Because precise mechanisms for panobinostat's anti-MM action still remain elusive, we aimed to clarify the mechanisms of anti-MM effects of panobinostat and its synergism with proteasome inhibitors. Although the transcription factor Sp1 was overexpressed in MM cells, the Sp1 inhibitor terameprocol induced MM cell death in parallel with reduction of IRF4 and cMyc. Panobinostat induced activation of caspase-8, which was inversely correlated with reduction of Sp1 protein levels in MM cells. The panobinostat-mediated effects were further potentiated to effectively induce MM cell death in combination with bortezomib or carfilzomib even at suboptimal concentrations as a single agent. Addition of the caspase-8 inhibitor z-IETD-FMK abolished the Sp1 reduction not only by panobinostat alone but also by its combination with bortezomib, suggesting caspase-8-mediated Sp1 degradation. The synergistic Sp1 reduction markedly suppressed Sp1-driven prosurvival factors, IRF4 and cMyc. Besides, the combinatory treatment reduced HDAC1, another Sp1 target, in MM cells, which may potentiate HDAC inhibition. Collectively, caspase-8-mediated post-translational Sp1 degradation appears to be among major mechanisms for synergistic anti-MM effects of panobinostat and proteasome inhibitors in combination. (徳島大学機関リポジトリ) ● Metadata: 109988 (出版サイトへのリンク) ● Publication site (DOI): 10.18632/oncotarget.12594 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27738323 ● Search Scopus @ Elsevier (PMID): 27738323 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.12594 (徳島大学機関リポジトリ: 109988, DOI: 10.18632/oncotarget.12594, PubMed: 27738323)
52.	Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, Takeshi Harada, Asuka Oda, Shingen Nakamura, Derek Hanson, Keiichiro Watanabe, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Masami Iwasa, Itsuro Endo, Takeshi Kondo, Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Yoshiaki Kuroda, Hideaki Horikawa, Eiji Tanaka, Masahiro Abe and Toshio Matsumoto : A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration., Oncotarget, Vol.7, No.43, 70447-70461, 2016. (要約) Myeloma (MM) cells and osteoclasts are mutually interacted to enhance MM growth while creating acidic bone lesions. Here, we explored acid sensing of MM cells and its role in MM cell response to acidic conditions. Acidic conditions activated the PI3K-Akt signaling in MM cells while upregulating the pH sensor transient receptor potential cation channel subfamily V member 1 (TRPV1) in a manner inhibitable by PI3K inhibition. The acid-activated PI3K-Akt signaling facilitated the nuclear localization of the transcription factor Sp1 to trigger the expression of its target genes, including TRPV1 and HDAC1. Consistently, histone deacetylation was enhanced in MM cells in acidic conditions, while repressing a wide variety of genes, including DR4. Indeed, acidic conditions deacetylated histone H3K9 in a DR4 gene promoter and curtailed DR4 expression in MM cells. However, inhibition of HDAC as well as either Sp1 or PI3K was able to restore DR4 expression in MM cells suppressed in acidic conditions. These results collectively demonstrate that acid activates the TRPV1-PI3K-Akt-Sp1 signaling in MM cells while inducing HDAC-mediated gene repression, and suggest that a positive feedback loop between acid sensing and the PI3K-Akt signaling is formed in MM cells, leading to MM cell response to acidic bone lesions. (徳島大学機関リポジトリ) ● Metadata: 113048 (出版サイトへのリンク) ● Publication site (DOI): 10.18632/oncotarget.11927 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27626482 ● Search Scopus @ Elsevier (PMID): 27626482 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.11927 (徳島大学機関リポジトリ: 113048, DOI: 10.18632/oncotarget.11927, PubMed: 27626482)
53.	Takeshi Harada, Hirokazu Miki, Q Cui, A Oda, Ryota Amachi, Jumpei Teramachi, A Bat-Erdene, K Sogabe, M Iwasa, Shiroh Fujii, Shingen Nakamura, Kumiko Kagawa, Sumiko Yoshida, I Endo, Ken-ichi Aihara, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe : Expansion of Th1-like V9V2T cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid., Leukemia, Vol.31, No.1, 258-262, 2016. (出版サイトへのリンク) ● Publication site (DOI): 10.1038/leu.2016.273 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27698446 ● Search Scopus @ Elsevier (PMID): 27698446 ● Search Scopus @ Elsevier (DOI): 10.1038/leu.2016.273 (DOI: 10.1038/leu.2016.273, PubMed: 27698446)
54.	Naoto Okada, Shuji Fushitani, Momoyo Azuma, Shingen Nakamura, Toshimi Nakamura, Kazuhiko Teraoka, Hiroyoshi Watanabe, Masahiro Abe, Kazuyoshi Kawazoe and Keisuke Ishizawa : Clinical evaluation of pharmacist interventions in patients treated with anti-methicillin-resistant Staphylococcus aureus agents in a hematological ward, Biological & Pharmaceutical Bulletin, Vol.39, No.2, 295-300, 2015. (要約) The therapeutic effects of anti-methicillin-resistant Staphylococcus aureus (MRSA) agents, vancomycin (VCM), teicoplanin (TEIC), and arbekacin (ABK), depend on their concentrations in blood. Therefore, therapeutic drug monitoring (TDM) is important when these antibiotics are used. In the hematological ward at Tokushima University Hospital, pharmacists have ordered the measurement of blood VCM, TEIC, and ABK concentrations to promote the use of TDM in accordance with an agreed protocol since 2013. Moreover, the infection control team includes several medical disciplines and has advised on the optimal treatment using VCM, TEIC, and ABK since 2013. This study aimed to investigate the clinical effectiveness of these pharmacist interventions. We retrospectively studied 145 cases in which patients were treated with VCM, TEIC, or ABK between January 2012 and December 2013 in the hematological ward at Tokushima University Hospital. The patients were divided into a control group (71 cases) and an intervention group (74 cases), and their clinical outcomes were compared. The rate of achievement of effective drug concentrations significantly increased in the intervention group (74%), compared to the rate in the control group (55%). Moreover, univariate and multivariate Cox proportional hazard regression revealed that pharmacist intervention and appropriate concentrations of anti-MRSA agents were independent factors associated with reduced hospitalization periods in patients with lymphoma. Our study revealed that proactive pharmacist intervention may improve the therapeutic effect of anti-MRSA agents in hematology ward patients. (出版サイトへのリンク) ● Publication site (DOI): 10.1248/bpb.b15-00774 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26830489 ● Search Scopus @ Elsevier (PMID): 26830489 ● Search Scopus @ Elsevier (DOI): 10.1248/bpb.b15-00774 (DOI: 10.1248/bpb.b15-00774, PubMed: 26830489)
55.	James Derek Hanson, Shingen Nakamura, Ryota Amachi, Masahiro Hiasa, Asuka Oda, Daisuke Tsuji, Kohji Itoh, Takeshi Harada, Kazuki Horikawa, Jumpei Teramachi, Hirokazu Miki, Toshio Matsumoto and Masahiro Abe : Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation., Oncotarget, Vol.6, No.32, 33568-33586, 2015. (要約) Cancer cells robustly expel lactate produced through enhanced glycolysis via monocarboxylate transporters (MCTs) and maintain alkaline intracellular pH. To develop a novel therapeutic strategy against multiple myeloma (MM), which still remains incurable, we explored the impact of perturbing a metabolism via inhibiting MCTs. All MM cells tested constitutively expressed MCT1 and MCT4, and most expressed MCT2. Lactate export was substantially suppressed to induce death along with lowering intracellular pH in MM cells by blockade of all three MCT molecules with -cyano-4-hydroxy cinnamate (CHC) or the MCT1 and MCT2 inhibitor AR-C155858 in combination with MCT4 knockdown, although only partially by knockdown of each MCT. CHC lowered intracellular pH and severely curtailed lactate secretion even when combined with metformin, which further lowered intracellular pH and enhanced cytotoxicity. Interestingly, an ambient acidic pH markedly enhanced CHC-mediated cytotoxicity, suggesting preferential targeting of MM cells in acidic MM bone lesions. Furthermore, treatment with CHC suppressed hexokinase II expression and ATP production to reduce side populations and colony formation. Finally, CHC caused downregulation of homing receptor CXCR4 and abrogated SDF-1-induced migration. Targeting tumor metabolism by MCT blockade therefore may become an effective therapeutic option for drug-resistant MM cells with elevated glycolysis. (徳島大学機関リポジトリ) ● Metadata: 109501 (出版サイトへのリンク) ● Publication site (DOI): 10.18632/oncotarget.5598 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26384349 ● Summary page in Scopus @ Elsevier: 2-s2.0-84946086135 (徳島大学機関リポジトリ: 109501, DOI: 10.18632/oncotarget.5598, PubMed: 26384349, Elsevier: Scopus)
56.	Michiko Yamashita, Yoshiyuki Fujii, Keiji Ozaki, Yoshio Urano, Masami Iwasa, Shingen Nakamura, Shiroh Fujii, Masahiro Abe, Yasuharu Sato and Tadashi Yoshino : Human immunodeficiency virus-positive secondary syphilis mimicking cutaneous T-cell lymphoma., Diagnostic Pathology, Vol.10, 185, 2015. (要約) Malignant syphilis or lues maligna is a severe form of secondary syphilis that was commonly reported in the pre-antibiotic era, and has now reemerged with the advent of the human immunodeficiency virus (HIV) epidemic. However, the characteristic histopathological findings of malignant syphilis remain controversial. The aim of this case report was to clarify the clinical and histopathological findings of HIV-positive malignant secondary syphilis. A Japanese man in his forties complained of fever, skin lesions, headache, and myalgia without lymphadenopathy during the previous 4 weeks. The skin lesions manifested as erythematous, nonhealing, ulcerated papules scattered on his trunk, extremities, palm, and face. Although the skin lesions were suspected to be cutaneous T-cell lymphomas on histological analyses, they lacked T-cell receptor Jγ rearrangement; moreover, immunohistochemical analyses confirmed the presence of spirochetes. The patient was administered antibiotics and anti-retroviral therapy, which dramatically improved the symptoms. On the basis of these observations of the skin lesions, we finally diagnosed the patient with HIV-associated secondary syphilis that mimicked cutaneous T-cell lymphoma. The patient's systemic CD4+ lymphocyte count was very low, and the infiltrate was almost exclusively composed of CD8+ atypical lymphocytes; therefore, the condition was easily misdiagnosed as cutaneous lymphoma. Although the abundance of plasma cells is a good indicator of malignant syphilis on skin histological analyses, in some cases, the plasma cell count may be very low. Therefore, a diagnosis of malignant secondary syphilis should be considered before making a diagnosis of primary cutaneous peripheral T-cell lymphoma or lymphoma associated with HIV infection. (キーワード) AIDS-Related Opportunistic Infections / Anti-Bacterial Agents / Anti-HIV Agents / Biopsy / Coinfection / Diagnosis, Differential / HIV Infections / Humans / 免疫組織化学 (immunohistochemistry) / Lymphoma, T-Cell, Cutaneous / 男性 (male) / Predictive Value of Tests / 皮膚 (skin) / Skin Neoplasms / Syphilis / Syphilis, Cutaneous / Treatment Outcome (出版サイトへのリンク) ● Publication site (DOI): 10.1186/s13000-015-0419-5 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26449225 ● Summary page in Scopus @ Elsevier: 2-s2.0-84943540407 (DOI: 10.1186/s13000-015-0419-5, PubMed: 26449225, Elsevier: Scopus)
57.	Shingen Nakamura, Hirokazu Miki, Asuka Oda, Ryota Amachi, Jumpei Teramachi, Kimiko Sogabe, Hikaru Fujino, Tomoko Maruhashi, Shiroh Fujii, Kumiko Kagawa and Masahiro Abe : Susceptibility to bendamustine considerably varies among myeloma cells, but is enhanced in acidic conditions, International Journal of Myeloma, Vol.6, No.1, 7-11, 2015.
58.	T Watanabe, M Mitsuhashi, M Sagawa, M Ri, K Suzuki, Masahiro Abe, K Ohmachi, Y Nakagawa, Shingen Nakamura, S Iida and M Kizaki : Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma, PLoS ONE, Vol.10, No.6, e0128662, 2015. (要約) To identify predictive biomarkers for clinical responses to bortezomib treatment, 0.06 mL of each whole blood without any cell separation procedures was stimulated ex vivo using five agents, and eight mRNAs were quantified. In six centers, heparinized peripheral blood was prospectively obtained from 80 previously treated or untreated, symptomatic multiple myeloma (MM) patients with measurable levels of M-proteins. The blood sample was procured prior to treatment as well as 2-3 days and 1-3 weeks after the first dose of bortezomib, which was intravenously administered biweekly or weekly, during the first cycle. Six stimulant-mRNA combinations; that is, lipopolysaccharide (LPS)-granulocyte-macrophage colony-stimulating factor (GM-CSF), LPS-CXCL chemokine 10 (CXCL10), LPS-CCL chemokine 4 (CCL4), phytohemagglutinin-CCL4, zymosan A (ZA)-GMCSF and ZA-CCL4 showed significantly higher induction in the complete and very good partial response group than in the stable and progressive disease group, as determined by both parametric (t-test) and non-parametric (unpaired Mann-Whitney test) tests. Moreover, LPS-induced CXCL10 mRNA expression was significantly suppressed 2-3 days after the first dose of bortezomib in all patients, as determined by both parametric (t-test) and non-parametric (paired Wilcoxon test) tests, whereas the complete and very good partial response group showed sustained suppression 1-3 weeks after the first dose. Thus, pretreatment LPS-CXCL10 mRNA and/or the six combinations may serve as potential biomarkers for the response to bortezomib treatment in MM patients. (徳島大学機関リポジトリ) ● Metadata: 114924 (出版サイトへのリンク) ● Publication site (DOI): 10.1371/journal.pone.0128662 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26115406 ● Summary page in Scopus @ Elsevier: 2-s2.0-84938631804 (徳島大学機関リポジトリ: 114924, DOI: 10.1371/journal.pone.0128662, PubMed: 26115406, Elsevier: Scopus)
59.	Hirokazu Miki, Shingen Nakamura, A Oda, R Amachi, Keiichiro Watanabe, D Hanson, Jumpei Teramachi, Masahiro Hiasa, H Yagi, K Sogabe, M Takahashi, T Maruhashi, K Udaka, T Harada, Shiroh Fujii, A Nakano, Kumiko Kagawa, M Ri, S Iida, Shuji Ozaki, T Matsumoto and Masahiro Abe : Induction of endoplasmic reticulum stress by bortezomib sensitizes myeloma cells to DR5-mediated cell death, International Journal of Myeloma, Vol.5, No.1, 1-7, 2015. (要約) <p>TNF-related apoptosis-including ligand/Apo2 (TRAIL)-mediated immunotherapy is an attractive anti-tumor modality with high tumor specificity. In order to improve its therapeutic efficacy, we further need to implement a novel maneuver for sensitization of malignant cells to TRAIL. Bortezomib (BTZ), a novel anti-myeloma (MM) agent, potently induces endoplasmic reticulum (ER) stress to cause apoptosis. Here, we explored the roles of BTZ in the cytotoxicity of anti-TRAIL receptor agonistic antibodies against MM cells with special reference to ER stress. BTZ enhanced the expression of death receptor 5 (DR5) but not DR4 in MM cells at surface protein as well as mRNA levels. However, the DR5 expression was not affected by BTZ without ER stress induction in MM cells with a point mutation in a BTZ-binding proteasome β<sub>5</sub> subunit. Tunicamycin, an ER stress inducer, was able to enhance the DR5 expression even in the BTZ-resistant MM cells, suggesting the role of ER stress in up-regulation of DR5 expression. Interestingly, BTZ facilitated extrinsic caspase-mediated apoptosis by anti-DR5 agonistic antibody in MM cells along with reducing c-FLICE-like interleukin protein, a caspase 8 inhibitor. These results suggest that BTZ enhances DR5 expression and its downstream apoptotic signaling through ER stress to sensitize MM cells to TRAIL-mediated immunotherapy.</p> (キーワード) multiple myeloma / bortezomib / TRAIL / DR5 / ER stress (出版サイトへのリンク) ● Publication site (DOI): 10.57352/ijm.5.1_1 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390292815284471040 ● Search Scopus @ Elsevier (DOI): 10.57352/ijm.5.1_1 (DOI: 10.57352/ijm.5.1_1, CiNii: 1390292815284471040)
60.	賀川久美子, 中村信元, 八木ひかる, 曽我部公子, 髙橋真美子, 丸橋朋子, 宇髙憲吾, 藤井志朗, 三木浩和, 安倍正博 : 同系骨髄移植が著効した最重症再生不良性貧血の1例, 四国医学雑誌, Vol.70, No.3,4, 77-80, 2014年. (要約) Aplastic anemia is a bone marrow failure caused by severely curtailed hematopoietic stem cells (HSCs) and dysregulation of ambient immune cells. Immumo-suppressive conditioning followed by allogeneic HSC transplantation is currently a mainstay in treatment for patients at a younger age or those refractory to conventional immunosuppressive remedies. Syngeneic HSC transplantation appears to be promising, but has been very rarely performed ; therefore, its impact on a long-term outcome as well as the best preparative measures for HSC engraftment and immune amelioration are still largely unknown. Here, we reported a successful and beneficial syngeneic HSC transplantation for a refractory case with very severe aplastic anemia. A 30-year-old female presented high fever after tooth extraction, and was diagnosed with very severe aplastic anemia. Cyclosporine and anti-thymocyte globulin were initiated, but showed no hematological effects. After obtaining an informed consent, she underwent bone marrow transplantation from a genetically identical twin following an non-myeloablative conditioning regimen consisted of cyclophosphamide (750mg/m2, 4 days), fludarabine phosphate (25mg/m2, 4 days). Cyclosporine was given for acute GvHD prophylaxis. Her neutrophils recovered over 500/μl on 12 days after the transplantation, and her blood counts have been maintained in a normal range over 7 years thereafter. Although a fate of HSCs from a genetically identical twin and an immune response of ambient cells in the bone marrow in recipients remains largely unknown, from the present case and previously reported cases, we dare to recommend immunoablative conditioning and acute GvHD prophylaxis in syngeneic HSC transplantation for a refractory case with aplastic anemia for better engraftment and sustained onward recovery of hematopoiesis. (キーワード) aplastic anemia / genetically identical twin / syngeneic hematopoietic stem cell transplantation (徳島大学機関リポジトリ) ● Metadata: 109757 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1050302172854348416 (徳島大学機関リポジトリ: 109757, CiNii: 1050302172854348416)
61.	Masahiro Hiasa, Jumpei Teramachi, A Oda, Ryota Amachi, T Harada, Shingen Nakamura, Hirokazu Miki, Shiroh Fujii, Kumiko Kagawa, Keiichiro Watanabe, Itsuro Endo, Y Kuroda, T Yoneda, Daisuke Tsuji, Michiyasu Nakao, Eiji Tanaka, Kenichi Hamada, Shigeki Sano, Kouji Itou, Toshio Matsumoto and Masahiro Abe : Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma., Leukemia, 2014. (要約) Pim-2 kinase is overexpressed in multiple myeloma (MM) cells to enhance their growth and survival, and regarded as a novel therapeutic target in MM. However, the impact of Pim-2 inhibition on bone disease in MM remains unknown. We demonstrated here that Pim-2 expression was also upregulated in bone marrow stromal cells and MC3T3-E1 preosteoblastic cells in the presence of cytokines known as the inhibitors of osteoblastogenesis in MM, including interleukin-3 (IL-3), IL-7, tumor necrosis factor-, transforming growth factor- (TGF-) and activin A, as well as MM cell conditioned media. The enforced expression of Pim-2 abrogated in vitro osteoblastogenesis by BMP-2, which suggested Pim-2 as a negative regulator for osteoblastogenesis. Treatment with Pim-2 short-interference RNA as well as the Pim inhibitor SMI-16a successfully restored osteoblastogenesis suppressed by all the above inhibitory factors and MM cells. The SMI-16a treatment potentiated BMP-2-mediated anabolic signaling while suppressing TGF- signaling. Furthermore, treatment with the newly synthesized thiazolidine-2,4-dione congener, 12a-OH, as well as its prototypic SMI-16a effectively prevented bone destruction while suppressing MM tumor growth in MM animal models. Thus, Pim-2 may have a pivotal role in tumor progression and bone loss in MM, and Pim-2 inhibition may become an important therapeutic strategy to target the MM cell-bone marrow interaction.Leukemia advance online publication, 30 May 2014; doi:10.1038/leu.2014.147. (出版サイトへのリンク) ● Publication site (DOI): 10.1038/leu.2014.147 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24787487 ● Search Scopus @ Elsevier (PMID): 24787487 ● Search Scopus @ Elsevier (DOI): 10.1038/leu.2014.147 (DOI: 10.1038/leu.2014.147, PubMed: 24787487)
62.	Takeshi Harada, Shuji Ozaki, Asuka Oda, Daisuke Tsuji, Akishige Ikegame, Masami Iwasa, Kengo Udaka, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Yoshiaki Kuroda, Shigeto Kawai, Kouji Itou, Hisafumi Yamada-Okabe, Toshio Matsumoto and Masahiro Abe : Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors, PLoS ONE, Vol.8, No.12, e83905, 2013. (要約) The immunomodulatory drug lenalidomide (Len) has drawn attention to potentiate antibody-dependent cellular cytotoxicity (ADCC)-mediated immunotherapies. We developed the defucosylated version (YB-AHM) of humanized monoclonal antibody against HM1.24 (CD317) overexpressed in multiple myeloma (MM) cells. In this study, we evaluated ADCC by YB-AHM and Len in combination against MM cells and their progenitors. YB-AHM was able to selectively kill via ADCC MM cells in bone marrow samples from patients with MM with low effector/target ratios, which was further enhanced by treatment with Len. Interestingly, Len also up-regulated HM1.24 expression on MM cells in an effector-dependent manner. HM1.24 was found to be highly expressed in a drug-resistant clonogenic "side population" in MM cells; and this combinatory treatment successfully reduced SP fractions in RPMI 8226 and KMS-11 cells in the presence of effector cells, and suppressed a clonogenic potential of MM cells in colony-forming assays. Collectively, the present study suggests that YB-AHM and Len in combination may become an effective therapeutic strategy in MM, warranting further study to target drug-resistant MM clonogenic cells. (キーワード) Aged / Aged, 80 and over / Antibodies, Monoclonal, Humanized / Antibody-Dependent Cell Cytotoxicity / Antigens, CD / Antineoplastic Combined Chemotherapy Protocols / Cell Line, Tumor / Drug Synergism / Female / GPI-Linked Proteins / Glycosylation / Humans / 免疫療法 (immunotherapy) / Lenalidomide / Male / Middle Aged / Multiple Myeloma / Neoplastic Stem Cells / Side-Population Cells / Thalidomide / Up-Regulation (徳島大学機関リポジトリ) ● Metadata: 106068 (出版サイトへのリンク) ● Publication site (DOI): 10.1371/journal.pone.0083905 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24386306 ● Summary page in Scopus @ Elsevier: 2-s2.0-84891280322 (徳島大学機関リポジトリ: 106068, DOI: 10.1371/journal.pone.0083905, PubMed: 24386306, Elsevier: Scopus)
63.	Shingen Nakamura, Hirokazu Miki, Shinsuke Kido, Ayako Nakano, Masahiro Hiasa, Asuka Oda, Hiroe Amou, Keiichiro Watanabe, Takeshi Harada, Shiroh Fujii, Kyoko Takeuchi, Kumiko Kagawa, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe : Activating transcription factor 4, an ER stress mediator, is required for, but exce ssive ER stress suppresses osteoblastogenesis by bortezomib., International Journal of Hematology, Vol.98, No.1, 66-73, 2013. (要約) Endoplasmic reticulum (ER) stress is induced in matrix-producing osteoblasts and plays an essential role in osteoblastogenesis. Although the bone anabolic activity of proteasome inhibitors has been demonstrated, the roles of ER stress induced by proteasome inhibition in osteoblastogenesis remain largely unknown. Here we show that bortezomib translationally increases protein levels of activating transcription factor 4 (ATF4), a downstream mediator of ER stress, in bone marrow stromal cells and MC3T3-E1 preosteoblastic cells. The suppression of ATF4 expression by siRNA abrogated osteocalcin expression and mineralized nodule formation by MC3T3-E1 cells induced by bortezomib, indicating a critical role for ATF4 in bortezomib-mediated osteoblastogenesis. However, bortezomib at 20 nM or higher abolished the mineralized nodule formation along with reductions in the expression of osteoblastogenesis mediators β-catenin and Osterix. Furthermore, at 50 nM, bortezomib induced the expression of C/EBP homologous protein (CHOP), suggesting activation of the ATF4-CHOP pro-apoptotic pathway. These results suggest that a low dose of bortezomib induces osteogenic activity, but that, in contrast, excessive ER stress caused by bortezomib at higher doses hampers osteoblastogenesis. Therefore, dosing schedules for proteasome inhibitors warrant further study to maximize anabolic actions without compromising anti-MM activity in patients with multiple myeloma (MM). (キーワード) 3T3 Cells / Activating Transcription Factor 4 / Animals / Antineoplastic Agents / Biological Markers / Bone Marrow Cells / Boronic Acids / Calcification, Physiologic / Cells, Cultured / Endoplasmic Reticulum Stress / Gene Expression Regulation / Gene Silencing / Humans / Mice / Multiple Myeloma / Neoplasm Proteins / Osteoblasts / Osteocalcin / Osteogenesis / Proteasome Inhibitors / Pyrazines / RNA, Small Interfering / Stromal Cells (徳島大学機関リポジトリ) ● Metadata: 105938 (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s12185-013-1367-z (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23708974 ● Summary page in Scopus @ Elsevier: 2-s2.0-84880304849 (徳島大学機関リポジトリ: 105938, DOI: 10.1007/s12185-013-1367-z, PubMed: 23708974, Elsevier: Scopus)
64.	藤岡啓介, 西條敦郎, 豊田優子, 柿内聡司, 埴淵昌毅, 吾妻雅彦, 竹内恭子, 藤井志朗, 中村信元, 宇高憲吾, 賀川久美子, 安倍正博, 水谷友哉, 西岡安彦 : 皮膚ランダム生検が診断に有用であった血管内リンパ腫の一例, 四国医学雑誌, Vol.67, No.5,6, 257-262, 2011年. (要約) A62‐year‐old woman was referred to our hospital for further examination of fever of unknownorigin, splenomegaly and pancytopenia. On admission, she had persistent fever and psychologicalsymptoms. Blood examination showed pancytopenia and elevated level of LDH, soluble IL‐2receptorand ferritin. Computed tomography showed multiple low density areas in the spleen, but no systemiclymphadenopathy. In magnetic resonance imaging of the pons, a low and high intensity area onT1‐and T2‐weighted image, respectively, was detected. Taken together these findings, she wassuspected to have hepatosplentic T-cell lymphoma or intravascular large B-cell lymphoma. To makea definite diagnosis, random skin biopsy was performed. Immunohistochemical stainings revealedthe massive infiltration of CD20‐and CD79α‐positive large lymphoid cells inside the vessels, whichyielded the diagnosis of intravascular large B-cell lymphoma. (キーワード) fever of unknown origin / intravascular large B-cell lymphoma / random skin biopsy (徳島大学機関リポジトリ) ● Metadata: 97858 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1050020697877915520 (徳島大学機関リポジトリ: 97858, CiNii: 1050020697877915520)
65.	Hirokazu Miki, Shingen Nakamura, Shuji Ozaki, A Oda, H Amou, Akishige Ikegame, Keiichiro Watanabe, Masahiro Hiasa, Q Cui, T Harada, Shiroh Fujii, A Nakano, Kumiko Kagawa, Kyoko Takeuchi, Ken-ichiro Yata, A Sakai, Masahiro Abe and Toshio Matsumoto : KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts., British Journal of Haematology, Vol.155, No.3, 328-339, 2011. (要約) The spicamycin analogue KRN5500 alters glycoprotein processing and induces damage in the endoplasmic reticulum (ER)-Golgi apparatus in cancer cells. In the present study, we explored the cytotoxic effects of KRN5500 on multiple myeloma (MM) cells and the bone marrow microenvironment with special reference to ER stress. Cell proliferation assay showed that KRN5500 induced G1 arrest and apoptosis in MM cells in a time- and dose-dependent manner. KRN5500 enhanced ER stress independently of caspase activation in MM cells. This cell death was observed even in the presence of bone marrow stroma cells or osteoclasts. Notably, KRN5500 induced cell death also in osteoclasts. In vivo effects of KRN5500 were evaluated using two xenograft models established in severe combined immunodeficient (SCID) mice by either subcutaneous injection of RPMI 8226 cells or intra-bone injection of INA-6 cells to subcutaneously implanted rabbit bones (SCID-rab model). KRN5500 significantly inhibited tumour growth in both animal models, and decreased the number of osteoclasts, which resulted in prevention of bone destruction in the SCID-rab model. These results suggest that KRN5500 exerts anti-MM effects through impairing both MM cells and osteoclasts. Therefore, this unique mechanism of KRN5500 might be a useful therapeutic option in patients with MM. (キーワード) Animals / Apoptosis / Bone Marrow Cells / Caspases / Cell Line, Tumor / Cell Proliferation / Dose-Response Relationship, Drug / Female / G1 Phase / Humans / Mice / Mice, SCID / Multiple Myeloma / Osteoclasts / Purine Nucleosides / Rabbits / Random Allocation / Stromal Cells / Tumor Microenvironment / Xenograft Model Antitumor Assays (出版サイトへのリンク) ● Publication site (DOI): 10.1111/j.1365-2141.2011.08844.x (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21902681 ● Search Scopus @ Elsevier (PMID): 21902681 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1365-2141.2011.08844.x (DOI: 10.1111/j.1365-2141.2011.08844.x, PubMed: 21902681)
66.	Qu Cui, Hironobu Shibata, Asuka Oda, Hiroe Amou, Ayako Nakano, Kenichiro Yata, Masahiro Hiasa, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Takeshi Harada, Shiroh Fujii, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe : Targeting myeloma-osteoclast interaction with V9V2 T cells., International Journal of Hematology, Vol.94, No.1, 63-70, 2011. (要約) Multiple myeloma (MM) cells stimulate osteoclastogenesis, and osteoclasts (OCs) in turn enhance MM growth and drug resistance, resulting in a vicious cycle. V9V2 T cells exert potent anti-tumor effects, making T cell-based immunotherapies using these cells attractive candidates for currently incurable malignancies, such as MM. However, the impact of such treatments on the MM-OC interaction is largely unknown. We demonstrate here that V9V2 T cells expanded by zoledronic acid and IL-2 exerted potent cytotoxic effects on both MM cells and OCs, even in coculture settings, but showed no such effect on bone marrow stromal cells. V9V2 T cells marginally affected colony formation from normal hematopoietic progenitors, and furthermore migrated toward osteopontin and MIP-1, factors produced by the MM-OC interaction. These results suggest that V9V2 T cells expanded by zoledronic acid and IL-2 are able to migrate to MM bone lesions and preferentially target OCs as well as MM cells, thereby inhibiting both tumor expansion and bone destruction. (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s12185-011-0885-9 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21698356 ● Search Scopus @ Elsevier (PMID): 21698356 ● Search Scopus @ Elsevier (DOI): 10.1007/s12185-011-0885-9 (DOI: 10.1007/s12185-011-0885-9, PubMed: 21698356)
67.	中村信元, 矢田健一郎, 神野雅, 原田武志, 藤井志朗, 三木浩和, 中野綾子, 賀川久美子, 竹内恭子, 尾崎修治, 安倍正博, 松本俊夫 : ボルテゾミブ療法後に播種性接合菌症を合併した多発性骨髄腫, 臨床血液, Vol.51, No.8, 690-695, 2010年. (要約) 67歳男性，背部痛を契機に2001年10月に多発性骨髄腫IgA-<i>λ</i> stage IIIAと診断された．VAD療法5コース後の2003年3月に自家末梢血幹細胞移植併用大量化学療法を行うも再発した．以後，サリドマイド療法などを行うも再燃し，2007年6月入院した．入院後のボルテゾミブ(Bor)療法で，2度の腫瘍崩壊症候群をきたした．その後のCTで右肺上葉，膵尾部，脾臓の腫瘤が急速に出現し，ミカファンギンやボリコナゾールを投与するも，入院85日後に死亡した．剖検で，肺，脾臓に多発性の真菌塊と出血性梗塞が認められ，僧帽弁には真菌塊の疣贅を認め，組織学的に播種性接合菌症と診断した．Bor療法後の腫瘍崩壊によるアシドーシスや，コントロール不良の糖尿病，輸血による鉄過剰，抗真菌薬投与中のブレークスルー感染症などが発症の誘因と考えられた． (キーワード) Zygomycosis / Multiple myeloma / Bortezomib / Tumor lysis syndrome (出版サイトへのリンク) ● Publication site (DOI): 10.11406/rinketsu.51.690 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20805677 ● CiNii @ 国立情報学研究所 (CRID): 1390001205037088512 ● Summary page in Scopus @ Elsevier: 2-s2.0-78349258607 (DOI: 10.11406/rinketsu.51.690, PubMed: 20805677, CiNii: 1390001205037088512, Elsevier: Scopus)
68.	中村信元, Shigeaki Kimura, Masahiro Kashima, Kana Shichijo, 吉田守美子, Eiji Harada, 松下隆哉, Yasutami Tamaki, Noriaki Horiuchi, Toshiaki Takeichi, Hiroshi Fujimoto, Kazuhiko Masuda, Naohito Iwasaka, Sadao Shinomiya : [A case of peritonitis carcinomatosa from goblet cell carcinoid of the appendix treated by intraperitoneal paclitaxel and systemic S-1 chemotherapy]., 癌と化学療法, Vol.35, No.13, 2425-2428, 2008年. (要約) Goblet cell carcinoid of the appendix is a rare neoplasm and clinically tends to take a malignant course. Most cases are young and early stage, and the surgical strategy is available. But appropriate chemotherapy for inoperable cases with peritoneal dissemination is not established. A 77-year-old woman with a past history of appendectomy was admitted to our hospital complaining of abdominal fullness. Abdominal computed tomography showed massive ascites and slight contrast enhancement of appendix. A tumor was found by colonoscopic examination at the orifice of vermiform and was diagnosed pathologically as goblet cell carcinoid of the appendix. Laparoscopy showed multiple peritoneal dissemination. We performed intraperitoneal paclitaxel(PTX)administration at 70 mg/m(2) week without any resection of the tumor. Ascites were reduced immediately, but drug-induced interstitial pneumonia occurred due to PTX. After steroid therapy, we switched to systemic S-1 therapy. For about one year, her tumor was controlled but became worse thirteen months after diagnosis and died. It is thought that intraabdominal paclitaxel administration and systemic S-1 therapy can be one of appropriate forms of chemotherapy for inoperable peritoneal carcinomatosis from goblet cell carcinoid of appendix. (キーワード) Aged / Antineoplastic Combined Chemotherapy Protocols / Carcinoid Tumor / Colonic Neoplasms / Colonoscopy / Drug Combinations / Female / Humans / Injections, Intraperitoneal / Oxonic Acid / Paclitaxel / Peritonitis / Tegafur / Tomography, X-Ray Computed / Treatment Failure (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19098416 ● Search Scopus @ Elsevier (PMID): 19098416 (PubMed: 19098416)
69.	中村信元, Noriaki Horiuchi, Daisuke Katsura, Kana Shichijo, 吉田守美子, Eiji Harada, 松下隆哉, Yasuyuki Matsuzaki, Yasutami Tamaki, Shigeaki Kimura, Toshiaki Takeichi, Hiroshi Fujimoto, Kazuhiko Masuda, Naohito Iwasaka, Sadao Shinomiya : [A long-surviving patient with lung pleomorphic carcinoma treated with postoperative carboplatin and paclitaxel combination chemotherapy]., 癌と化学療法, Vol.35, No.6, 965-968, 2008年. (要約) We presented the case of a 46-year-old man with no medical or family history but with a history of smoking 3 packs of cigarettes per day for the past 25 years. He was admitted to our hospital due to hemoptysis. Chest computed tomography revealed a tumor of right upper lung and interstitial pneumonia in the surrounding lung parenchyma. He was operated upon and diagnosed with stage IIB pleomorphic carcinoma of the lung with invasion of the chest wall. He underwent three courses of postoperative carboplatin (CBDCA) (area under the curve 5 on day 1, every 3 weeks and paclitaxel(PTX) (200 mg/m(2); day 1, every 3 weeks) combination chemotherapy. No recurrence was observed for a period of 760 days after the operation. According to previous reports, lung pleomorphic carcinoma is aggressive and has a poor prognosis. Further, the significance of chemotherapy in the management of this disease has not been established. Postoperative combination chemotherapy of CBDCA and PTX may result in a good prognosis for this disease. (キーワード) Antineoplastic Combined Chemotherapy Protocols / Carboplatin / Humans / Lung Neoplasms / Male / Middle Aged / Paclitaxel / Time Factors / Tomography, X-Ray Computed (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 18633226 ● Summary page in Scopus @ Elsevier: 2-s2.0-48249146275 (PubMed: 18633226, Elsevier: Scopus)

学術論文(紀要・その他):

1.	中村信元, 安倍正博, 松本俊夫 : Part7. 2. 新規治療薬の開発と臨床応用の可能性を探る (抗RANKL抗体などを中心に). がん骨転移治療ビスフォスフォネート治療によるBone Management, 先端医学者高橋俊二編集, 206-214, 2012年.

学術レター:

1.	Yusaku Maeda, Shoichiro Takao, Shiori Morita, Shin Kondo, Michiko Yamashita, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Mamiko Takahashi, Shiroh Fujii, Takeshi Harada, Hirokazu Miki, Masahiro Abe and Shingen Nakamura : Quality of skeletal muscles during allogeneic stem-cell transplantation: a pilot study, BMJ Supportive & Palliative Care, 2024. (出版サイトへのリンク) ● Publication site (DOI): 10.1136/spcare-2024-005070 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1136/spcare-2024-005070 (DOI: 10.1136/spcare-2024-005070)

総説・解説:

1.	中村信元, 三木浩和, 安倍正博 : 【最新の骨粗鬆症学(第2版)-骨粗鬆症学の最新知見-】続発性骨粗鬆症の診断と治療抗悪性腫瘍薬に伴う骨粗鬆症, 日本臨床, Vol.81, 580-584, 2023年1月. (キーワード) Cyclophosphamide(毒性・副作用) Doxorubicin(毒性・副作用) Ifosfamide(毒性・副作用) 性腺刺激ホルモン放出ホルモン(毒性・副作用,拮抗物質・阻害物質) Methotrexate(毒性・副作用) 抗腫瘍剤(毒性・副作用) 骨粗鬆症(化学的誘発,治療) アルゴリズム Estrogen Receptor Modulators(毒性・副作用) Aromatase Inhibitors(毒性・副作用) ヒト
2.	中村信元, 三木浩和, 安倍正博 : 【最新の骨粗鬆症学(第2版)-骨粗鬆症学の最新知見-】続発性骨粗鬆症の診断と治療抗悪性腫瘍薬に伴う骨粗鬆症(解説), 日本臨床(0047-1852)81巻増刊1 最新の骨粗鬆症学 Page580-584(2023.01), 2023年.
3.	中村信元, 三木浩和, 安倍正博 : 【骨髄腫と類縁疾患-全身をみわたす診断・治療】Overview 多発性骨髄腫の発症・進展機序, 臨床雑誌内科, Vol.130, No.4, 691-694, 2022年10月. (要約) <文献概要>▼多発性骨髄腫(MM)はゲノム不安定性や遺伝子プロモーターのメチル化などのepigeneticな制御の異常に加え多段階の分子遺伝学的異常により,意義不明の単クローン性ガンマグロブリン血症(MGUS)を経て発症・進展する.▼MMの発症原因は不明であるが,疫学調査により性差,地域差,人種差,遺伝学的要因,被曝歴,年齢との関連が示唆されている.▼全ゲノム解析やマウスモデル,腸内細菌叢の解析などからMMのさまざまな発症機序が推測されている. (キーワード) myc遺伝子 / 骨髄腫-多発性(病理学,遺伝学) / 疾患モデル(動物) / 人種 / 性因子 / 分子生物学 (molecular biology) / 放射線障害 (radiation injury) / 有病率 / DNAメチル化 / 単クローン性免疫グロブリン血症-良性(病理学,遺伝学) / ゲノム不安定性 / 消化管微生物叢 / 全ゲノム配列分析 / ヒト (Homo sapiens) / マウス / 動物 (animal) (出版サイトへのリンク) ● Publication site (DOI): 10.15106/j_naika130_691 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390293412208923264 ● Search Scopus @ Elsevier (DOI): 10.15106/j_naika130_691 (DOI: 10.15106/j_naika130_691, CiNii: 1390293412208923264)
4.	中村信元, 三木浩和, 安倍正博 : 【腎臓症候群(第3版)-その他の腎臓疾患を含めて-】各種病態にみられる腎障害造血器疾患多発性骨髄腫, 日本臨牀, 124-130, 2022年10月.
5.	中村信元, 安倍正博 : 【骨粗鬆症最新の知見に基づいた治療薬の考え方・使い方】薬剤性骨粗鬆症に対するマネジメントの勘所がん治療に伴う骨粗鬆症, 薬局, Vol.71, No.11, 3313-3321, 2020年10月. (要約) <Key Points>◎がん治療およびがん治療の支持療法に使用する多くの薬剤が直接または間接的に骨吸収を亢進し骨喪失を来す．◎特に内分泌療法や造血幹細胞移植などのがん治療では急速に骨喪失がもたらされる．◎がん治療に伴う骨粗鬆症はQOLの低下や予後の悪化を来す．◎がんの治療と並行しがん治療に伴う骨粗鬆症に対する適切なスクリーニングと予防および治療を行う．(著者抄録) (キーワード) コロナウイルス感染症 Diphosphonates(治療的利用) Vitamin D(治療的利用) 胃切除(有害作用) 運動療法危険因子抗腫瘍剤(毒性・副作用,治療的利用) 骨粗鬆症(薬物療法,予防,病因) 腫瘍(薬物療法,放射線療法) 食事療法食品中のカルシウム(治療的利用) 肺炎-ウイルス性放射線療法(有害作用) 早期診断 Denosumab(治療的利用) 疾病の流行 COVID-19 ヒト
6.	中村信元, 安倍正博 : 骨髄腫骨病変の治療, 血液内科, Vol.69, No.4, 525-533, 2014年10月.
7.	中村信元, 安倍正博 : 【続発性骨粗鬆症-診断と対策-】移植医療と骨粗鬆症, THE BONE, Vol.27, No.2, 187-192, 2013年5月. (要約) 移植医療によって臓器不全の予後は飛躍的に向上しつつあるが，その一方で移植後の合併症の予防，対策の重要性が増している．骨粗鬆症とそれによる骨折は，移植医療における頻度の高い合併症であるが，その実態の解析は十分ではない．移植前の患者個々の背景因子や原疾患の病態，治療に伴う骨障害に加え，移植医療に伴うカルシニューリン阻害薬，ステロイドなどの免疫抑制薬の長期投与など，種々の要因が影響し，移植後骨粗鬆症が発症する．ビスフォスフォネートやビタミンDなどを早期から投与することにより，骨折を防ぎ移植後のQoLを維持することが重要である．(著者抄録) (キーワード) Diphosphonates(治療的利用) / Vitamin D(治療的利用) / 抗腫瘍剤(毒性・副作用) / 骨粗鬆症(病因,予防) / 術後合併症 / 臓器移植(有害作用) / 診療ガイドライン / 大量薬物療法(有害作用) / Calcineurin(類似体・誘導体) / ヒト (Homo sapiens)
8.	中村信元, 安倍正博 : 骨病変/局所病変の管理 (特集多発性骨髄腫診療の新時代を迎えて--診断と治療に吹き込む「新しい風」) -- (多発性骨髄腫の合併症の管理), 内科, Vol.108, No.2, 274-281, 2011年8月. (要約) 骨髄腫骨病変は，患者のQOLを大幅に低下させるだけでなく，放置すれば高カルシウム血症や脊髄圧迫などをきたし予後を悪化させる．・全身の骨単純X線写真(skeletal survey)で骨病変を評価する．MRIやPET/CTは病変の検出感度が高いため，これらを組み入れた評価が有用である．・骨病変の治療は，抗腫瘍療法が基本であるが，補助療法としてビスホスホネートの点滴投与を反復する．顎骨壊死や腎障害に対する予防策を行う．また，局所の疼痛に対し放射線照射や椎体形成術などが有用である．・高カルシウム血症は，進行例に出現する緊急性を要する病態である．初期には特徴的な症状がなく消化器症状や脱水症状からはじまり，腎不全や意識障害をきたす．(著者抄録) (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390001288080663552 (CiNii: 1390001288080663552)

国際会議:

1.	Shingen Nakamura, Yusaku Maeda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Hikaru Yagi, Shiro Fujii, Takeshi Harada and Hirokazu Miki : False-positive aspergillus galactomannan test in multiple myeloma, ID week 2024, Oct. 2024.
2.	Yosuke Kaneko, Saya Yasui, Minae Hosoi, Akihiro Tani, Hiroki Yamagami, Hiroyasu Mori, Tomoyo Hara, Yukari Mitsui, Kiyoe Kurahashi, Sumiko Yoshida, Shingen Nakamura, Akio Kuroda, Toshiki Otoda, Tomoyuki Yuasa, Itsuro Endo, Takeshi Soeki, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Dehydroepiandrosterone sulfate and skeletal muscle disorders in patients with type 2 diabetes, IDF-WPR Congress 2023/15th Scientific Meeting of AASD, Tokyo, Jul. 2023.
3.	Seijiro Tsuji, Kensuke Mori, Yosuke Kaneko, Saki Kawata, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa and Ken-ichi Aihara : Association between serum dehydroepiandrosterone sulfate levels and annual eGFR changes in people with type 2 diabetes, IDF-WPR Congress 2023/15th Scientific Meeting of AASD, Jul. 2023.
4.	Minae Hosoki, Hiroki Yamagami, Taiki Hori, Saya Yasui, Tomoyo Hara, Kiyoe Kurahashi, Sumiko Yoshida, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Itsuro Endo, Masahiro Abe and Ken-ichi Aihara : Pharmaceutical Influences on In-hospital Death in Patients with and Those without Diabetes at a Japanese General Hospital, The 29th Scientific Meeting of the International Society of Hypertension, Oct. 2022.
5.	Shiho Masuda, Tomoyo Hara, Hiroki Yamagami, Mitsui Yukari, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Shingen Nakamura, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Evaluation of Vascular Function for Prediction of Renal Prognosis in Japanese Patients with Lifestyle-Related Diseases, The 29th Scientific Meeting of the International Society of Hypertension, Oct. 2022.
6.	Takeshi Harada, Asuka Oda, Yosuke Matsushita, Ryohei Sumitani, Yusuke Inoue, Tomoyo Hara, Masahiro Oura, Kimiko Sogabe, Tomoko Maruhashi, Mamiko Takahashi, Kiyoe Kurahashi, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Masahiro Hiasa, Jumpei Teramachi, Toyomasa Katagiri and Masahiro Abe : ADAR1-dsRNA metabolism in myeloma cells with 1q amplification: a novel therapeutic target, 19th International Myeloma Society Annual Meeting, Aug. 2022.
7.	Hiroki Yamagami, Yasui Saya, Hosoki Minae, Hori Taiki, Tomoyo Hara, Kiyoe Kurahashi, Sumiko Yoshida, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Itsuro Endo, Masahiro Abe and Ken-ichi Aihara : Skin autofluorescence is associated with tubular injury represented by urinary excretion of liver-type fatty acid-binding protein in patients with diabetes, American Diabetes Association 82nd Scientific Sessions, Jun. 2022.
8.	Ken-ichi Aihara, Yamagami Hiroki, Yasui Saya, Hosoki Minae, Hori Taiki, Shingen Nakamura, Toshiki Otoda and Tomoyuki Yuasa : Clinical Significance of Dehydroepiandrosterone Sulfate in Carotid Atherosclerosis and Nonalcoholic Fatty Liver Disease, ESMED Congress 2021, Nov. 2021.
9.	Takeshi Harada, Yusuke Inoue, Hirofumi Tenshin, Asuka Oda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe : Novel strategy of elotuzumab and zoledronic acid with Th1-like T cells against myeloma, 18th International Myeloma Workshop, Wien, Sep. 2021.
10.	Takeshi Harada, Yusuke Inoue, Hirofumi Tenshin, Asuka Oda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe : Induction of elotuzumabs ADCC activity by Th1-like T cells towards osteoclasts as well as myeloma cells, EHA2021 Virtual Congress, Jun. 2021.
11.	Hirokazu Miki, Shingen Nakamura, Masafumi Nakamura, Makiko Mizuguchi, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Mamiko Takahasi, Tomoko Maruhashi, Takeshi Harada, Shiro Fujii, Kumiko Kagawa, Hirofumi Hamano, Masateru Kondou, Naoto Okada, Yoshimi Bando, Itsuro Endo and Masahiro Abe : The importance of retaining physical functions to prevent skeletal-related events in multiple myeloma patients with bone disease., The 48th annual meeting of European Calcified Tissue Society (ECTS), Online, May 2021.
12.	Yuka Sogawa, Makoto Fukui, Shingen Nakamura, Kimiko Sogabe, Ryohei Sumitani, Masami Yoshioka, Masahiro Abe and Daisuke Hinode : Risk factors for chemotherapy-induced febrile neutropenia in hematological cancer patients, 106th Annual Meeting of American Academy of Periodontology, Honolulu, Nov. 2020. (要約) 1
13.	Takeshi Harada, Asuka Oda, Hiroto Ohguchi, Yohann Grondin, Hirofumi Tenshin, Masahiro Hiasa, Jumpei Teramachi, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Teru Hideshima, Kenneth C. Anderson and Masahiro Abe : Novel therapeutic rationale for targeting HDAC1 and PIM2 in multiple myeloma, 61th ASH Annual Meeting & Exposition, Orlando, Dec. 2019. (出版サイトへのリンク) ● Publication site (DOI): 10.1182/blood-2019-127679 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1182/blood-2019-127679 (DOI: 10.1182/blood-2019-127679)
14.	Takeshi Harada, Asuka Oda, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Teru Hideshima, C. Kenneth Anderson and Masahiro Abe : Targeting myeloma metabolisms regulated by HDAC1-IRF4 axis can be a novel therapeutic strategy, 17th International Myeloma Workshop, Sep. 2019.
15.	Mohannad Ashtar, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Oda Asuka, Iwasa Masami, Takeshi Harada, Bat-Erdene Ariunzaya, Kimiko Sogabe, Masahiro Oura, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Toshio Matsumoto, Masahiro Abe and Eiji Tanaka : Peri-implantitis and the role of Febuxostat in osteoclast differentiation., AEEDC Dubai World Orthodontic Conference, Dubai, UAE, Feb. 2019.
16.	Takeshi Harada, Asuka Oda, Yohann Grondin, Jumpei Teramachi, Ariunzaya Bat-Erdene, Masami Iwasa, Masahiro Oura, Shingen Nakamura, Kumiko Kagawa, Yasunobu Okamoto, Kimiko Sogabe, Shiroh Fujii, Hirokazu Miki, Shuji Ozaki, Teru Hideshima, Kenneth C. Anderson and Masahiro Abe : The critical role of the HDAC1-IRF4-Pim-2 axis in myeloma cell growth and survival: therapeutic impacts of targeting the HDAC1-IRF4-Pim-2 axis, 60th ASH Annual Meeting & Exposition, San Diego, Dec. 2018.
17.	Shingen Nakamura, Hirokazu Miki, Ariunzaya Bat-Erdene, Yasunobu Okamoto, Kimiko Sogabe, Masahiro Oura, Mamiko Takahashi, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kumiko Kagawa and Masahiro Abe : Alteration of muscle mass after chemotherapy in patients with newly diagnosed multiple myeloma., Esmo asia 2018, Nov. 2018.
18.	Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Oda Asuka, Bat-Erdene Ariunzaya, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Toshio Matsumoto and Masahiro Abe : Disruption of a progressive vicious cycle between myeloma tumor growth and bone destruction by TAK1 inhibition, ASBMR 2018 Annual Meeting, Montreal, Sep. 2018.
19.	Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Oda Asuka, Ashtar Mohannad, Kotaro Tanimoto, Iwasa Masami, Bat-Erdene Ariunzaya, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe : Opposite effects of TRAIL on the Sp-1-c-FLIP survival pathway in myeloma cells and osteoclasts., ASBMR 2018 Annual Meeting, Montreal, Sep. 2018.
20.	Takeshi Harada, Oda Asuka, Jumpei Teramachi, Bat-Erdene Ariunzaya, Iwasa Masami, Oura Masahiro, Shingen Nakamura, Kumiko Kagawa, Okamoto Yasunobu, Kimiko Sogabe, Shiroh Fujii, Hirokazu Miki, Hideshima Teru, Anderson C. Kenneth and Masahiro Abe : Selective inhibition of class-I HDAC induces myeloma cell death through targeting IRF4-Pim-2 axis, The 9th JSH International Symposium 2018 in Kyoto, Jul. 2018. (キーワード) Multiple myeloma / Class-I HDAC / IRF4 / Pim2
21.	Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Oda Asuka, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Tatsuji Haneji, Itsuro Endo, Toshio Matsumoto and Masahiro Abe : Therapeutic impact of TAK1 inhibition on myeloma tumor progression and bone destruction, 8th International Workshop on Advances in the Molecular Pharmacology and Therapeutics of Bone and other Musculoskeletal Diseases and Cancer and Bone Society 2018 Meeting, Oxford, Jun. 2018.
22.	Jumpei Teramachi, Masahiro Hiasa, Oda Asuka, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe : TAK1 inhibition impairs myeloma cell-bone marrow interaction to reduce myeloma tumor growth and bone destruction, American Society for Bone and Mineral Research (ASBMR) 2017 Annual Meeting, Denver, Sep. 2017.
23.	Jumpei Teramachi, Masahiro Hiasa, Oda Asuka, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe : Therapeutic impact of TAK1 inhibition on myeloma tumor progression and bone destruction, International Society for Experimental Hematology 46th Annual Scientific Meeting, Frankfurt, Aug. 2017.
24.	Hirofumi Tenshin, Jumpei Teramachi, A Oda, Ryota Amachi, Masahiro Hiasa, A Baterdene, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe : Osteoclasts utilize TRAIL for their NF-B activation, but TAK1 inhibition resumes TRAIL-induced apoptosis in osteoclasts., Australian and New Zealand Bone and Mineral Society 2017, Brisbane, Australia., Jun. 2017.
25.	Jumpei Teramachi, Masahiro Hiasa, Oda Asuka, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Akihito Yamamoto, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe : Therapeutic impact of TAK1 inhibition on myeloma tumor progression and bone destruction, Cancer and Bone Society Conference 2017, Indianapolis, May 2017.
26.	Ryota Amachi, Masahiro Hiasa, Oda Asuka, Bat-Erdene Ariunzaya, Jumpei Teramachi, Hirofumi Tenshin, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shiroh Fujii, Toshio Matsumoto, Eiji Tanaka and Masahiro Abe : Osteoblast Creates a Non-permissive Niche for Myeloma Cells, 95th General Session & Exhibition of the IADR program book, San Francisco, Mar. 2017.
27.	Shingen Nakamura and Momoyo Azuma : Pseudo-outbreak of Mycobacterium chimaera in hematopoietic stem cell transplantation center due to sterile hand-washing machine, ID week 2016, Vol.3, New Orleans, Oct. 2016. (出版サイトへのリンク) ● Publication site (DOI): 10.1093/ofid/ofw172.1105 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1093/ofid/ofw172.1105 (DOI: 10.1093/ofid/ofw172.1105)
28.	Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Kiyoe Kurahashi, Takeshi Kondo, Hirokazu Miki, Itsuro Endo, Toshio Matsumoto and Masahiro Abe : TAK-1 inhibition disrupts Pim-2-associated and Pim-2-independent key signaling pathways to effectively suppress tumor growth and restore bone formation in myeloma, American Society for Bone and Mineral Research 2016 Annual Meeting, Atlanta, Sep. 2016.
29.	Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe : Therapeutic impact of TAK-1 inhibition on tumor growth and bone destruction in myeloma, 21st Congress European Hematology Association, Copenhagen, Jun. 2016.
30.	Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Derek Hanson, Keiichiro Watanabe, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe : Pim inhibition suppresses osteoclastogenesis and tumor growth in myeloma, 57th ASH Annual Meeting and Exposition, Orlando, Dec. 2015.
31.	Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, Asuka Oda, Hirofumi Tenshin, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shiroh Fujii, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe : Up-regulation of the pH sensor TRPV1 in myeloma cells and their adaption to an acidic microenvironment, ASBMR 2015 Annual Meeting, Seattle, Oct. 2015.
32.	Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Keiichiro Watanabe, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe : Pivotal role of TAK-1 in tumor growth and bone destruction in myeloma: Therapeutic impact of TAK-1 inhibition, American Society for Bone and Mineral Research 2015 Annual Meeting, Oct. 2015.
33.	Hirokazu Miki, Shingen Nakamura, Hirofumi Tenshin, Ryota Amachi, Keiichiro Watanabe, Jumpei Teramachi, Shiroh Fujii, Kumiko Kagawa and Masahiro Abe : Effective impairment of myeloma progenitors by hyperthermia: augmentation with bortezomib and Pim inhibition in combination, Clinical Lymphoma, Myeloma & Leukemia, Vol.15, No.S3, e217-e218, Sep. 2015. (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.clml.2015.07.470 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1016/j.clml.2015.07.470 (DOI: 10.1016/j.clml.2015.07.470)
34.	Shingen Nakamura, Hirokazu Miki, Hirofumi Tenshin, Ryota Amachi, Keiichiro Watanabe, Jumpei Teramachi, Shiroh Fujii, Kumiko Kagawa and Masahiro Abe : Alteration of Pim-2 expression by clinically available anti-myeloma agents: combinatory anti-myeloma effects with Pim inhibition, Clinical Lymphoma, Myeloma & Leukemia, Vol.15, No.S3, e243, Sep. 2015. (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.clml.2015.07.517 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1016/j.clml.2015.07.517 (DOI: 10.1016/j.clml.2015.07.517)
35.	Jumpei Teramachi, Masahiro Hiasa, 小田明日香, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Kumiko Kagawa, Hirokazu Miki, Shiroh Fujii, Keiichiro Watanabe, Itsuro Endo, Toshio Matsumoto and Masahiro Abe : Critical role of Pim-2 in NF-B-mediated suppression of osteoblastogenesis and stimulation of osteoclastogenesis: Therapeutic impact of Pim inhibition on myeloma bone disease., 2014 ASBMR Annual Meeting, Houston, Sep. 2014.
36.	Keiichiro Watanabe, Masahiro Abe, Ryota Amachi, Masahiro Hiasa, T Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, H Mori, Itsuro Endo, Eiji Tanaka and Toshio Matsumoto : Induction of bone formation in myeloma osteolytic lesions by cathepsinK inhibition, Kyoto, Apr. 2013.
37.	Ryota Amachi, Keiichiro Watanabe, Shiroh Fujii, T Harada, Hirokazu Miki, Shingen Nakamura, A Oda, Masahiro Hiasa, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe : An acidic milieu suppersses histone acetylation in myeloma cells to down-regulate the TRAIL receptor DR4 expression., Kyoto, Apr. 2013.
38.	Harada Takeshi, Ozaki Shuji, Oda Asuka, Iwasa Masami, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe, Shibata Hironobu, Akishige Ikegame, Daisuke Tsuji, Ito Kohji, Ri Masaki, Iida Shinsuke, Shiotsu Yukimasa, Kawai Shigeto, Yamada-Okabe Hisafumi and Toshio Matsumoto : Combination therapy of a defucosylated anti-HM1.24 monoclonal antibody plus Ienalidomide induces marked antibody-dependent cellular cytotoxicity and inhibits the clonogenic potential of myeloma cancer stem-like cells. Atlanta, Dec. 2012., The 54th Annual Meeting of the American Society of Hamatology, Dec. 2012.
39.	T Harada, Shuji Ozaki, A Oda, M Iwasa, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe, Hirofumi Shibata, Akishige Ikegame, Daisuke Tsuji, Kouji Itou, M Ri, S Iida, Y Shiotsu, S Kawai, H Yamada-Okabe and Toshio Matsumoto : Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Induces Marked Antibody-Dependent Cellular Cytotoxicity and Inhibits the Clonogenic Potential of Myeloma Cancer Stem-Like Cells., 54th ASH Annual Meeting and Exposition, USA, Atlanta, Dec. 2012.
40.	Masahiro Hiasa, Keiichiro Watanabe, Shingen Nakamura, Harada Takeshi, Itsuro Endo, Toshio Matsumoto and Masahiro Abe : Prevention of tumor growth and bone destruction in myeloma by Pim kinase inhibition, 12th Int'l Meeting on Cancer Induced Bone Disease, Lyon, Nov. 2012.
41.	Masahiro Hiasa, Ryota Amachi, Keiichiro Watanabe, Harada Takeshi, Fujii Shirou, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Itsuro Endo, Toshio Matsumoto and Masahiro Abe : Pim-2 suppresses BMP-2 signaling as a common inhibitory mediator of osteoblastogenesis in myeloma, ASBMR 2012 Anuual Meeting, Minneapolis, Oct. 2012.
42.	Keiichiro Watanabe, Masahiro Abe, M Kawatani, Masahiro Hiasa, A Kawano, T Jinno, T Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Eiji Tanaka, H Osada and Toshio Matsumoto : Aggravation of myeloma growth and drug resistance by an acidic created in myeloma-osteoclast interaction., ASBMR 2011 Annual Meeting, San Diego, Sep. 2011.
43.	Masahiro Hiasa, nakano ayako, Keiichiro Watanabe, C Qu, T Harada, Shiroh Fujii, Hirokazu Miki, Shingen Nakamura, Kumiko Kagawa, Kyoko Takeuchi, Eiji Tanaka, Kenzo Asaoka, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe : Prevention of tumor growth and bone destruction in myeloma by Pim kinase inhibition., ASBMR 2011 Annual Meeting, San Diego, Sep. 2011.
44.	Masahiro Hiasa, nakano ayako, Keiichiro Watanabe, C Qu, T Harada, Shiroh Fujii, Hirokazu Miki, Shingen Nakamura, Kumiko Kagawa, Kyoko Takeuchi, Eiji Tanaka, Kenzo Asaoka, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe : Dual effects of Pim inhibition on myeloma: induction of bone formation and tumor suppression., IOF-ANZBMS 2011 Annual Meeting, Gold Coast, Sep. 2011.
45.	Keiichiro Watanabe, Masahiro Abe, Cui Qu, Kawatani Makoto, Masahiro Hiasa, Nakano Ayako, Jinno Tadashi, Harada Takeshi, Shiroh Fujii, Shingen Nakamura, Miki Hirokazu, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Eiji Tanaka, Osada Hiroyuki and Toshio Matsumoto : An Acidic Mileu Created In Myeloma-Osteoclast Interaction Enhances Tumor Growth, but Triggers Anti-Myeloma Activity of Reveromycin A, a Novel Anti-Resorptive Agent, 52th American Society of Hematology, Orlando, Dec. 2010.
46.	Cui Qu, Masahiro Abe, Miki Hirokazu, Shingen Nakamura, Keiichiro Watanabe, Akishige Ikegame, Masahiro Hiasa, Nakano Ayako, Harada Takeshi, Shiroh Fujii, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki and Toshio Matsumoto : Lenalidomide In Combination with Zoledronic Acid Restores the Activation and Anti-Myeloma Effects of γδT Cells Attenuated by the Bone Marrow Microenvironment, 52th American Society of Hematology, Orlando, Dec. 2010.
47.	Keiichiro Watanabe, Masahiro Abe, Cui Qu, Kawatani Makoto, Masahiro Hiasa, Nakano Ayako, Jinno Tadashi, Harada Takeshi, Shiroh Fujii, Shingen Nakamura, Miki Hirokazu, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Eiji Tanaka, Osada Hiroyuki and Toshio Matsumoto : A Novel Anti-resorptive Agent, Reveromycin A, Ameliorates Bone Destruction and Tumor Growth in Myeloma, ASBMR 2010 Annual Meeting, Toronto, Oct. 2010.
48.	Masahiro Hiasa, Masahiro Abe, nakano ayako, oda aska, amo hiroe, Keiichiro Watanabe, Shingen Nakamura, miki hirokazu, Kyoko Takeuchi, Kumiko Kagawa, Shuji Ozaki, Eiji Tanaka, Kenzo Asaoka and Toshio Matsumoto : Bone Marrow Stromal Cells Suppress TACE-mediated M-CSFR and RANK Shedding to Facilitate Osteoclastogenesis and Suppress DC Differentiation from Monocytes., ASBMR 2010 Annual Meeting, Toronto, Oct. 2010.
49.	Masahiro Abe, Masahiro Hiasa, Nakano A, Shingen Nakamura, Miki H, Qu C, Keiichiro Watanabe, Harada T, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki and Toshio Matsumoto : TIMP-3 up-regulation facilitates osteoclastogenesis and suppresses DC differentiation from monocytes in the bone marrow microenvironment in myeloma, 10th International Conference Cancer-induced Bone Disease, Sep. 2010. (キーワード) Sheffield (United Kingdom)
50.	Keiichiro Watanabe, Masahiro Abe, Cui Qu, Kawatani Makoto, Masahiro Hiasa, Nakano Ayako, Jinno Tadashi, Harada Takeshi, Shiroh Fujii, Shingen Nakamura, Miki Hirokazu, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Eiji Tanaka, Osada Hiroyuki and Toshio Matsumoto : The novel anti-resorptive agent reveromycin A ameliorates bone destruction and tumor growth in myeloma, 10th International Conference Cancer-induced Bone Disease, Sheffield (United Kingdom), Sep. 2010.

国内講演発表:

1.	村井純平, 中村信元, 辻誠士郎, 山下理子, 上原久典, 滝下誠 : 著明な腹水貯留と腎機能障害で発症し Fluid Overload-associated Large B cell lymphoma(FO-LBCL)と思われた1例, 第129回日本内科学会四国地方会,
2.	住谷龍平, 中村信元, 大浦雅博, 曽我部公子, 高橋真美子, 藤井志朗, 原田武志, 三木浩和, 安倍正博 : 周期的な発熱，血小板減少，高LDH血症で発症したびまん性大細胞型B細胞リンパ腫の1例, 第128回日本内科学会四国地方会,
3.	前田悠作, 中村信元, 西條早希, 住谷龍平, 大浦雅博, 曽我部公子, 高橋真美子, 藤井志朗, 原田武志, 三木浩和 : 多職種による集学的ケアを行ったインヒビター保有重症先天性血友病Aの1例, 第129回内科学会四国地方会,
4.	阪本朋香, 今井芳枝, 三木こずえ, 藤井志朗, 三木浩和, 曽我部公子, 大浦雅博, 住谷龍平, 八木ひかる, 高橋真美子, 原田武志, 前田悠作, 中村信元, 松岡賢市 : 治療過程にある多発性骨髄腫患者が治療を続ける意味, 第39回日本がん看護学会学術集会, 2025年2月.
5.	粟飯原賢一, 湯浅智之, 中村信元, 村井純平, 岡本恵暢, 金子遥祐, 森建介, 細木美苗, 堀太貴, 河田沙紀, 辻誠士郎, 安井沙耶, 山上紘規, 原倫世, 乙田敏城, 遠藤逸朗 : 来院時心肺停止・死亡転帰患者の臨床背景における糖尿病有無の影響に関する検討, 第24回日本内分泌学会四国支部学術集会, 2024年9月.
6.	三宅南帆, 辻誠士郎, 河田沙紀, 中村信元, 乙田敏城, 湯浅智之, 粟飯原賢一 : 2型糖尿病患者の推定食塩摂取量と糖尿病性腎臓病指標の連関解析, 第67回日本糖尿病学会年次学術集会, 2024年5月.
7.	明石和子, 今井芳枝, 中村信元, 住谷龍平, 大浦雅博, 曽我部公子, 髙橋真美子, 原田武志, 藤井志朗, 三木浩和 : 初回再発した老年期の造血器腫瘍患者が捉える化学療法への構え, 第9回日本がんサポーティブケア学会学術集会, 2024年5月.
8.	金子遥祐, 森建介, 細木美苗, 堀太貴, 辻誠士郎, 乙田敏城, 湯浅智之, 中村信元, 粟飯原賢一 : 2型糖尿病患者の年間HbA1c変動と肝線維化指標の連関解析, 第67回日本糖尿病学会年次学術集会, 2024年5月.
9.	辻誠士郎, 河田沙紀, 金子遥祐, 森建介, 細木美苗, 中村信元, 乙田敏城, 湯浅智之, 粟飯原賢一 : 2型糖尿病患者におけるdehydroepiandrosterone sulfate(DHEAS)と尿中アルブミン，尿中L型脂肪酸結合蛋白(L-FABP)との関連, 第67回日本糖尿病学会年次学術集会, 2024年5月.
10.	金子遥祐, 河田沙紀, 森建介, 細木美苗, 堀太貴, 辻誠士郎, 乙田敏城, 湯浅智之, 中村信元, 粟飯原賢一 : 赤血球のmean corpuscular volumeと代謝異常関連脂肪肝疾患の連関解析, 日本内分泌学会雑誌, Vol.100, No.1, 339, 2024年5月.
11.	粟飯原賢一, 三宅南帆, 辻誠士郎, 河田沙紀, 中村信元, 乙田敏城, 湯浅智之 : 2型糖尿病患者の糖尿病性腎臓病における推定食塩摂取量の意義, 日本内分泌学会雑誌, Vol.100, No.1, 348, 2024年5月.
12.	住谷龍平, 三木浩和, 岡村和美, 前田悠作, 大浦雅博, 曽我部公子, 八木ひかる, 高橋真美子, 丸橋朋子, 原田武志, 藤井志朗, 中村信元, 尾矢剛志, 安倍正博, 佐藤亜紀 : KRAS変異を認めた治療抵抗性Rosai-Dorfman病の1例, 臨床血液, Vol.65, No.5, 473, 2024年5月.
13.	堀太貴, 石田晃基, 稲葉香織, 稲葉圭佑, 金子遙祐, 細木美苗, 森建, 粟飯原賢一, 中村信元 : 内科救急疾患患者におけるRespiratory adjusted shock indexの有用性, 第121回日本内科学会総会・講演会, 2024年4月.
14.	辻誠士郎, 河田沙紀, 村井純平, 乙田敏城, 湯浅智之, 中村信元, 滝下誠, 粟飯原賢一 : 2型糖尿病患者における年間腎機能変化とdehydroepiandrosterone sulfate(DHEAS)の連関解析, 第121回日本内科学会総会・講演会, 2024年4月.
15.	金子遥祐, 森建介, 堀太貴, 細木美苗, 辻誠士郎, 河田沙紀, 乙田敏城, 湯浅智之, 中村信元, 粟飯原賢一 : 代謝異常関連脂肪肝疾患におけるmean corpuscular volumeの意義, 第121回日本内科学会総会・講演会, 2024年4月.
16.	堀太貴, 粟飯原賢一, 石田晃基, 稲葉香織, 稲葉圭佑, 金子遥祐, 川人圭祐, 別宮彰起, 細木美苗, 森建介, 伊丹加奈子, 勝瀬昌代, 花岡賀美, 影治照喜, 浦岡秀行, 中村信元 : 非がん在宅療養患者における予後予測指標の有用性についての検討, 第268回徳島医学会学術集会, 2024年3月.
17.	大原菜摘, 山下由美子, 倍味歩実, 中村信元, 小川博久, 常山幸一, 山下理子 : Fluid overload large B cell lymphoma FO-LBCLとの鑑別を要した腹水plasmacytosisの1例, 四国医学雑誌, Vol.79, No.5-6, 277, 2024年3月.
18.	三宅南帆, 辻誠士郎, 河田沙紀, 粟飯原賢一, 中村信元, 乙田敏城, 湯浅智之 : 2型糖尿病患者における推定塩分摂取量に関わる臨床因子の探索, 四国医学雑誌, Vol.79, No.5-6, 283-284, 2024年3月.
19.	明石和子, 今井芳枝, 中村信元, 西條早希, 前田悠作, 住谷龍平, 大浦雅博, 曽我部公子, 髙橋真美子, 原田武志, 藤井志朗, 三木浩和 : 初回再発した成人期の造血器腫瘍患者が捉える化学療法への構え, 第21回日本臨床腫瘍学会学術集, 2024年2月.
20.	堀太貴, 石田晃基, 稲葉香織, 稲葉圭佑, 金子遥祐, 川人圭祐, 細木美苗, 森建介, 粟飯原賢一, 中村信元 : 内科救急疾患患者におけるRespiratory adjusted shock indexの有用性, 日本内科学会雑誌, Vol.113, 195, 2024年2月. (キーワード) *救急疾患(予後) 脈拍呼吸数ヒト男女
21.	村井純平, 中村信元, 辻誠士郎, 粟飯原賢一, 滝下誠 : 造血器疾患患者へのチキサゲビマブ/シルガビマブ投与による抗SARS-CoV-2 IgG抗体価経時的変化と予防効果の検討, 日本内科学会雑誌, Vol.113, 158, 2024年2月. (キーワード) IgG 血液疾患(薬物療法) モノクローナル抗体(治療的利用,毒性・副作用) 配合製剤(治療的利用,毒性・副作用) 中和抗体(治療的利用,毒性・副作用) COVID-19(予防) 造血器疾患(薬物療法) Tixagevimab(治療的利用,毒性・副作用) Cilgavimab(治療的利用,毒性・副作用) *Cilgavimab-Tixagevimab(治療的利用,毒性・副作用) ヒト中年(45∼64) 高齢者(65∼79) 高齢者(80∼) 男女
22.	中村信元, 手束宏明, 山上圭, 和泉唯信, 西條早希, 前田悠作, 住谷龍平, 大浦雅博, 曽我部公子, 高橋真美子, 藤井志朗, 原田武志, 三木浩和 : 免疫再構築症候群により急速な経過で死亡に至ったHIV関連進行性多巣性白質脳症の一剖検例, 日本エイズ学会誌, Vol.25, No.4, 461, 2023年11月. (キーワード) AIDS(合併症,薬物療法,病理学) 白質脳症-進行性多巣性(病因,薬物療法,病理学) 剖検免疫再構築症候群(病因,病理学) ヒト中年(45∼64) 男
23.	中村信元, 手束宏明, 山上圭, 和泉唯信, 西條早希, 前田悠作, 住谷龍平, 大浦雅博, 曽我部公子, 高橋真美子, 藤井志朗, 原田武志, 三木浩和 : 免疫再構築症候群により急速な経過で死亡に至ったHIV関連進行性多巣性白質脳症の一剖検例, 日本エイズ学会誌, Vol.25, No.4, 461, 2023年11月. (キーワード) AIDS(合併症,薬物療法,病理学) 白質脳症-進行性多巣性(病因,薬物療法,病理学) 剖検免疫再構築症候群(病因,病理学) ヒト中年(45∼64) 男
24.	三宅南帆, 辻誠士郎, 河田沙紀, 中村信元, 乙田敏城, 湯浅智之, 粟飯原賢一 : 2型糖尿病患者の推定塩分摂取量に関わる臨床因子解析, 日本糖尿病学会中国四国地方会第61回総会, 2023年10月.
25.	辻誠士郎, 河田沙紀, 中村信元, 乙田敏城, 湯浅智之, 粟飯原賢一 : 当院糖尿病患者における高血圧治療の現況, 日本糖尿病学会中国四国地方会第61回総会, 2023年10月.
26.	明石和子, 今井芳枝, 中村信元, 西條早希, 前田悠作, 住谷龍平, 大浦雅博, 曽我部公子, 髙橋真美子, 原田武志, 藤井志朗, 三木浩和 : 再発・難治性造血器腫瘍患者が捉えるアドバンス・ケア・プランニング, 第61回日本癌治療学会学術集会, 2023年10月.
27.	堀太貴, 金子遥祐, 細木美苗, 森建介, 村井純平, 乙田敏城, 湯浅智之, 粟飯原賢一, 滝下誠, 中村信元 : 生活習慣病患者におけるヘモグロビン値と関連因子の検討, 日本血液学会学術集会, 689, 2023年10月. (キーワード) Hemoglobins 生活習慣病(診断,予後) ヒト中年(45∼64) 高齢者(65∼79) 男女
28.	原倫世, 山上紘規, 三井由加里, 倉橋清衛, 中村信元, 乙田敏城, 湯浅智之, 遠藤逸朗, 粟飯原賢一 : 2 型糖尿病患者における血圧・血糖管理目標達成下での腎糸球体・尿細管障害のリスク因子の検討, 第45回日本高血圧学会総会, 2023年9月.
29.	森建介, 金子遥祐, 辻誠士郎, 河田沙紀, 三宅南帆, 中村信元, 乙田敏城, 湯浅智之, 粟飯原賢一 : 2 型糖尿病患者の年間収縮期血圧変動に関連する臨床因子の解析, 第45回日本高血圧学会総会, 2023年9月.
30.	三宅南帆, 辻誠士郎, 河田沙紀, 原倫世, 山上紘規, 中村信元, 乙田敏城, 湯浅智之, 粟飯原賢一 : 2 型糖尿病患者における推定塩分摂取量に関連する臨床因子の検討, 第45回日本高血圧学会総会, 2023年9月.
31.	堀太貴, 石田晃基, 稲葉香織, 稲葉圭佑, 金子遙祐, 川人圭祐, 細木美苗, 森建介, 影治照喜, 浦岡秀行, 粟飯原賢一, 中村信元 : 非がん在宅療養患者の予後予測についての検討, Palliative Care Research, Vol.18, No.Suppl._Chugoku-Shikoku, S646, 2023年9月. (キーワード) Albumins 好中球白血球計数ターミナルケア予後リスク評価リンパ球計数在宅死 *臨床意思決定ルールヒト
32.	三宅南帆, 辻誠士郎, 河田沙紀, 中村信元, 乙田敏城, 湯浅智之, 粟飯原賢一 : 2型糖尿病患者における推定塩分摂取量に関わる臨床因子の探索, 第267回徳島医学会, 2023年8月.
33.	大原菜摘, 山下由美子, 倍味歩実, 中村信元, 小川博久, 常山幸一, 山下理子 : Fluid overload large B cell lymphoma FO-LBCLとの鑑別を要した腹水 plasmacytosisの1例, 第267回徳島医学会学術集会, 2023年8月.
34.	菅崎幹樹, 中村信元, 新井慎平, 漆原南実, 寺本継脩, 秦真公人, 井上雄介, 中尾隆之, 西岡安彦, 佐田政隆 : 新規変異BβCys76Pheを伴った低フィブリノゲン血症の1症例, 日本検査血液学会雑誌, Vol.24, S147, 2023年7月. (キーワード) Fibrinogen 変異先天性低フィブリノーゲン血症(診断) ヒト成人(19∼44) 女
35.	住谷龍平, 中村信元, 大浦雅博, 曽我部公子, 髙橋真美子, 藤井志朗, 原田武志, 三木浩和, 安倍正博 : 周期的な発熱，血小板減少，高LDH血症で発症したびまん性大細胞型B細胞リンパ腫の1例, 第128回日本内科学会四国地方会, 2023年7月.
36.	河田沙紀, 金子遥祐, 森建介, 辻誠士郎, 中村信元, 乙田敏城, 湯浅智之, 粟飯原賢一 : 運動習慣及び体組成が2型糖尿病患者受診時HbA1cに及ぼす影響の解析, 第96回日本内分泌学会学術総会, 2023年6月.
37.	森建介, 金子遥祐, 辻誠士郎, 河田沙紀, 中村信元, 乙田敏城, 湯浅智之, 粟飯原賢一 : 2型糖尿病患者における糖尿病治療薬の年間収縮期血圧変動への影響, 第96回日本内分泌学会学術集会, 2023年6月.
38.	辻誠士郎, 森建介, 金子遥祐, 河田沙紀, 中村信元, 乙田敏城, 湯浅智之, 粟飯原賢一 : 2型糖尿病患者における年間腎機能変化とdehydroepiandrosterone sulfate(DHEAS)の連関解析, 第96回日本内分泌学会学術総会, 2023年6月.
39.	住谷龍平, 中村信元, 林成樹, 大浦雅博, 曽我部公子, 高橋真美子, 原田武志, 藤井志朗, 三木浩和, 東航平, 安倍正博 : Lipiodolでのリンパ管造影により難治性乳糜腹水が軽快した濾胞性リンパ腫, 臨床血液, Vol.64, No.6, 560, 2023年6月. (キーワード) エチヨード化油(診断的利用,治療的利用) 乳び腹水(治療,X線診断,合併症) リンパ管造影リンパ腫-濾胞性(合併症) ヒト高齢者(65∼79) 女
40.	森建介, 河田沙紀, 金子遥祐, 辻誠士郎, 中村信元, 乙田敏城, 湯浅智之, 粟飯原賢一 : 2型糖尿病患者の年間収縮期血圧変動における糖尿病治療薬の影響, 第66回日本糖尿病学会年次学術集会, 2023年5月.
41.	金子遥祐, 河田沙紀, 森建, 辻誠士郎, 中村信元, 乙田敏城, 湯浅智之, 粟飯原賢一 : 2型糖尿病患者の年間HbA1c変動における糖尿病治療薬の影響, 第66回日本糖尿病学会年次学術集会, 2023年5月.
42.	辻誠士郎, 森建介, 金子遥祐, 河田沙紀, 中村信元, 乙田敏城, 湯浅智之, 粟飯原賢一 : 2型糖尿病患者のeGFR slopeにおけるdehydroepiandrosterone sulfate(DHEAS)の意義, 第66回日本糖尿病学会年次学術集会, 2023年5月.
43.	河田沙紀, 金子遥祐, 森建介, 辻誠士郎, 中村信元, 乙田敏城, 湯浅智之, 粟飯原賢一 : 2型糖尿病患者の受診時HbA1cにおける運動習慣及び体組成の影響, 第66回日本糖尿病学会年次学術集会, 2023年5月.
44.	金子遥祐, 河田沙紀, 森建介, 辻誠士郎, 中村信元, 乙田敏城, 湯浅智之, 井上善雄, 粟飯原賢一 : 多発腹腔内リンパ節腫脹を契機に診断に至ったPSA正常進行前立腺癌の一例, 第266回徳島医学会学術集会, 2023年2月.
45.	森建介, 河田沙紀, 金子遥祐, 谷彰浩, 辻誠士郎, 中村信元, 乙田敏城, 湯浅智之, 添木武, 粟飯原賢一 : 高齢2型糖尿病患者におけるGNRIスコアと骨格筋異常病態の検討, 第266回徳島医学会学術集会, 2023年2月.
46.	河田沙紀, 金子遥祐, 森建介, 谷彰浩, 辻誠士郎, 湯浅智之, 乙田敏城, 中村信元, 戸田直紀, 粟飯原賢一 : 集学的治療にて救命し得た未治療糖尿病合併咽後膿瘍の1例, 第266回徳島医学会学術集会, 2023年2月.
47.	林成樹, 住谷龍平, 大浦雅博, 原田武志, 中村信元, 森彩花, 田蒔昌憲, 安倍正博 : ITP，自己免疫性出血病F13に続発しTAFRO症候群を発症した1例, 第127回日本内科学会四国地方会, 2022年12月.
48.	辻誠士郎, 中村信元, 河田沙紀, 金子遥祐, 森建介, 滝下誠, 祖川麻衣子, 粟飯原賢一 : 帯状疱疹後急速に汎発性帯状疱疹に移行した2例, 第127回日本内科学会四国地方会, 2022年12月.
49.	佃恵里加, 李悦子, 瀧本朋美, 小田直輝, 原田武志, 藤井志朗, 中村信元, 三木浩和, 安倍正博 : ダラツムマブ投与患者における間接抗グロブリン試験干渉期間の検討, 日本輸血細胞治療学会誌, Vol.68, No.6, 582-583, 2022年12月.
50.	森建介, 河田沙紀, 金子遥祐, 谷彰浩, 辻誠士郎, 中村信元, 乙田敏城, 湯浅智之, 添木武, 粟飯原賢一 : 2型糖尿病患者の骨格筋異常におけるGNRIスコアの意義, 日本糖尿病学会中国四国地方会第60回総会, 2022年11月.
51.	Mamiko Takahashi, Shingen Nakamura, Shin Kondo, Masafuumi Nakamura, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Takeshi Harada, Shiroh Fujii, Hirokazu Miki and Masahiro Abe : Importance of skeletal muscle mass during chemotherapies in patients with hematological malignancies, JSH2022, Oct. 2022.
52.	Takeshi Harada, Ryohei Sumitani, Asuka Oda, Yusuke Inoue, Masahiro Oura, Kimiko Sogabe, Tomoko Maruhashi, Mamiko Takahashi, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Hirofumi Tenshin, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe : The therapeutic potential targeting ADAR1-dsRNA metabolism in myeloma cells with 1q amplification, The 84th Annual Meeting of the Japanese Society of Hematology, Oct. 2022.
53.	中村信元, 堀太貴, 谷彰浩, 細木美苗, 安井沙耶, 宮田好裕, 山上紘規, 滝下誠, 粟飯原賢一 : 新型コロナワクチン接種後にvaccine-induced immune thrombotic thrombocytopeniaを疑われた症例, 日本老年医学会雑誌, Vol.59, No.4, 594, 2022年10月.
54.	岡田直人, 中村信元, 清水太郎, 安藤英紀, 相澤風花, 新村貴博, 八木健太, 合田光寛, 石田竜弘, 石澤啓介 : 免疫不全リスクを有する患者における新型コロナワクチンによる抗体獲得能に関連する因子の検討, 第32回日本医療薬学学会, 2022年9月.
55.	谷口元基, 本田剛士, 柳谷伸一郎, 髙成広起, 南康夫, 中村信元, 三木浩和, 安倍正博, 坂東良美, 常山幸一 : ALアミロイドーシス無染色標本のラマン分光顕微観察, 2022年第83回応用物理学会秋季学術講演会, 20p-C301-12, 2022年9月. (キーワード) ラマン分光 / アミロイドーシス
56.	岡田直人, 中村信元, 清水太郎, 安藤英紀, 相澤風花, 新村貴博, 八木健太, 合田光寛, 石田竜弘, 石澤啓介 : 免疫不全リスクを有する患者における新型コロナワクチンによる抗体獲得能に影響を与える因子の検討, 第32回日本医療薬学会年会, 2022年9月.
57.	細木美苗, 山上紘規, 安井沙耶, 堀太貴, 中村信元, 乙田敏城, 湯浅智之, 粟飯原賢一 : 当院10年間における死亡患者の年齢・死因および併存合併症における糖尿病と治療薬剤の影響, 第22回日本糖尿病インフォマティクス学会年次学術集会, 2022年8月.
58.	新居寛子, 髙橋真美子, 藤井志朗, 曽我部公子, 林成樹, 住谷龍平, 大浦雅博, 原田武志, 中村信元, 安積麻衣, 湊将典, 三木浩和, 安倍正博 : ループス腎炎に対してミコフェノール酸モフェチル投与中に発症した他の医原性免疫不全関連リンパ増殖性疾患の1例, 第265回徳島医学会学術集会, 2022年7月.
59.	米田健一, 金子遥祐, 河田沙紀, 森建介, 谷彰浩, 辻誠士郎, 湯浅智之, 乙田敏城, 中村信元, 粟飯原賢一 : SGLT2阻害薬内服中のシックデイ対応困難が契機となり，糖尿病性ケトアシドーシスを認めた認知症高齢2型糖尿病の1例, 第265回徳島医学会学術集会, 2022年7月.
60.	田中茉里子, 日浅雅博, 谷本幸多朗, 天眞寛文, 清水宗, 比嘉佳基, 中上絵美子, 金秀河, 寺町順平, 原田武志, 中村信元, 遠藤逸朗, 田中栄二, 松本俊夫, 安倍正博 : 不動は骨髄腫骨病変部DPP-4発現増加と骨髄腫の腫瘍進展・髄外播種を加速させる, 第40回日本骨代謝学会学術集会, 2022年7月.
61.	堀太貴, 中村信元, 谷彰浩, 細木美苗, 安井沙耶, 宮田好裕, 山上紘規, 辻誠士郎, 粟飯原賢一, 滝下誠 : 初発時にヘルペスウイルス属の再活性化と中枢浸潤を伴い急速に悪化した成人T細胞白血病リンパ腫の1例, 第126回日本内科学会四国地方会, 2022年6月.
62.	Ryohei Sumitani, Makiko Mizuguchi, Masahiro Oura, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Toshihiro Hashimoto, Takeshi Harada and Masahiro Abe : 126, 第126回日本内科学会四国地方会, Jun. 2022.
63.	Shingen Nakamura, HORI Taiki, Minae Hosoki, Saya Yasui, Hiroki Yamagami, 赤澤啓人, 滝下誠 and Ken-ichi Aihara : FXIII/13, 第126回日本内科学会四国地方会, Jun. 2022.
64.	中村信元, 堀太貴, 細木美苗, 安井沙耶, 山上紘規, 赤澤啓人, 滝下誠, 粟飯原賢一 : 新型コロナワクチン接種後に発覚した自己免疫性出血病FXIII/13, 第126回日本内科学会四国地方会, 2022年6月.
65.	本田壮一, 中村信元, 高橋啓輝, 堀太貴, 安倍正博 : 地域での造血腫瘍の診療を考える, 第126回日本内科学会四国地方会, 2022年6月.
66.	中村昌史, 三木浩和, 住谷龍平, 大浦雅博, 曽我部公子, 丸橋朋子, 高橋真美子, 原田武志, 藤井志朗, 中村信元, 西尾進, 友成哲, 安倍正博 : ALアミロイドーシスの肝病変の評価における超音波エラストグラフィの有用性, 臨床血液, Vol.63, No.6, 685-686, 2022年6月. (キーワード) 肝臓疾患(超音波診断,薬物療法) 組織弾性イメージング *アミロイドーシス-免疫グロブリン軽鎖(超音波診断,薬物療法) ヒト中年(45∼64) 男女
67.	中村信元, 堀太貴, 細木美苗, 安井沙耶, 山上紘規, 滝下誠, 答島章公, 粟飯原賢一 : 血液疾患，自己免疫疾患における新型コロナワクチン接種後の抗体獲得能の検討, 第96回日本感染症学会総会, 2022年5月.
68.	Shingen Nakamura, HORI Taiki, Masafumi Nakamura, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Tomoko Maruhashi, 高橋真美子, Shiroh Fujii, Hirokazu Miki, Takeshi Harada and Masahiro Abe : Humoral response of the mRNA vaccine against SARS-CoV-2 in patients with plasma cell dyscrasia, The 47th annual meeting of Japanese Society of Myeloma, May 2022.
69.	天眞寛文, 原田武志, 井上雄介, 菊池次郎, 小田明日香, 住谷龍平, 大浦雅博, 曽我部公子, 丸橋朋子, 高橋真美子, 藤井志朗, 中村信元, 三木浩和, 日浅雅博, 寺町順平, 鈴木敦, 角川学士, 峯畑健一, 古川雄祐, 安倍正博 : 破骨細胞はSLAMF7を強発現し可溶性SLAMF7を産生する, 第47回日本骨髄腫学会学術集会, 2022年5月.
70.	井上雄介, 原田武志, 天眞寛文, 小田明日香, 住谷龍平, 大浦雅博, 曽我部公子, 丸橋朋子, 高橋真美子, 藤井志朗, 三木浩和, 中村信元, 日浅雅博, 寺町順平, 安倍正博 : 骨髄腫に対する抗体免疫療法へのTh1様γδT細胞の応用, 第47回日本骨髄腫学会学術集会, 2022年5月.
71.	原田武志, 住谷龍平, 小田明日香, 井上雄介, 大浦雅博, 曽我部公子, 丸橋朋子, 高橋真美子, 藤井志朗, 中村信元, 三木浩和, 天眞寛文, 日浅雅博, 寺町順平, 安倍正博 : RNA編集酵素ADAR1を標的にする1q増幅骨髄腫細胞に対する治療法の開発, 第47回日本骨髄腫学会学術集会, 2022年5月.
72.	寺町順平, 天眞寛文, 日浅雅博, 小田明日香, 清水宗, 住谷龍平, 大浦雅博, 曽我部公子, 丸橋朋子, 藤井志朗, 中村信元, 三木浩和, 遠藤逸朗, 原田武志, 安倍正博 : TAK1 阻害は骨髄腫の細胞間相互作用による骨破壊と薬剤耐性を改善する, 第47回日本骨髄腫学会学術集会, 2022年5月.
73.	丸橋朋子, 三木浩和, 曽我部公子, 原田武志, 小田明日香, 中村信元, 中村昌史, 住谷龍平, 大浦雅博, 高橋真美子, 藤井志朗, 安倍正博 : 骨髄腫細胞のプロテアソーム阻害薬への抵抗性の機序と温熱療法によるその克服の可能性, 第47回日本骨髄腫学会学術集会, 2022年5月.
74.	中村信元, 堀太貴, 中村昌史, 住谷龍平, 大浦雅博, 曽我部公子, 丸橋朋子, 髙橋真美子, 藤井志朗, 三木浩和, 原田武志, 安倍正博 : 形質細胞疾患における新型コロナワクチンの有効性, 第47回日本骨髄腫学会学術集会, 2022年5月.
75.	三木浩和, 中村信元, 中村昌史, 住谷龍平, 大浦雅博, 曽我部公子, 髙橋真美子, 丸橋朋子, 原田武志, 藤井志朗, 西尾進, 友成哲, 安倍正博 : 肝臓アミロイドーシスに対する超音波エラストグラフィを用いた非侵襲的診断法の有用性, 第47回日本骨髄腫学会学術集会, 2022年5月.
76.	山上紘規, 細木美苗, 堀太貴, 安井沙耶, 中村信元, 谷口達哉, 乙田敏城, 湯浅智之, 添木武, 粟飯原賢一 : Skin Autofluorescenceの糖尿病性腎臓病における臨床的意義の解析, 第65回日本糖尿病学会年次学術集会, 2022年5月.
77.	細木美苗, 山上紘規, 安井沙耶, 堀太貴, 中村信元, 乙田敏城, 湯浅智之, 粟飯原賢一 : 当院10年間における死亡患者の年齢・死因および併存合併症における糖尿病と治療薬剤の影響, 第65回日本糖尿病学会年次学術集会, 2022年5月.
78.	中村信元, 堀太貴, 中村昌史, 住谷龍平, 大浦雅博, 曽我部公子, 丸橋朋子, 高橋真美子, 藤井志朗, 三木浩和, 原田武志, 粟飯原賢一, 安倍正博 : 形質細胞異常症患者におけるSARS-CoV-2に対するmRNAワクチンの液性免疫応答の評価(Humoral response of the mRNA vaccine against SARS-CoV-2 in patients with plasma cell dyscrasia), International Journal of Myeloma, Vol.12, No.3, 199, 2022年5月. (キーワード) 予防接種単クローン性免疫グロブリン血症-良性(免疫学) 液性免疫アミロイドーシス-免疫グロブリン軽鎖(免疫学) *COVID-19ワクチン(治療的利用,薬理学)
79.	中上絵美子, 天眞寛文, 寺町順平, 日浅雅博, 原田武志, 谷本幸多朗, 清水宗, 比嘉佳基, 住谷龍平, 丸橋朋子, 大浦雅博, 曽我部公子, 中村信元, 三木浩和, 遠藤逸朗, 田中栄二, 安倍正博 : プロテアソーム阻害薬のパルス投与の骨代謝への影響, International Journal of Myeloma, Vol.12, No.3, 152, 2022年5月. (キーワード) 骨髄腫-多発性(薬物療法,病理学) / 骨組織リモデリング / パルス療法(薬物療法) / Proteasome Inhibitors(治療的利用,薬理学) / ヒト (Homo sapiens)
80.	天眞寛文, 原田武志, 井上雄介, 菊池次郎, 小田明日香, 住谷龍平, 大浦雅博, 曽我部公子, 丸橋朋子, 高橋真美子, 藤井志朗, 中村信元, 三木浩和, 日浅雅博, 寺町順平, 鈴木敦, 角川学士, 峯畑健一, 古川雄祐, 安倍正博 : 破骨細胞はSLAMF7を強発現し可溶性SLAMF7を産生する(Osteoclasts robustly express SLAMF7 and secrete soluble SLAMF7), International Journal of Myeloma, Vol.12, No.3, 150, 2022年5月. (キーワード) 骨髄腫-多発性(遺伝学,病理学) 破骨細胞 Signaling Lymphocytic Activation Molecule Family(血液) SLAMF7 Protein(血液) ヒト
81.	吉田守美子, 辻誠士郎, 宮恵子, 島久登, 田代学, 井上朋子, 水口潤, 岡田一義, 中村信元, 安倍正博 : 高齢者透析患者における新型コロナワクチン抗体価に影響する因子の検討, 日本老年医学会雑誌, Vol.59, No.Suppl., 107, 2022年5月. (キーワード) IgG 血液透析ウイルス抗体腎不全-慢性(治療) 予防接種年齢因子 *COVID-19(免疫学) COVID-19ワクチン(治療的利用) ヒト成人(19∼44) 中年(45∼64) 高齢者(65∼79) 高齢者(80∼) 男女
82.	山上紘規, 中村信元, 谷彰浩, 細木美苗, 安井沙耶, 宮田好裕, 堀太貴, 答島章公, 粟飯原賢一, 滝下誠 : 自己免疫疾患における新型コロナワクチンによる抗体獲得能の検討, 第119回日本内科学会総会, 2022年4月.
83.	堀太貴, 中村信元, 谷彰浩, 細木美苗, 安井沙耶, 宮田好裕, 山上紘規, 答島章公, 粟飯原賢一, 滝下誠 : 血液疾患患者における新型コロナウイルスワクチン接種による抗体獲得能の検討, 第119回日本内科学会総会, 2022年4月.
84.	吉田守美子, 辻誠士郎, 倉橋清衛, 宮恵子, 島久登, 田代学, 井上朋子, 水口潤, 中村信元, 黒田暁生, 遠藤逸朗, 安倍正博, 松久宗英 : 透析患者における新型コロナワクチン抗体と糖尿病の関連の検討, 糖尿病, Vol.65, No.Suppl.1, S-165, 2022年4月. (キーワード) 血液透析ウイルス抗体腎不全-慢性(治療) 糖尿病性腎症(治療) 予防接種 COVID-19ワクチン(治療的利用) *Tozinameran(治療的利用) ヒト男女
85.	高原由実子, 三木浩和, 中村信元, 中村昌史, 住谷龍平, 大浦雅博, 曽我部公子, 高橋真美子, 丸橋朋子, 原田武志, 藤井志朗, 安倍正博, 岡本秀樹, 岡田直人, 矢野由美子, 高橋真理, 青田桂子, 尾崎修治 : HIV感染症および後天性免疫不全症候群患者の臨床的特徴と今後の課題, 四国医学雑誌, Vol.78, No.1-2, 89, 2022年4月.
86.	中村信元, 堀太貴, 細木美苗, 安井沙耶, 山上紘規, 答島章公, 滝下誠, 粟飯原賢一 : 血液疾患，自己免疫疾患における新型コロナワクチン接種後の抗体獲得能の検討, 感染症学雑誌, Vol.96, 130, 2022年3月. (キーワード) 血液疾患(薬物療法) ウイルス抗体自己免疫疾患(薬物療法) 予防接種 *COVID-19ワクチン(治療的利用) ヒト中年(45∼64) 高齢者(65∼79) 高齢者(80∼) 男女
87.	住谷龍平, 原田武志, 中村昌史, 水口槙子, 大浦雅博, 曽我部公子, 丸橋朋子, 髙橋真美子, 藤井志朗, 中村信元, 三木浩和, 賀川久美子, 矢田未央, 松立吉弘, 上原久典, 安倍正博 : 少量methotrexate療法が有効であった進行期原発性皮膚未分化大細胞型リンパ腫., 臨床血液, Vol.63, No.6, 536-543, 2022年3月. (要約) 進行期の原発性皮膚未分化大細胞リンパ腫(pcALCL)に対する標準治療は定まっていない．症例は71歳,男性．多発性の皮膚紅斑と結節病変を認め,左耳介後部からの生検でリンパ腫性丘疹症(LyP)と診断された．局所電子線照射にて全ての病変は消退したが,5ヵ月後に両内眼角に結節病変が出現し,同部位の生検ではCD30陽性大型細胞が大部分を占めpcALCLと診断された．PET/CTにて右口蓋扁桃腫大,頸部,鼠径部の表在リンパ節腫大およびFDG集積を認め,TNM分類T3bN3M0であった．慢性閉塞性肺疾患による呼吸機能低下と肺炎を反復していたため,多剤併用化学療法ではなくmethotrexate(MTX)15mg/週の内服療法を選択した．皮膚,リンパ節病変は縮小し,副作用なく長期間病勢コントロールが可能であった．pcALCLの標準治療は確立されていないが様々な治療法が開発されてきており,少量MTX療法は呼吸器感染症を繰り返すフレイルな患者に有用であった．LyPにpcALCLが続発する機序や本疾患群に対する少量MTX療法の作用機序の解明が望まれる．(著者抄録) (キーワード) Etoposid / Methotrexate / 顔面腫瘍 / 肺疾患 (lung disease) / 皮膚疾患-顔面 / 皮膚腫瘍 / 扁桃腫瘍 / 放射線療法 / Folic Acid / リンパ腫-未分化大細胞 / 心筋症-たこつぼ型 / PET-CT検査 / フレイル / ヒト (Homo sapiens) / 高齢者 (出版サイトへのリンク) ● Publication site (DOI): 10.11406/rinketsu.63.536 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.11406/rinketsu.63.536 (DOI: 10.11406/rinketsu.63.536)
88.	中村信元, 堀太貴, 細木美苗, 安井沙耶, 山上紘規, 滝下誠, 粟飯原賢一 : 新型コロナワクチン接種後にvaccine-induced immune thrombotic thrombocytopeniaを疑われた症例., 第33回日本老年病学会四国地方会, 2022年1月23日(Web開催), 2022年2月.
89.	高原由実子, 三木浩和, 中村信元, 中村昌史, 住谷龍平, 大浦雅博, 曽我部公子, 髙橋真美子, 丸橋朋子, 岡本秀樹, 岡田直人, 矢野由美子, 高橋真理, 原田武志, 藤井志朗, 青田桂子, 尾崎修治, 安倍正博 : HIV感染症および後天性免疫不全症候群患者の臨床的特徴と今後の課題., 第264回徳島医学会学術集会(令和3年度冬期), 2022年2月20日(Web開催), 2022年2月.
90.	山上紘規, 中村信元, 細木美苗, 堀太貴, 安井沙耶, 粟飯原賢一, 答島章公, 滝下誠 : 自己免疫疾患における新型コロナワクチンによる抗体獲得能の検討, 日本内科学会雑誌, Vol.111, No.Suppl., 218, 2022年2月. (キーワード) Azathioprine(治療的利用) Methotrexate(治療的利用) Steroids(治療的利用) 関節炎-乾癬性(薬物療法) 関節リウマチ(薬物療法) ウイルス抗体予防接種 Janus Kinase Inhibitors(治療的利用) COVID-19(予防,薬物療法) *COVID-19ワクチン(治療的利用) ヒト中年(45∼64) 高齢者(65∼79) 高齢者(80∼) 男女
91.	堀太貴, 中村信元, 谷彰浩, 細木美苗, 安井沙耶, 宮田好裕, 山上紘規, 答島章公, 粟飯原賢一, 滝下誠 : 血液疾患患者における新型コロナウイルスワクチン接種による抗体獲得能の検討, 日本内科学会雑誌, Vol.111, No.Suppl., 220, 2022年2月. (キーワード) コロナウイルス感染症(予防,薬物療法) ウイルスワクチン(治療的利用) 血液疾患ウイルス抗体肺炎-ウイルス性(予防,薬物療法) 予防接種 COVID-19(予防,薬物療法) *COVID-19ワクチン(治療的利用) ヒト成人(19∼44) 中年(45∼64) 高齢者(65∼79) 高齢者(80∼) 男女
92.	辻誠士郎, 吉田守美子, 宮恵子, 島久登, 田代学, 井上朋子, 水口潤, 中村信元, 遠藤逸朗, 安倍正博 : 65歳以上の透析患者における新型コロナワクチン抗体価の検討, 第33回日本老年医学会四国地方会, 2022年1月.
93.	堀太貴, Shingen Nakamura, Akihiro Tani, Minae Hosoki, Saya Yasui, Hiroki Yamagami, Ken-ichi Aihara, Yuko Miyagami, Takeshi Oya and 滝下誠 : T1, 第125回日本内科学会四国地方会, Dec. 2021.
94.	堀太貴, 中村信元, 細木美苗, 安井沙耶, 山上紘規, 滝下誠, 粟飯原賢一 : 血管中心性に浸潤し急速な経過で死に至った末梢性T細胞リンパ腫の1剖検例, 第125回日本内科学会四国地方会, 2021年12月.
95.	菅崎幹樹, 中村信元, 寺本継脩, 漆原南実, 秦真公人, 三好雅士, 中尾隆之 : アミノグリコシド系抗菌薬がAPTTに与える影響の検討, 日本臨床衛生検査技師会中四国支部医学検査学会抄録集, 28, 2021年12月. (キーワード) Amikacin(治療的利用) Gentamicins(治療的利用) *部分トロンボプラスチン時間ヒト
96.	山田博貴, 大森理央, 岡田直人, 中村信元, 賀川久美子, 藤井志朗, 三木浩和, 石澤啓介, 安倍正博, 佐藤陽一 : ゲノムワイド関連解析によるビンクリスチン副作用発現関連遺伝子の同定と機械学習を用いた副作用発現予測モデルの構築, 第60回日本薬学会中国四国支部学術大会, 2021年11月.
97.	細木美苗, 山上紘規, 安井沙耶, 堀太貴, 中村信元, 乙田敏城, 湯浅智之, 粟飯原賢一 : 当院死亡患者の年齢・死因および併存合併症における糖尿病の影響, 第59回日本糖尿病学会中国四国地方会, 2021年10月.
98.	曽我部公子, 原田武志, 中村信元, 三木浩和, 小田明日香, 井上雄介, 住谷龍平, 丸橋朋子, 大浦雅博, 藤井志朗, 賀川久美子, 天眞寛文, 日浅雅博, 寺町順平, 安倍正博 : PIMとAkt阻害は骨髄腫細胞におけるプロテアソーム阻害薬感受性を増強する, The 83rd Annual Meeting of the Japanese Society of Hematology, 2021年9月.
99.	原田武志, 井上雄介, 天眞寛文, 小田明日香, 住谷龍平, 大浦雅博, 曽我部公子, 藤井志朗, 中村信元, 三木浩和, 賀川久美子, 日浅雅博, 寺町順平, 安倍正博 : CELMoDsを用いたγδT細胞増幅法とエロツズマブによるγδT細胞の抗骨髄腫作用の増強法の開発, 第83回日本血液学会学術集会, 2021年9月.
100.	細木美苗, 山上紘規, 安井沙耶, 堀太貴, 中村信元, 乙田敏城, 湯浅智之, 粟飯原賢一 : 糖尿病の有無からみた当院死亡患者の年齢・死因および併存合併症に関する検討, 第21回日本内分泌学会四国支部学術集会, 2021年9月.
101.	中村信元, 上野宜久, 吉田守美子, 中村昌史, 水口槙子, 住谷龍平, 大浦雅博, 曽我部公子, 高橋真美子, 丸橋朋子, 原田武志, 藤井志朗, 三木浩和, 賀川久美子, 広津崇亮, 安倍正博 : 血液がんにおける線虫がん検査 N-NOSEの検討(Detection of hematological malignancies using N-NOSE(Nematode-NOSE)), 日本血液学会学術集会, OS1-11B-2, 2021年9月. (キーワード) 検尿走化性 Caenorhabditis elegans 造血器腫瘍(診断) ヒト男女
102.	三木浩和, 中村信元, 藤井志朗, 中村昌史, 水口槙子, 住谷龍平, 大浦雅博, 曽我部公子, 髙橋真美子, 丸橋朋子, 原田武志, 賀川久美子, Nishio Susumu, 友成哲, 安倍正博 : 肝臓アミロイドーシスに対する超音波エラストグラフィの診断的有用性., 第83回日本血液学会学術集会, OS1-8D-2, 2021年9月.
103.	曽我部公子, 原田武志, 中村信元, 三木浩和, 小田明日香, 井上雄介, 住谷龍平, 丸橋朋子, 大浦雅博, 藤井志朗, 賀川久美子, 天眞寛文, 日浅雅博, 寺町順平, 安倍正博 : PIMとAkt阻害による骨髄腫細胞のプロテアソーム阻害薬感受性の増強(Sensitization of myeloma cells to proteasome inhibitors by PIM and Akt inhibition), 日本血液学会学術集会, OS2-11D-3, 2021年9月.
104.	西條早希, 中村信元, 三木浩和, 谷口早紀, 岡本秀樹, 岡田直人, 矢野由美子, 高橋真理, 青田桂子, 菅俊行, 渡邊浩良, 大坂朱美, 安倍正博 : 当院における先天性血友病患者(成人例)の実態調査∼移行期医療の重要性∼, 第263回徳島医学会学術集会(令和3年度夏期), 2021年8月.
105.	庄野隆志, 青山万理子, 南城和正, 山本清成, 牧秀則, 乾友浩, 坂本晋一, 小林智子, 中村信元, 滝沢宏光, 丹黒章 : アブスコパル効果を示した甲状腺原発形質細胞腫の1例, 第33回日本内分泌外科学会総会, 2021年6月.
106.	Shingen Nakamura : Detection of hematological malignancies using N-NOSE (Nematode-NOSE), Annals of Oncology, Vol.32, No.suppl4, S312, Jun. 2021. (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.annonc.2021.05.622 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1016/j.annonc.2021.05.622 (DOI: 10.1016/j.annonc.2021.05.622)
107.	原田武志, 井上雄介, 天眞寛文, 小田明日香, 住谷龍平, 大浦雅博, 曽我部公子, 藤井志朗, 中村信元, 三木浩和, 賀川久美子, 日浅雅博, 寺町順平, 安倍正博 : Development of combinatory treatment of Th1-like γδT cells with elotuzumab against osteoclasts as well as myeloma cells, 第46回日本骨髄腫学会学術集会, 2021年5月.
108.	金子遥祐, 安井沙耶, 山上紘規, 堀太貴, 中村信元, 谷口達哉, 乙田敏城, 湯浅智之, 添木武, 粟飯原賢一 : 糖尿病患者における歩行速度規定臨床因子の解析, 第64回日本糖尿病学会年次学術集会, 2021年5月.
109.	粟飯原賢一, 堀太貴, 山上紘規, 安井沙耶, 金子遥祐, 中村信元, 谷口達哉, 乙田敏城, 湯浅智之, 添木武, 安倍正博 : 生体電気インピーダンス法による細胞外水分比および位相角と糖尿病患者における血中HbおよびHtレベルの連関解析, 第64回日本糖尿病学会年次学術集会, 2021年5月.
110.	山上紘規, 安井沙耶, 金子遥祐, 堀太貴, 中村信元, 谷口達哉, 乙田敏城, 湯浅智之, 添木武, 粟飯原賢一 : 糖尿病患者におけるDehydroepiandrosterone sulfate (DHEAS)の糖尿病性腎臓病進展および高血圧症罹患における意義, 第64回日本糖尿病学会年次学術集会, 2021年5月.
111.	安井沙耶, 山上紘規, 金子遥祐, 堀太貴, 中村信元, 谷口達哉, 乙田敏城, 湯浅智之, 添木武, 粟飯原賢一 : 糖尿病患者における非アルコール性脂肪肝疾患および骨格筋異常症におけるDehydroepiandrosterone sulfate (DHEAS)の意義, 第64回日本糖尿病学会年次学術集会, 2021年5月.
112.	堀太貴, 中村信元, 金子遥祐, 安井沙耶, 山上紘規, 粟飯原賢一, 滝下誠 : 1, 第124回日本内科学会四国地方会, 2021年5月.
113.	堀太貴, 中村信元, 細木美苗, 安井沙耶, 山上紘規, 滝下誠, 粟飯原賢一 : 腫大リンパ節に著明なアミロイド沈着を認めたリンパ形質細胞性リンパ腫の1例, 第124回日本内科学会四国地方会, 2021年5月.
114.	三木浩和, 中村信元, 中村昌史, 水口槙子, 住谷龍平, 大浦雅博, 曽我部公子, 髙橋真美子, 丸橋朋子, 原田武志, 藤井志朗, 賀川久美子, 近藤正輝, 岡田直人, 坂東良美, 遠藤逸朗, 安倍正博 : 骨髄腫骨関連事象の発生予防における身体機能維持の重要性, 第46回日本骨髄腫学会学術集会, 2021年5月.
115.	曽我部公子, 原田武志, 中村信元, 三木浩和, 小田明日香, 井上雄介, 住谷龍平, 大浦雅博, 藤井志朗, 賀川久美子, 天眞寛文, 日浅雅博, 寺町順平, 李政樹, 飯田真介, 安倍正博 : 骨髄腫細胞のプロテアソーム阻害薬の耐性機序におけるPIM2とAkt活性およびNRF2蓄積の役割(Mechanisms for the resistance to proteasome inhibitors in myeloma cells: the role of PIM2 and Akt kinase activation and NRF2 accumulation), International Journal of Myeloma, Vol.11, No.2, 85, 2021年5月. (キーワード) 癌原遺伝子タンパク質骨髄腫-多発性(遺伝学,実験的) Protein-Serine-Threonine Kinases 抗腫瘍剤耐性 c-akt癌原遺伝子タンパク質 NF-E2-Related Factor 2 Proteasome Inhibitors(薬理学) *PIM2 Protein
116.	安井沙耶, 山上紘規, 金子遥祐, 堀太貴, 中村信元, 谷口達哉, 乙田敏城, 湯浅智之, 添木武, 粟飯原賢一 : 糖尿病患者における非アルコール性脂肪肝疾患および骨格筋異常症におけるDehydroepiandrosterone sulfate(DHEAS)の意義, 糖尿病, Vol.64, No.Suppl.1, I-11-3, 2021年5月. (キーワード) 糖尿病 (diabetes) / Dehydroepiandrosterone Sulfate / 骨格筋 / 筋肉減少症 / 肝疾患 / 非アルコール性脂肪性 / ヒト / 男性 (male) / 女性 (female)
117.	金子遥祐, 湯浅智之, 添木武, 乙田敏城, 谷口達哉, 粟飯原賢一, 安井沙耶, 堀太貴, 山上紘規, 中村信元 : 糖尿病患者における歩行速度規定臨床因子の解析, 糖尿病, Vol.64, No.Suppl.1, III-133-4, 2021年5月.
118.	山上紘規, 安井沙耶, 金子遥祐, 堀太貴, 中村信元, 谷口達哉, 乙田敏城, 湯浅智之, 添木武, 粟飯原賢一 : 糖尿病患者におけるDehydroepiandrosterone sulfate(DHEAS)の糖尿病性腎臓病進展および高血圧症罹患における意義, 糖尿病, Vol.64, No.Suppl.1, P-35-6, 2021年5月.
119.	堀太貴, 山上紘規, 安井沙耶, 金子遥祐, 中村信元, 谷口達哉, 乙田敏城, 湯浅智之, 添木武, 安倍正博, 粟飯原賢一 : 生体電気インピーダンス法による細胞外水分比および位相角は糖尿病患者の血中HbおよびHtレベルを規定する, 第94回日本内分泌学会学術総会, 2021年4月.
120.	山上紘規, 安井沙耶, 金子遥祐, 堀太貴, 中村信元, 谷口達哉, 乙田敏城, 湯浅智之, 添木武, 粟飯原賢一 : Dehydroepiandrosterone sulfate (DHEAS)高値は糖尿病性腎臓病進展および高血圧症罹患のリスクとなる, 第94回日本内分泌学会学術総会, 2021年4月.
121.	金子遥祐, 安井沙耶, 山上紘規, 堀太貴, 中村信元, 谷口達哉, 乙田敏城, 湯浅智之, 添木武, 粟飯原賢一 : 生活習慣病患者の歩行速度は骨格筋量よりも筋力が規定する, 第94回日本内分泌学会学術総会, 2021年4月.
122.	金子遥祐, 安井沙耶, 山上紘規, 堀太貴, 中村信元, 谷口達哉, 乙田敏城, 湯浅智之, 添木武, 粟飯原賢一 : 生活習慣病患者の歩行速度は骨格筋量よりも筋力が規定する, 日本内分泌学会雑誌, Vol.97, No.1, 366, 2021年4月. (キーワード) 筋骨格系生理学的現象骨格筋身体組成筋力生活習慣病(診断) 歩行速度 *筋量ヒト男女
123.	山上紘規, 金子遥祐, 安井沙耶, 堀太貴, 中村信元, 谷口達哉, 乙田敏城, 湯浅智之, 添木武, 粟飯原賢一 : Dehydroepiandrosterone sulfate(DHEAS)高値は糖尿病性腎臓病進展および高血圧症罹患のリスクとなる, 日本内分泌学会雑誌, Vol.97, No.1, 340, 2021年4月. (キーワード) 高血圧(病因,診断) 糖尿病性腎症(病因,診断) *Dehydroepiandrosterone Sulfate(血液) ヒト男女
124.	安井沙耶, 山上紘規, 金子遥祐, 堀太貴, 中村信元, 谷口達哉, 乙田敏城, 湯浅智之, 添木武, 粟飯原賢一 : Dehydroepiandrosterone sulfate(DHEAS)は生活習慣病患者における非アルコール性脂肪肝疾患およびダイナペニアの発症抑制因子である, 日本内分泌学会雑誌, Vol.97, No.1, 287, 2021年4月. (キーワード) Dehydroepiandrosterone Sulfate(血液) 生活習慣病(診断,病因,合併症) *肝疾患-非アルコール性脂肪性(診断,病因,合併症) ヒト男女
125.	石田卓也, 三木浩和, 髙橋真美子, 中村昌史, 水口槙子, 住谷龍平, 大浦雅博, 曽我部公子, 丸橋朋子, 岡本秀樹, 岡田直人, 矢野由美子, 高橋真理, 友成哲, 原田武志, 藤井志朗, 中村信元, 賀川久美子, 青田桂子, 渡邊浩良, 安倍正博 : HIV感染血友病患者における臨床的特徴と今後の課題, 第262回徳島医学会学術集会, 2021年3月.
126.	丸橋朋子, 藤井志朗, 賀川久美子, 中村昌史, 川田知代, 水口槇子, 住谷龍平, 大浦雅博, 曽我部公子, 高橋真美子, 原田武志, 中村信元, 三木浩和, 安倍正博 : 造血幹細胞移植(allo-SCT)が奏効したMLL遺伝子変異合併CML急性転化(CML-BP)の2例, 第43回日本造血細胞移植学会総会, 2021年3月.
127.	東桃代, 中村信元, 吉田志緒美 : ∼抗酸菌症にチームで立ち向かう∼最新の知見と新たな光∼ 無菌手洗い装置によるMycobacterium chimaeraの偽アウトブレイク, 日本化学療法学会雑誌, Vol.69, No.2, 177-178, 2021年3月. (キーワード) Mycobacterium 抗酸菌症環境微生物学給水院内感染 *保菌者状態ヒト
128.	東桃代, 中村信元, 吉田志緒美 : ~抗酸菌症にチームで立ち向かう~最新の知見と新たな光~ 無菌手洗い装置によるMycobacterium chimaeraの偽アウトブレイク, 日本化学療法学会雑誌, Vol.69, No.2, 177-178, 2021年3月. (キーワード) Mycobacterium / 抗酸菌症 / 環境微生物学 / 給水 / 院内感染 / 保菌者状態 / ヒト
129.	安井沙耶, 山上紘規, 金子遥祐, 堀太貴, 中村信元, 谷口達哉, 乙田敏城, 湯浅智之, 添木武, 粟飯原賢一 : 当院生活習慣病患者における骨格筋量に影響を与える因子の検討, 日本内分泌学会雑誌, Vol.96, No.3, 822, 2021年1月. (キーワード) 筋骨格系生理学的現象 / 骨格筋 / 身体組成 / 生活習慣病(診断) / 筋量 / ヒト / 中年(45~64) / 高齢者(65~79) / 男 / 女
130.	山上紘規, 安井沙耶, 金子遥祐, 堀太貴, 中村信元, 谷口達哉, 乙田敏城, 湯浅智之, 添木武, 粟飯原賢一 : 当院生活習慣病患者における握力と歩行速度に影響を与える因子の検討, 日本内分泌学会雑誌, Vol.96, No.3, 822, 2021年1月. (キーワード) 加齢 / 握力 / 生活習慣病(診断) / 歩行速度 / 中年(45~64) / 高齢者(65~79) / 男 / 女
131.	武井みのり, 岡田直人, 中村信元, 賀川久美子, 藤井志朗, 三木浩和, 石澤啓介, 安倍正博, 佐藤陽一 : 機械学習による遺伝情報を用いた抗がん剤投与の味覚障害発現予測モデルの構築, 第59回中国四国支部学術大会, 2020年12月.
132.	遠藤優香, 田島穂澄, 岡田直人, 中村信元, 賀川久美子, 藤井志朗, 三木浩和, 石澤啓介, 安倍正博, 佐藤陽一 : ゲノム情報を用いた機械学習によるシタラビン投与後の副作用発現予測モデルの構築, 第59回中国四国支部学術大会, 2020年12月.
133.	清重尚希, 住谷龍平, 水口槙子, 中村昌史, 大浦雅博, 曽我部公子, 高橋真美子, 原田武志, 藤井志朗, 賀川久美子, 安倍正博, 中村信元, 三木浩和, 曽賀愛未, 一宮由貴, 山本由理 : 急性転化をきたしたAYA世代慢性骨髄性白血病の1例, 四国医学雑誌, Vol.76, No.5-6, 354-355, 2020年12月. (キーワード) 同種移植抗腫瘍剤(治療的利用) *白血病-BCR-ABL陽性慢性骨髄性(診断,治療,薬物療法) 急性転化(白血病) 障害者の子供造血幹細胞移植家族介護者ヒト青年期(13~18) 女
134.	高原実香, 山本伸昭, 宮本亮介, 藤田浩司, 和泉唯信, 住谷龍平, 中村信元, 安倍正博, 島津秀紀, 西田善彦 : 意識障害，高アンモニア血症を呈した78歳男性, 四国医学雑誌, Vol.76, No.5-6, 346, 2020年12月. (キーワード) Dexamethasone(治療的利用) / 意識障害(病因) / 腫瘍多剤併用療法 / 骨髄腫-多発性(合併症,病理学,薬物療法) / 高アンモニア血症(病因,診断) / Bortezomib(治療的利用) / BD Protocol (Bortezomib-Dexamethasone) / ヒト / 高齢者(65~79) / 男
135.	三木浩和, 李悦子, 佃恵里加, 小田直輝, 瀧本朋美, 中村昌史, 水口槙子, 住谷龍平, 大浦雅博, 曽我部公子, 高橋真美子, 原田武志, 藤井志朗, 賀川久美子, 安倍正博, 中村信元 : Daratumumab投与による輸血関連検査への影響とその対策, 四国医学雑誌, Vol.76, No.5-6, 341, 2020年12月. (キーワード) Coombsテスト / 骨髄腫-多発性(診断,薬物療法) / Daratumumab(治療的利用) / ヒト / 中年(45~64) / 高齢者(65~79) / 高齢者(80~) / 男 / 女
136.	宮田好裕, 板垣達三, 藤本美幸, 答島章公, 滝下誠, 日比野真吾, 中村信元 : リツキシマブもしくはリツキシマブ併用化学療法を要した濾胞性リンパ腫の十二指腸病変の検討, 日本消化器病学会四国支部例会プログラム・抄録集, 60, 2020年12月. (キーワード) 腫瘍多剤併用療法十二指腸腫瘍(診断,薬物療法,予後) リンパ腫-濾胞性(診断,薬物療法,予後) *Rituximab(治療的利用) ヒト中年(45~64) 高齢者(65~79) 男女
137.	市原聖也, 住谷龍平, 中村昌史, 水口槙子, 原田武志, 藤井志朗, 中村信元, 三木浩和, 賀川久美子, 安倍正博 : ウイルス関連血球貪食症候群が疑われたアグレッシブNK細胞白血病の1例, 第123回日本内科学会四国地方会, 2020年11月.
138.	金山涼加, 倉橋清衛, 明比祐子, 岡本耕一, 中村信元, 吉田守美子, 遠藤逸朗, 高山哲治, 安倍正博 : 潰瘍性大腸炎とバセドウ病の治療中に汎血球減少を契機に自己免疫性胃炎が判明した一例, 第123回日本内科学会四国地方会, 2020年11月.
139.	金子遥祐, 中村信元, 細木美苗, 安井沙耶, 山上紘規, 堀太貴, 滝下誠, 粟飯原賢一 : アミカシンによるAPTT偽延長を来したSerratia marcescens菌血症の1例, 第123回日本内科学会四国地方会, 2020年11月.
140.	金山涼加, 中村信元 : 潰瘍性大腸炎とバセドウ病の治療中にLDH著明高値を伴った汎血球減少を契機に自己免疫性胃炎が判明した1例, 第123回日本内科学会四国地方会, 2020年11月.
141.	曽我部公子, 中村信元, 藤井志朗, 三木浩和, 小田明日香, 原田武志, 住谷龍平, 大浦雅博, 賀川久美子, 天眞寛文, 寺町順平, Masaki Ri, Shinsuke Iida, 安倍正博 : プロテアソーム阻害薬による骨髄腫細胞の抗アポトーシス因子PIM2の急速な蓄積, 第82回日本血液学会学術集会, 2020年10月.
142.	大浦雅博, 原田武志, 寺町順平, 小田明日香, 井上雄介, 曽我部公子, 住谷龍平, 藤井志朗, 中村信元, 三木浩和, 賀川久美子, Hasegawa Hiroo, Fujiwara Hiroshi, 安倍正博 : ATL新規治療標的としてのTAK1-c-Myc相互連関の重要な役割, 第82回日本血液学会学術集会, 2020年10月.
143.	谷本幸多朗, 日浅雅博, 天眞寛文, ASHTAR MOHANNAD, 清水宗, 比嘉佳基, 寺町順平, 原田武志, 中村信元, 三木浩和, 遠藤逸朗, 田中栄二, 松本俊夫, 安倍正博 : 不動は骨吸収と骨髄腫進展を促進させる, 日本骨代謝学会学術集会プログラム抄録集, 149, 2020年10月.
144.	天眞寛文, ASHTAR MOHANNAD, 寺町順平, 日浅雅博, 谷本幸多朗, 清水宗, 比嘉佳基, 原田武志, 大浦雅博, 曽我部公子, 中村信元, 三木浩和, 遠藤逸朗, 田中栄二, 松本俊夫, 安倍正博 : 抗腫瘍薬が誘導するROSは破骨細胞分化を促進する:Xanthine oxidase阻害剤febuxostatの治療効果．, 日本骨代謝学会学術集会プログラム抄録集, 148, 2020年10月.
145.	Takeshi Harada, Yusuke Inoue, Hirofumi Tenshin, Asuka Oda, Masahiro Oura, Kimiko Sogabe, Ryohei Sumitani, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe : Versatile anti-myeloma effects by elotuzumab: impact on γδT cells and osteoclasts, The 82nd Annual Meeting of Japanese Soceity of Hematology, Oct. 2020.
146.	倉橋清衛, 村井純平, 堀太貴, 住谷龍平, 原田武志, 中村信元, 金井麻衣, 櫻井明子, 原倫世, 桝田志保, 吉田守美子, 遠藤逸朗, 松本俊夫, 安倍正博, 福本誠二 : 高1,25(OH)2D血症による高Ca血症を来したホジキンリンパ腫の一例, 日本骨代謝学会学術集会プログラム抄録集, 150, 2020年10月. (キーワード) Calcitriol Dacarbazine(治療的利用) Doxorubicin(治療的利用) Hodgkin病(合併症,病理学,薬物療法) Vinblastine(治療的利用) *高カルシウム血症(病因,病理学,薬物療法) 免疫組織化学 Brentuximab Vedotin(治療的利用) ヒト高齢者(65~79) 男
147.	Hirofumi Tenshin, アシテルモハナッド, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Sou Shimizu, 比嘉佳基, Takeshi Harada, Masahiro Oura, Kimiko Sogabe, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe : 抗腫瘍薬が誘導するROSは破骨細胞分化を促進する Xanthine oxidase阻害剤febuxostatの治療効果, The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts, 148, Oct. 2020. (キーワード) Xanthine Oxidase(拮抗物質・阻害物質) / 活性酸素 (reactive oxygen species) / 抗腫瘍剤(毒性・副作用) / 骨吸収(化学的誘発,薬物療法,実験的) / 細胞分化 (cell differentiation) / 破骨細胞 (osteoclast) / 破骨細胞分化因子 / Febuxostat(治療的利用) / RAW264.7細胞 / マウス / 動物 (animal)
148.	大浦雅博, 中村信元, 堀太貴, 曽我部公子, 原田武志, 藤井志朗, 三木浩和, 賀川久美子, 小林智子, 尾矢剛志, 安倍正博 : 結節性紅斑と悪性腫瘍関連血球貪食症候群を惹起した骨髄異形成症候群の1例, 臨床血液, Vol.61, No.10, 1542, 2020年10月. (キーワード) 骨髄異形成症候群(合併症) 紅斑-結節性(病因) *血球貪食性リンパ組織球症(病因) ヒト中年(45~64) 男
149.	中村昌史, 三木浩和, 大浦雅博, 川田知代, 堀太貴, 村井純平, 住谷龍平, 曽我部公子, 高橋真美子, 原田武志, 藤井志朗, 中村信元, 賀川久美子, 菅崎幹樹, 徳永尚樹, 池亀彰茂, 森下英理子, 安倍正博 : クロスミキシングテストの特徴的な所見が診断の契機となったプレカリクレイン欠乏症の1例, 臨床血液, Vol.61, No.10, 1537-1538, 2020年10月. (キーワード) Prekallikrein(欠損・欠乏) 血液凝固異常(診断) *血液凝固検査ヒト中年(45~64) 男
150.	山上紘規, 安井沙耶, 金子遥祐, 堀太貴, 中村信元, 谷口達哉, 乙田敏城, 湯浅智之, 添木武, 粟飯原賢一 : 当院生活習慣病患者における握力と歩行速度に影響を与える因子の検討, 第20回日本内分泌学会四国支部学術集会, 2020年9月.
151.	安井沙耶, 山上紘規, 金子遥祐, 堀太貴, 中村信元, 谷口達哉, 乙田敏城, 湯浅智之, 添木武, 粟飯原賢一 : 当院生活習慣病患者における骨格筋量に影響を与える因子の検討, 第20回日本内分泌学会四国支部学術集会, 2020年9月.
152.	堀大貴, 中村信元, 原田武志, 住谷龍平, 村井純平, 高松信敏, 手束文威, 安倍正博 : 若年で発症しアトピー性皮膚炎に合併した化膿性脊椎炎の1例, 第123回日本内科学会四国地方会, 2020年7月.
153.	岡田直人, 神農麻里奈, 中村信元, 三木浩和, 渡邊浩良, 合田光寛, 中馬真幸, 武智研志, 座間味義人, 桐野靖, 中村敏己, 寺岡和彦, 安倍正博, 石澤啓介 : 血液凝固因子製剤の在庫適正化に向けた取り組みによる薬剤廃棄額の削減効果, 日本病院薬剤師会雑誌, Vol.56, No.7, 803-808, 2020年7月. (要約) 血友病治療に用いる血液凝固因子製剤(coagulation factor:以下，CF)は高価である一方で，在庫流動性が低いという製剤的性質を有するが，これまで適切な在庫管理法の報告はない．徳島大学病院は2017年4月から，診療科と連携したCFの在庫適正化の取り組みを開始した．取り組み開始前である2015年4月~2017年3月の期間と，取り組み開始後である2017年4月~2019年3月の期間における血友病患者数，CF調剤薬剤数に差はなかったが，取り組み開始後のCF廃棄額は取り組み開始前と比較して78.4 (キーワード) 血液凝固因子(治療的利用) / 血友病A(薬物療法) / 病院在庫管理 / ヒト / 新生児 / 乳児(1~23ヶ月) / 幼児(2~5) / 小児(6~12) / 青年期(13~18) / 成人(19~44) / 中年(45~64) / 高齢者(65~79) / 男 / 女
154.	山崎佳那子, 祖川麻衣子, 村尾和俊, 久保宜明, 大浦雅博, 原田武志, 中村信元, 賀川久美子 : 骨髄異形成症候群の患者に生じた晩発性皮膚ポルフィリン症の1例, 西日本皮膚科, Vol.82, No.3, 238-239, 2020年6月. (キーワード) 骨髄異形成症候群(合併症) Uroporphyrins(尿) ポルフィリン症-晩発性皮膚(合併症,診断) ヒト中年(45~64) 男
155.	秦真公人, 菅崎幹樹, 井上雄介, 多田智紀, 吉田裕子, 中尾隆之, 住谷龍平, 中村信元, 安倍正博, 高山哲治 : 特徴的な形態像を呈し鑑別に苦慮したIgDκ型多発性骨髄腫の一症例, 日本検査血液学会雑誌, Vol.21, S244, 2020年6月. (キーワード) IgD(血液) 骨髄腫-多発性(診断,免疫学) ヒト高齢者(65~79) 男
156.	村井純平, 堀太貴, 川田知代, Ryohei Sumitani, 宇高憲吾, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Kumiko Kagawa, Masahiro Abe, Hirokazu Miki, 桝田志保, Itsuro Endo and Seiji Fukumoto : 高ビタミンD血症による高Ca血症を来したホジキンリンパ腫の一例, Shikoku Acta Medica, Vol.76, No.1-2, 124, Apr. 2020. (キーワード) Calcitriol(毒性・副作用,血液) / Hodgkin病(合併症,薬物療法) / Vitamin D(毒性・副作用,血液) / 高カルシウム血症(化学的誘発) / 腫瘍多剤併用療法 / ヒト / 高齢者(65~79) / 男
157.	遠藤優香, 田島穂澄, 岡田直人, 中村信元, 賀川久美子, 藤井志朗, 三木浩和, 石澤啓介, 安倍正博, 佐藤陽一 : 機械学習を用いたゲノム情報によるシタラビン投与の副作用発現予測モデルの構築, 日本薬学会第140年会, 2020年3月.
158.	武井みのり, 岡田直人, 中村信元, 賀川久美子, 藤井志朗, 三木浩和, 石澤啓介, 安倍正博, 佐藤陽一 : 遺伝情報を用いた機械学習による抗がん剤投与の味覚障害発現予測モデルの構築, 日本薬学会第140年会, 2020年3月.
159.	遠藤優香, 田島穂澄, 岡田直人, 中村信元, 賀川久美子, 藤井志朗, 三木浩和, 石澤啓介, 安倍正博, 佐藤陽一 : 機械学習を用いたゲノム情報によるシタラビン投与の副作用発現予測モデルの構築, 日本薬学会年会要旨集, 26M-am07S, 2020年3月. (キーワード) Cytarabine(毒性・副作用) / 皮膚疾患(化学的誘発) / リスク評価 / 機械学習 / ヒト
160.	阿部彰子, 岩佐武, 山本由理, 森本雅美, 中村信元, 桑原章 : 徳島県におけるがん生殖医療の現状と課題, 日本がん·生殖医療学会誌, Vol.3, No.1, 106, 2020年1月. (キーワード) 腫瘍地域社会ネットワーク徳島県 *妊孕性温存ヒト女
161.	天眞寛文, 寺町順平, 日浅雅博, 谷本幸多朗, ASHTAR MOHANNAD, Bat-Erdene Ariunzaya, 岩佐昌美, 原田武志, 中村信元, 三木浩和, 遠藤逸朗, 田中栄二, 松本俊夫, 安倍正博 : TAK1阻害は関節リウマチにおけるNLRP3インフラマソーム誘導性の炎症および骨破壊を抑制する, 日本骨代謝学会学術集会プログラム抄録集, 190, 2019年10月.
162.	谷本幸多朗, 日浅雅博, 岩浅亮彦, 天眞寛文, 寺町順平, ASHTAR MOHANNAD, 岩佐昌美, 小田明日香, 曾我部公子, 大浦雅博, 原田武志, 中村信元, 三木浩和, 遠藤逸朗, 田中栄二, 松本俊夫, 安倍正博 : 不動性骨吸収の亢進は骨髄内の骨髄腫進展を促進させる．, 日本骨代謝学会学術集会プログラム抄録集, 2019年10月.
163.	天眞寛文, 寺町順平, 日浅雅博, 谷本幸多朗, ASHTAR MOHANNAD, Ariunzaya Bat-Erdene, 岩佐昌美, 原田武志, 中村信元, 三木浩和, 遠藤逸朗, 田中栄二, 松本俊夫, 安倍正博 : TAK1阻害は関節リウマチにおけるNLRP3インフラマソーム誘導性の炎症および骨破壊を抑制する．, 第37回日本骨代謝学会学術集会, 2019年10月.
164.	谷本幸太朗, 日浅雅博, 天眞寛文, 寺町順平, ASHTAR MOHANNAD, 岩佐昌美, 小田明日香, 曽我部公子, 大浦雅博, 原田武志, 中村信元, 三木浩和, 遠藤逸朗, 田中栄二, 松本俊夫, 安倍正博 : 不動性骨吸収の亢進は骨髄内の骨髄腫進展を促進させる, 第37回日本骨代謝学会学術集会, 2019年10月.
165.	Sakaida Emiko, Kanda Yoshinobu, Kimura Shunichi, Shingen Nakamura and Tamura Kazuo : D-index-guided early antifungal therapy for persistent FN in patients with hematological malignancies (CEDMIC trial), Annals of Oncology, Vol.30, No.6, VI84, Oct. 2019. (出版サイトへのリンク) ● Publication site (DOI): 10.1093/annonc/mdz339.008 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1093/annonc/mdz339.008 (DOI: 10.1093/annonc/mdz339.008)
166.	十川悠香, 吉岡昌美, 南明香, 福井誠, 日野出大輔, 中村信元, 安倍正博 : 自家末梢血幹細胞移植患者の口腔ケアによる口腔粘膜炎障害の低減効果, 第68回日本口腔衛生学会総会, 2019年5月.
167.	安宅克博, 中村信元, 大浦雅博, 曽我部公子, 原田武志, 藤井志朗, 三木浩和, 賀川久美子, 西岡安彦, 安倍正博 : 長期にわたる血小板減少が先行した芽球性形質細胞様樹状細胞腫瘍の1例, 第120回日本内科学会四国地方会, 2019年5月.
168.	谷垣雄都, 山口裕大, 岡田直人, 中村信元, 賀川久美子, 藤井志朗, 三木浩和, 石澤啓介, 安倍正博, 佐藤陽一 : ゲノムワイド関連解析を用いたテイコプラニン・バンコマイシン投与による皮疹発現および血中濃度関連遺伝子座の同定, 日本薬学会第139年会, 2019年3月.
169.	大森理央, 岡田直人, 中村信元, 賀川久美子, 藤井志朗, 三木浩和, 石澤啓介, 安倍正博, 佐藤陽一 : ゲノムワイド関連解析を用いたビンクリスチンによる末梢神経障害発現関連遺伝子の同定, 第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2018年11月.
170.	山口裕大, 谷垣雄都, 岡田直人, 中村信元, 賀川久美子, 藤井志朗, 三木浩和, 石澤啓介, 安倍正博, 佐藤陽一 : CYP遺伝子多型とバンコマイシンの副作用発現及び血中濃度との関連解析, 第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2018年11月.
171.	Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Oda Asuka, Bat-Erdene Ariunzaya, Takeshi Harada, Iwasa Masami, Shiroh Fujii, Kimiko Sogabe, Shingen Nakamura, Hirokazu Miki, Masahiro Oura, Kumiko Kagawa, Itsuro Endo, Toshio Matsumoto and Masahiro Abe : Mechanisms of TAK1 over-activation in myeloma cells and TAK1-mediated myeloma growth and bone destruction, 第80回日本血液学会学術集会, Oct. 2018.
172.	岩佐昌美, 原田武志, Ariunzaya Bat-Erdene, 小田明日香, 曽我部公子, 大浦雅博, 寺町順平, 藤井志朗, 中村信元, 三木浩和, 賀川久美子, 安倍正博 : HDAC阻害による骨髄腫細胞のIFN-γ-STAT1- PD-L1経路の増強効果, 第80回日本血液学会学術集会, 2018年10月. (キーワード) Multiple myeloma
173.	Ashtar Mohannad, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Oda Asuka, Iwasa Masami, Takeshi Harada, Ariunzaya Erdene Bat, Kimiko Sogabe, Oura Masahiro, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe : Roles of ROS in induction of bone disease and cancer treatment-induced bone loss in myeloma., The 80th Annual Meeting of the Japanese Society of Hematology, Oct. 2018.
174.	Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Mohannad Ashtar, Ariunzaya Bat-Erdene, Iwasa Masami, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Kimiko Sogabe, Oura Masahiro, Shiroh Fujii, Kumiko Kagawa, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe : Inverse regulation of c-FLIP-mediated survival in myeloma cells and osteoclasts by TRAIL., The 80th Annual Meeting of the Japanese Society of Hematology, Oct. 2018.
175.	Kotaro Tanimoto, Masahiro Hiasa, Hirofumi Tenshin, Jumpei Teramachi, Oda Asuka, Mohannad Ashtar, Ariunzaya Bat-Erdene, Iwasa Masami, Kimiko Sogabe, Oura Masahiro, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe : Impact of denervation-induced paralysis and mechanical unloading on tumor expansion in myeloma., The 80th Annual Meeting of the Japanese Society of Hematology, Oct. 2018.
176.	Masahiro Hiasa, Jumpei Teramachi, Hirofumi Tenshin, Kotaro Tanimoto, Ariunzaya Bat-Erdene, Mohannad Ashtar, Masami Iwasa, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Kimiko Sogabe, Oura Masahiro, Shiroh Fujii, Kumiko Kagawa, Oda Asuka, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe : The effects of cathepsin K inhibition on osteocytes: its role in bone restoration in MM bone disease., The 80th Annual Meeting of the Japanese Society of Hematology, Oct. 2018.
177.	日浅雅博, 寺町順平, 天眞寛文, 谷本幸多朗, ASHTAR MOHANNAD, Ariunzaya Bat-Erdene, 岩佐昌美, 原田武志, 中村信元, 三木浩和, 遠藤逸朗, 田中栄二, 松本俊夫, 安倍正博 : カテプシンK阻害による多発性骨髄腫骨病変部の骨量回復プロセスにおける骨細胞の役割．, 第36回日本骨代謝学会学術集会, 2018年7月.
178.	天眞寛文, 寺町順平, 日浅雅博, 谷本幸多朗, ASHTAR MOHANNAD, Ariunzaya Bat-Erdene, 岩佐昌美, 原田武志, 中村信元, 三木浩和, 遠藤逸朗, 田中栄二, 松本俊夫, 安倍正博 : TAK1阻害はTRAILによる破骨細胞活性化作用を遮断させると同時にTRAILの抗骨髄腫作用を増強する, 第36回日本骨代謝学会学術集会, 2018年7月.
179.	天眞寛文, 寺町順平, 日浅雅博, 小田明日香, 谷本幸多朗, ASHTAR MOHANNAD, Ariunzaya Bat-Erdene, 岩佐昌美, 原田武志, 中村信元, 三木浩和, 遠藤逸朗, 田中栄二, 松本俊夫, 安倍正博 : TAK1による破骨細胞に対するTRAILの生存・細胞死シグナル制御機構．, 第4回日本骨免疫学会, 2018年6月.
180.	谷本幸多朗, 日浅雅博, 天眞寛文, 寺町順平, 小田明日香, ASHTAR MOHANNAD, Ariunzaya Bat-Erdene, 岩佐昌美, 曽我部公子, 大浦雅弘, 原田武志, 中村信元, 三木浩和, 遠藤逸朗, 田中栄二, 松本俊夫, 安倍正博 : 神経切断による麻痺と免荷の骨髄腫の進展への影響．, 第4回日本骨免疫学会, 2018年6月.
181.	岩佐昌美, 原田武志, Ariunzaya Bat-Erdene, 小田明日香, 前田悠作, 高橋真美子, 大浦雅博, 寺町順平, 藤井志朗, 中村信元, 三木浩和, 賀川久美子, 安倍正博 : パノビスタットによる骨髄腫細胞のIFN-γ-STAT1- PD-L1経路の増強, The 43rd Annual Meeting of the Japanese Society of Myeloma, 2018年5月. (キーワード) Multiple myeloma
182.	原田武志, Oda Asuka, 寺町順平, Bat-Erdene Ariunzaya, 岩佐昌美, Maeda Yusaku, 中村信元, Oura Masahiro, 藤井志朗, 三木浩和, 賀川久美子, Hideshima Teru, Anderson C. Kenneth, 安倍正博 : HDAC1/3 inhibition disrupts the IRF4-Pim-2 pathway to induce effective myeloma cell death, The 43rd Annual Meeting of the Japanese Society of Myeloma, 2018年5月. (キーワード) Multiple myeloma / Class-I HDAC / IRF4 / Pim-2
183.	谷垣雄都, 佐藤陽一, 山口裕大, 岡田直人, 中村信元, 賀川久美子, 藤井志朗, 三木浩和, 石澤啓介, 安倍正博, 山内あい子 : テイコプラニン投与による副作用発現および血中濃度とCYP遺伝子多型との関連解析, 第56回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2017年10月.
184.	田島穂澄, 佐藤陽一, 岡田直人, 中村信元, 賀川久美子, 藤井志朗, 三木浩和, 石澤啓介, 安倍正博, 山内あい子 : シタラビン投与による副作用発現と代謝経路関連遺伝子多型の関連解析, 第56回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2017年10月.
185.	Jumpei Teramachi, Masahiro Hiasa, Oda Asuka, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Masami Iwasa, Masahiro Oura, Yusaku Maeda, Shiroh Fujii, Kumiko Kagawa, Hirokazu Miki, Itsuro Endo, Toshio Matsumoto and Masahiro Abe : Disruption of myeloma cell-bone marrow interaction by TAK-1 inhibition, 第80回日本血液学会学術集会, Oct. 2017.
186.	天眞寛文, 寺町順平, 小田明日香, 天知良太, 日浅雅博, 渡邉佳一郎, Ariunzaya Baterdene, 岩佐昌美, 藤井志朗, 賀川久美子, 中村信元, 三木浩和, 遠藤逸朗, 田中栄二, 松本俊夫, 安倍正博 : TRAILは破骨細胞を活性化させるが，TAK1阻害により骨髄腫細胞とともに破骨細胞にもTRAILのアポトーシス誘導活性が惹起できる, 第35回日本骨代謝学会学術集会, 2017年7月.
187.	大森理央, 佐藤陽一, 木口美沙妃, 岡田直人, 中村信元, 賀川久美子, 藤井志朗, 三木浩和, 石澤啓介, 安倍正博, 山内あい子 : ビンクリスチンによる副作用発現とMDR1遺伝子多型との関連性, 第20回日本医薬品情報学会総会・学術大会, 2017年7月.
188.	山口裕大, 佐藤陽一, 谷垣雄都, 岡田直人, 中村信元, 賀川久美子, 藤井志朗, 三木浩和, 石澤啓介, 安倍正博, 山内あい子 : バンコマイシン投与による副作用発現及び血中濃度とCYP遺伝子多型との関連解析, 第20回日本医薬品情報学会総会・学術大会, 2017年7月.
189.	天眞寛文, 寺町順平, 小田明日香, 天知良太, 日浅雅博, Baterdene Ariunzaya, 渡邉佳一郎, 中村信元, 三木浩和, 遠藤逸朗, 田中栄二, 松本俊夫, 安倍正博 : TAK1阻害はTRAILの抗骨髄腫作用を増強するともに骨吸収促進活性を抑制活性に変換する．, 第42回日本骨髄腫学会, 2017年5月.
190.	天知良太, 中村信元, 日浅雅博, 小田明日香, バットエルデネアリウンザヤ, 寺町順平, 天眞寛文, 渡邉佳一郎, 三木浩和, 賀川久美子, 藤井志朗, 田中栄二, 松本俊夫, 安倍正博 : 骨形成誘導による骨髄腫細胞のエネルギー代謝の抑制, 第42回日本骨髄腫学会学術集会, 2017年5月.
191.	住谷龍平, 中村信元 : 膵炎を契機に急性骨髄性白血病と診断した1例, 第115回内科学会四国地方会, 2016年12月.
192.	岡本恵暢, 中村信元, 上村宗範, 住谷龍平, 高橋真美子, 藤井志朗, 賀川久美子, 安倍正博, 三木浩和 : 発熱と下肢対麻痺で発症した血管内大細胞型B細胞性リンパ腫の2例, 四国医学雑誌, Vol.72, No.5-6, 236-237, 2016年12月. (キーワード) 下肢 / 発熱(病因) / 対麻痺(病因) / リンパ腫 / びまん性大細胞型B細胞性(合併症,薬物療法,病理学) / 血管腫瘍(合併症,薬物療法,病理学) / 血管内(合併症,薬物療法,病理学) / ヒト (Homo sapiens) / 中年(45∼64) / 高齢者(65∼79) / 女性 (female)
193.	曽我部公子, 中村信元 : IVLBCLに対する自家PBSCT後にITP，小脳に限局した進行性多巣性白質脳症(PML)を発症した1剖検例, 第115回日本内科学会四国地方会, 2016年11月.
194.	中村信元 : 化学療法中や造血幹細胞移植後に発症した偽痛風の3例, 第115回日本内科学会四国地方会, 2016年11月.
195.	天眞寛文, 寺町順平, 小田明日香, 天知良太, 日浅雅博, 渡邉佳一郎, 中村信元, 三木浩和, 遠藤逸朗, 田中栄二, 松本俊夫, 安倍正博 : 30. 天真寛文, 寺町順平, 小田明日香, 天知良太, , ,破骨細胞系細胞はアポトーシス誘引因子TRAILを生存促進・破骨細胞形成誘導因子として利用する:TAK1-Pim-2経路の役割, 第19回日本癌と骨病変研究会, 2016年11月.
196.	松井尚子, 山崎博輝, 中村信元, 和泉唯信, 中道一生, 西條政幸, 梶龍兒 : 非HIV関連進行性多巣性白質脳症の3例, 第21回日本神経感染症学会, 228, 2016年10月.
197.	寺町順平, 森裕史, 越智保夫, 天知良太, 小田明日香, 日浅雅博, 原田武志, 藤井志朗, 中村信元, 三木浩和, 賀川久美子, 遠藤逸朗, 田中栄二, 松本俊夫, 安倍正博 : Potent induction of bone formation by anti-resorptive cathepsin K inhibitor in myeloma., 第77回日本血液学会学術集会,, 2016年10月.
198.	天眞寛文, 寺町順平, 小田明日香, 天知良太, 日浅雅博, 渡邉佳一郎, 中村信元, 三木浩和, 遠藤逸朗, 田中栄二, 松本俊夫, 安倍正博 : TAK1 inhibition subverts TRAIL-mediated osteoclastogenesis., 第77回日本血液学会学術集会,, 2016年10月.
199.	天知良太, 日浅雅博, 寺町順平, 小田明日香, 天眞寛文, 渡邉佳一郎, 中村信元, 三木浩和, 賀川久美子, 藤井志朗, 遠藤逸郎, 田中栄二, 松本俊夫, 安倍正博 : Mechanism of the TRPV1 up-regulatation in myeloma cells and adaptation to an acidic microenvironment., 第77回日本血液学会学術集会,, 2016年10月.
200.	渡邉佳一郎, 寺町順平, 天知良太, 小田明日香, 天眞寛文, 岩浅正美, 日浅雅博, 中村信元, 遠藤逸郎, 川谷誠, 長田裕之, 田中栄二, 松本俊夫, 安倍正博 : Amelotin gene expression is temporarily being upregulated at the initiation of apoptosis induced by TGFb1 in mouse gingival epithelial cells, 第77回日本血液学会学術集会,, 2016年10月.
201.	中村信元 : Alteration of Pim-2 synthesis and degradation in myeloma cells by anti-myeloma agents., 日本血液学会総会, 2016年10月.
202.	(名) ariunzaya and Shingen Nakamura : Panobinostat and proteasome inhibitors cooperatvely degrade Sp1 to cause myeloma cell death, 日本血液学会総会, Oct. 2016.
203.	Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Kiyoe Kurahashi, Takeshi Kondo, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe : TAK-1 inhibition disrupts Pim-2-associated and Pim-2-independent key signaling pathways to effectively suppress tumor growth and restore bone formation in myeloma, 第78回日本血液学会学術集会, Oct. 2016.
204.	渡邉佳一郎, 寺町順平, 天知良太, 小田明日香, 天眞寛文, 日浅雅博, 中村信元, 三木浩和, 遠藤逸朗, 川谷誠, 長田裕之, 田中栄二, 松本俊夫, 安倍正博 : リベロマイシンAによる酸性環境での骨髄腫細胞の治療抵抗性の克服, 日本骨代謝学会学術集会プログラム抄録集 (1349-0761)34回 Page183(2016.07), 183, 2016年7月.
205.	天眞寛文, 寺町順平, 小田明日香, 天知良太, 日浅雅博, 渡邉佳一郎, 中村信元, 三木浩和, 遠藤逸朗, 田中栄二, 松本俊夫, 安倍正博 : 破骨細胞はTAK1の発現誘導を介しアポトーシスを抑制しTRAILにより成熟活性化される, 日本骨代謝学会学術集会プログラム抄録集 (1349-0761)34回 Page183(2016.07), 183, 2016年7月.
206.	寺町順平, 日浅雅博, 小田明日香, 天眞寛文, 天知良太, 原田武志, 渡邉佳一郎, 中村信元, 三木浩和, 遠藤逸朗, 羽地達次, 松本俊夫, 安倍正博 : 骨髄腫腫瘍進展と骨破壊病変形成におけるTAK1-Pim-2経路の役割, 日本骨代謝学会学術集会プログラム抄録集, 2016年7月.
207.	寺町順平, 日浅雅博, 小田明日香, 原田武志, 天眞寛文, 中村信元, 天知良太, 藤井志朗, 渡邉佳一郎, 賀川久美子, 三木浩和, 遠藤逸朗, 羽地達次, 松本俊夫, 安倍正博 : Pim-2は骨髄腫における破骨細胞形成促進の必須媒介因子である, 第41回日本骨髄腫学会学術集会, 2016年5月.
208.	天眞寛文, 寺町順平, 小田明日香, 天知良太, 日浅雅博, 渡邉佳一郎, 中村信元, 三木浩和, 遠藤逸朗, 田中栄二, 松本俊夫, 安倍正博 : TRAILは破骨細胞に細胞死を誘導せず，破骨細胞分化・生存を促進する., 第41回日本骨髄腫学会, 2016年5月.
209.	Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, A Oda, Hirofumi Tenshin, Keiichiro Watanabe, Shingen Nakamura, H Miki, Kumiko Kagawa, Shiroh Fujii, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe : Mechanism of the TRPV1 up-regulatation in myeloma cells and adaptation to an acidic microenvironment, 第77回日本血液学会学術集会, Oct. 2015.
210.	Keiichiro Watanabe, Jumpei Teramachi, H Mori, Y Ochi, Ryota Amachi, A Oda, Masahiro Hiasa, T Harada, Shiroh Fujii, Shingen Nakamura, H Miki, Kumiko Kagawa, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe : Potent induction of bone formation by anti-resorptive cathepsin K inhibitor in myeloma, 第77回日本血液学会学術集会, Oct. 2015.
211.	寺町順平, 日浅雅博, Asuka Oda, 天眞寛文, 天知良太, Takeshi Harada, 渡邉佳一郎, 藤井志朗, 賀川久美子, 中村信元, 三木浩和, 遠藤逸朗, 羽地達次, 松本俊夫, 安倍正博 : Potent suppression of osteoclastogenesis in myeloma by Pim inhibition, 第77回日本血液学会学術集会, 2015年10月.
212.	Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Keiichiro Watanabe, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe : Tumor reduction and bone restoration in myeloma by TAK-1 inhibition, 第77回日本血液学会学術集会, Oct. 2015.
213.	寺町順平, 日浅雅博, 小田明日香, 天眞寛文, 天知良太, 中村信元, 三木浩和, 遠藤逸朗, 羽地達次, 松本俊夫, 安倍正博 : Pim阻害による骨髄種骨病変の治療:破骨細胞形成の抑制, 日本骨代謝学会学術集会プログラム抄録集, 2015年7月.
214.	寺町順平, 日浅雅博, 小田明日香, 天眞寛文, 天知良太, 中村信元, 三木浩和, 遠藤逸朗, 羽地達次, 松本俊夫, 安倍正博 : 骨髄腫腫瘍進展と骨破壊病変形成における TAK-1の枢軸的役割, 日本骨代謝学会学術集会プログラム抄録集, 2015年7月.
215.	天眞寛文, 寺町順平, 小田明日香, 天知良太, 渡邉佳一郎, 中村信元, 三木浩和, 遠藤逸朗, 田中栄二, 松本俊夫, 安倍正博 : TRAILは破骨細胞分化・生存を促進する:TAK-1による生と死の運命制御, 第1回日本骨免疫学会, 137, 2015年7月.
216.	天知良太, 日浅雅博, 寺町順平, 小田明日香, 天眞寛文, 渡邉佳一郎, 中村信元, 賀川久美子, 三木浩和, 藤井志朗, 遠藤逸朗, 田中栄二, 松本俊夫, 安倍正博 : 酸環境での骨髄腫細胞のDR4発現抑制:酸によるエピジェネティックな遺伝子発現制御, 第1回日本骨免疫学会, 108, 2015年7月.
217.	天知良太, 日浅雅博, 寺町順平, 小田明日香, 渡邉佳一郎, 天眞寛文, 中村信元, 三木浩和, 遠藤逸朗, 近藤剛史, 田中栄二, 松本俊夫, 安倍正博 : 酸性環境での骨髄腫細胞のTRPV1の発現亢進と酸環境への適応, 日本骨代謝学会学術集会プログラム抄録集, 165, 2015年7月.
218.	天眞寛文, 寺町順平, 小田明日香, 天知良太, 日浅雅博, 渡邉佳一郎, 中村信元, 三木浩和, 遠藤逸朗, 田中栄二, 松本俊夫, 安倍正博 : アポトーシス誘導因子TRAILによる破骨細胞分化・生存の促進, 日本骨代謝学会学術集会プログラム抄録集, 164, 2015年7月.
219.	寺町順平, 日浅雅博, 小田明日香, 原田武志, 天知良太, 天眞寛文, 三木浩和, 中村信元, 藤井志朗, 賀川久美子, 遠藤逸朗, 松本俊夫, 安倍正博 : Pim阻害による骨髄腫骨吸収亢進の抑制, 第40回日本骨髄腫学会学術集会, 2015年5月.
220.	寺町順平, 日浅雅博, 小田明日香, 原田武志, 天知良太, 天眞寛文, 三木浩和, 中村信元, 藤井志朗, 賀川久美子, 遠藤逸朗, 松本俊夫, 安倍正博 : TAK-1は骨髄腫腫瘍進展と骨破壊病変形成の枢軸的な媒介因子である, 第40回日本骨髄腫学会学術集会, 2015年5月.
221.	中村信元, 三木浩和, 安倍正博 : Pim阻害薬と抗骨髄腫治療薬の併用効果の検討, 第40回日本骨髄腫学会, 2015年5月.
222.	中野万有里, 吉嶋輝実, 埴淵昌毅, 中村信元, 三木浩和, 賀川久美子, 西岡安彦 : Pneumocystis jiroveciに対しST合剤の脱感作療法を行った4症例の検討, 第89回日本感染症学会総会, 2015年4月.
223.	中村信元, 東桃代, 三木浩和, 賀川久美子, 安倍正博 : 当院で経験した重症熱性血小板減少症候群の3例, 第89回日本感染症学会, 2015年4月.
224.	丸橋朋子, 中村信元, 曽我部公子, 八木ひかる, 高橋真美子, 宇高憲吾, 藤井志朗, 三木浩和, 賀川久美子, 安倍正博, 西條敦郎, 中野万有里, 東桃代, 西岡安彦, 近藤憲保, 井内新, 藤田博己, 馬原文彦 : 当院で経験した重症熱性血小板減少症候群の3例, 第250回徳島医学会学術集会, 2015年2月.
225.	寺町順平, 日浅雅博, 原田武志, 天知良太, 賀川久美子, 三木浩和, 中村信元, 藤井志朗, 遠藤逸朗, 松本俊夫, 安倍正博 : Therapeutic impact of Pim inhibition on myeloma bone disease: blockade of NF-B-mediated suppression of osteoblastogenesis and stimulation of osteoclastogenesis, 日本血液学会, 2014年10月.
226.	天知良太, 日浅雅博, 渡邉佳一郎, 寺町順平, 小田明日香, 渡邉佳一郎, 中村信元, 遠藤逸朗, 田中栄二, 松本俊夫, 安倍正博 : 酸が惹起する骨髄腫細胞の酸感受と生存シグナルの悪循環, 日本骨代謝学会学術集会プログラム抄録集, 225, 2014年7月.
227.	寺町順平, 日浅雅博, 小田明日香, 天知良太, 中村信元, 遠藤逸朗, 松本俊夫, 安倍正博 : Pim-2キナーゼはTNF-αによる骨芽細胞分化抑制および破骨細胞形成促進の必須媒介因子である:Pim阻害薬の骨髄腫骨病変改善効果, 第32回日本骨代謝学会学術集会, 2014年7月.
228.	中村信元, 東桃代 : 多発性骨髄腫におけるガラクトマンナン抗原検査の有用性, 感染症学雑誌, 2014年.
229.	Keiichiro Watanabe, Masahiro Abe, H Mori, K Udaka, M Iwasa, D Hanson, Ryota Amachi, Masahiro Hiasa, T Harada, Shiroh Fujii, Shingen Nakamura, H Miki, Kumiko Kagawa, Itsuro Endo, Eiji Tanaka and Toshio Matsumoto : Bone restoration and tumor suppression in myeloma by cathepsin K inhibition with Bortezomib, 第75回日本血液学会学術集会, Oct. 2013.
230.	大黒由加里, 近藤剛史, 藤井志朗, 中村信元, 倉橋清衛, 黒田暁生, 遠藤逸朗, 粟飯原賢一, 松久宗英, 松本俊夫 : 著名な汎血球減少と肝筋逸脱酵素高値を呈した神経性食欲不振症の一例, 第13回日本内分泌学会四国支部学術集会, 2013年9月.
231.	三木浩和, 中村信元, 竹内恭子, 原田武志, 岩佐昌美, 藤井志朗, 賀川久美子, 安倍正博, 松本俊夫 : 赤芽球癆を合併した多中心性Castleman病の1例, 日本内科学会第107回四国地方会, 2012年12月.
232.	松浦元一, 山田諭, 柴田恵理子, 渡瀬謙仁, 岸史, 岸誠司, 美馬晶, 長井幸二郎, 安部秀斉, 中村信元, 安倍正博, 土井俊夫 : 腎生検にてγ重鎖沈着症が疑われた糸球体沈着症の一例, 第42回日本腎臓学会西部学術大会, 2012年10月.
233.	藤井志朗, 安倍正博, 天知良太, 渡邉佳一郎, 日浅雅博, 竹内恭子, 岩佐昌美, 原田武志, 中村信元, 三木浩和, 賀川久美子, 松本俊夫 : Pim inhibition preferentially induces anti-myeloma activity in an acidic milien, 第74回日本血液学会学術集会, 2012年10月.
234.	Masahiro Hiasa, Masahiro Abe, Kumiko Kagawa, Hirokazu Miki, Shingen Nakamura, Harada Takeshi, Fujii Shirou, Keiichiro Watanabe, Ryota Amachi, Kenzo Asaoka and Toshio Matsumoto : Pim-2 acts as a common downstream mediator to suppress bone formation in myeloma., 第74回に本血液学会, Oct. 2012.
235.	原田武志, 尾崎修治, 岩佐昌美, 藤井志朗, 中村信元, 三木浩和, 賀川久美子, 柴田泰伸, 重清俊雄, 岡田直人, 長尾多美子, 鈴木麗子, 先山正二, 安倍正博, 松本俊夫 : 徳島県のエイズ拠点病院におけるHIV感染症及び後天性免疫不全症候群の現状, 第245回徳島県医学会学術総会, 2012年7月.
236.	渡邉佳一郎, 安倍正博, 天知良太, 日浅雅博, 中村信元, 遠藤逸郎, 森裕史, 田中栄二, 松本俊夫 : カテプシンK 阻害剤KK1-300-01 は骨髄腫骨病変部の骨破壊を抑制し骨形成を惹起する, 第30回日本骨代謝学会学術大会, 217, 2012年7月.
237.	天知良太, 安倍正博, 渡邉佳一郎, 中村信元, 日浅雅博, 田中栄二, 松本俊夫 : 酸性環境は骨髄腫細胞にDR4 の発現抑制とcFLIP の活性化を惹起しTRAIL に対する抵抗性を獲得させる, 第30回日本骨代謝学会学術集会, 259, 2012年7月.
238.	大黒由加里, 中村信元, 岩佐昌美, 原田武志, 藤井志朗, 賀川久美子, 安倍正博, 松本俊夫, 三木浩和 : 腰痛と副腎不全症状で発症した両側副腎原発DLBCLの1例, 日本内科学会第106回四国地方会, 2012年6月.
239.	原田武志, 藤井志朗, 中村信元, 三木浩和, 中野綾子, 賀川久美子, 竹内恭子, 安倍正博, 松本俊夫 : 徳島県における多発性骨髄腫の治療成績の検討, 第109回日本内科学会総会・講演会, 2012年4月.
240.	原田武志, 尾崎修治, 小田明日香, 天羽宏枝, 藤井志朗, 中村信元, 三木浩和, 中野綾子, 賀川久美子, 竹内恭子, 安倍正博, 柴田泰伸, 松本俊夫 : Lenalidomide 治療中の多発性骨髄腫患者におけるCRP上昇の検討, 第51回日本血液学会中国四国地方会, 2012年3月.
241.	賀川久美子, 原田武志, 藤井志朗, 中村信元, 三木浩和, 竹内恭子, 安倍正博, 松本俊夫 : 遺伝子組み替えヒトトロンボモジュリン投与中に硬膜下血腫を来した同腫骨髄移植2症例, 第34回日本造血細胞移植学会, 2012年2月.
242.	賀川久美子, 原田武志, 藤井志朗, 中村信元, 三木浩和, 竹内恭子, 安倍正博, 松本俊夫 : 遺伝子組み換えヒトトロンボモジュリン投与中に硬膜下血腫を来した同腫骨髄移植2症例, 第34回日本造血細胞移植学会, 2012年2月.
243.	Keiichiro Watanabe, Masahiro Abe, Q Cui, Masahiro Hiasa, M Kawatani, T Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, A Nakano, K Kagawa, K Takeuchi, H Osada, Eiji Tanaka and Toshio Matsumoto : Targeting an acidic microenvironment by reveromycin A to overcome drug resistance to myeloma cells and ameliorate bone disease., 第36回日本骨髄腫研究会総会, Nov. 2011.
244.	日浅雅博, 安倍正博, 中野綾子, 竹内恭子, 賀川久美子, 中村信元, 三木浩和, 田中栄二, 淺岡憲三, 矢田健一郎, 松本俊夫 : Pimキナーゼ阻害による腫瘍進展と骨破壊の抑制, 第73回日本血液学会, 2011年10月.
245.	藤岡啓介, 西條敦郎, 豊田優子, 柿内聡司, 埴淵昌毅, 吾妻雅彦, 西岡安彦, 竹内恭子, 藤井志朗, 中村信元, 賀川久美子, 安倍正博, 水谷友哉 : 不明熱で発症し皮膚生検が診断に有効であった血管内リンパ腫の1例, 第243回徳島医学会学術集会, 2011年7月.
246.	日浅雅博, 安倍正博, 中野綾子, 渡邉佳一郎, 中村信元, 田中栄二, 淺岡憲三, 松本俊夫 : Pimキナーゼの阻害は骨芽細胞分化を促進し，骨髄腫骨病変の形成と腫瘍進展を抑制する, 日本骨代謝学会学術集会プログラム抄録集, 178, 2011年7月.
247.	渡邉佳一郎, 安倍正博, 川谷誠, 日浅雅博, 中村信元, 田中栄二, 長田裕之, 松本俊夫 : リベロマイシンAによる酸性環境がもたらす骨髄腫薬剤耐性の克服と骨病変形成の抑制, 日本骨代謝学会学術集会プログラム抄録集, 208, 2011年7月.
248.	日浅雅博, 安倍正博, 中野綾子, 渡邉佳一郎, 中村信元, 田中栄二, 淺岡憲三, 松本俊夫 : Pimキナーゼの阻害は骨芽細胞分化を促進し，骨髄腫骨病変の形成と腫瘍進展を抑制する, 日本骨代謝学会学術集会プログラム抄録集, 178, 2011年. (キーワード) 癌原遺伝子蛋白質(拮抗物質・阻害物質); 骨芽細胞; 骨疾患(病因,実験的); 骨髄腫(合併症,実験的); 細胞分化; Protein-Serine-Threonine Kinases(拮抗物質・阻害物質) / Mouse Pim2 Protein(拮抗物質・阻害物質) / マウス; 動物
249.	渡邉佳一郎, 安倍正博, 川谷誠, 日浅雅博, 中村信元, 田中栄二, 長田裕之, 松本俊夫 : リベロマイシンAによる酸性環境がもたらす骨髄腫薬剤耐性の克服と骨病変形成の抑制, 日本骨代謝学会学術集会プログラム抄録集, 208, 2011年. (キーワード) Pyrans; Spiro Compounds; 骨疾患; 骨髄腫; 抗腫瘍剤耐性 / Reveromycin A
250.	渡邉佳一郎, 安倍正博, Cui Qu, Kawatani Makoto, 日浅雅博, Nakano Ayako, Jinno Tadashi, Harada Takeshi, 藤井志朗, 中村信元, Miki Hirokazu, 賀川久美子, 竹内恭子, 尾崎修治, 田中栄二, Osada Hiroyuki, 松本俊夫 : Reveromycin A prevents bone destruction and suppresses tumor growth in myeloma, 第72回日本血液学会, 2010年12月.
251.	中村信元, 安倍正博, Cui Qu, 渡邉佳一郎, 池亀彰茂, 日浅雅博, 三木浩和, 中野綾子, 小田明日香, 天羽宏枝, 神野雅, 原田武志, 藤井志朗, 賀川久美子, 竹内恭子, 尾崎修治, 松本俊夫 : Bortezomib-induced osteoblast differentiation is hampered by excessive ER stress, 第72回日本血液学会, 2010年9月.
252.	日浅雅博, 安倍正博, 中野綾子, 小田明日香, 天羽宏枝, 竹内恭子, 賀川久美子, 中村信元, 三木浩和, 矢田健一郎, 渡邉佳一郎, 尾崎修治, 淺岡憲三, 田中栄二, 松本俊夫 : Bone marrow stromal cells supress TACE activity in monocytes to induce osteoclastogenesis, 第72回日本血液学会, 2010年9月.
253.	Cui Qu, Masahiro Abe, Miki Hirokazu, Shingen Nakamura, Keiichiro Watanabe, Akishige Ikegame, Masahiro Hiasa, Nakano Ayako, Jinnno Tadashi, Harada Takeshi, Shiroh Fujii, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki and Toshio Matsumoto : Bone marrow stromal cells attenuate gama delta T, 第72回日本血液学会, Sep. 2010.
254.	日浅雅博, 安倍正博, 中野綾子, 小田明日香, 天羽宏枝, 竹内恭子, 賀川久美子, 中村信元, 三木浩和, 矢田健一郎, 渡邉佳一郎, 尾崎修治, 淺岡憲三, 田中栄二, 松本俊夫 : 骨髄間質細胞は，単球のTACE活性を抑制し樹状細胞分化を抑制し破骨細胞文化を誘導する, 第28回日本骨代謝学会, 2010年7月.
255.	渡邉佳一郎, 安倍正博, Kawatani Makoto, 日浅雅博, 中村信元, 田中栄二, 長田裕之, 松本俊夫 : リベロマイシンAは骨髄腫骨破壊病変の形成と腫瘍進展を抑制する, 第28回日本骨代謝学会, 2010年7月.
256.	中村信元, 安倍正博, Cui Qu, 渡邉佳一郎, 池亀彰茂, 日浅雅博, 三木浩和, 中野綾子, 小田明日香, 天羽宏枝, 神野雅, 原田武志, 藤井志朗, 賀川久美子, 竹内恭子, 尾崎修治, 松本俊夫 : ボルテゾミブによる骨芽細胞分化の促進は過剰な小胞体ストレスによって抑制される, 第28回日本骨代謝学会, 2010年7月.
257.	賀川久美子, 矢田健一郎, 田中修, 中村信元, 三木浩和, 竹内恭子, 安倍正博, 尾崎修治, 吉田守美子, 遠藤逸朗 : 心筋への広範な直接浸潤を来したNK/T cell lymphoma 鼻型の一例, 第48回に本血液学会中国四国地方会, 2009年3月.

その他・研究会:

1.	西添ひかる, 藤井観月, 中村信元, 髙尾正一郎, 山下理子 : 血液疾患における筋肉量，脂肪量の検討, 徳島県臨床検査技師会誌, 24, 2022年12月.
2.	庄野隆志, 青山万理子, 南城和正, 山本清成, 牧秀則, 乾友浩, 坂本晋一, 小林智子, 中村信元, 滝沢宏光, 丹黒章 : アブスコパル効果を示した甲状腺原発形質細胞腫の1例, 第49回中国四国甲状腺外科研究会(ハイブリッド開催), 2021年2月.
3.	梶田敬介, 中村信元, 曽我部公子, 藤野ひかる, 丸橋朋子, 藤井志朗, 三木浩和, 賀川久美子, 鳥羽博明, 阿部正博 : 胸腺腫瘍に合併した赤芽球癆の二例-病態解明へのアプローチ-, 第252回徳島医学会学術集会, 2016年2月.
4.	Keiichiro Watanabe, Ryota Amachi, Masahiro Hiasa, Shingen Nakamura, Itsuro Endo, Hiroshi Mori, Eiji Tanaka and Toshio Matsumoto : The cathepsinK inhibitor ONO-KK1-300-01 (ONO-KK1) prevents bone destruction and restores bone formation in myeloma bone lesions, Bone Seminar, Aug. 2012.
5.	天知良太, 安倍正博, 渡邉佳一郎, 賀川久美子, 藤井志郎, 原田武志, 三木浩和, 中村信元, 小田明日香, 日浅雅博, 田中栄二, 松本俊夫 : 酸環境は骨髄腫細胞のTRAILに対する抵抗性を増強する, 第3回骨バイオサイエンス研究会, 2012年7月.
6.	日浅雅博, 安倍正博, 中野綾子, 渡邉佳一郎, 竹内恭子, 賀川久美子, 三木浩和, 中村信元, 藤井志朗, 原田武志, 尾崎修治, 田中栄二, 淺岡憲三, 松本俊夫 : Pimキナーゼの阻害による骨髄腫の進展抑制, 癌と骨病変研究会, 2011年11月.
7.	日浅雅博, 安倍正博, 中野綾子, 小田明日香, 天羽宏枝, 竹内恭子, 賀川久美子, 中村信元, 三木浩和, 矢田健一郎, 渡邉佳一郎, 尾崎修治, 淺岡憲三, 田中栄二, 松本俊夫 : 骨髄間質細胞は，単球のTACE活性を抑制し樹状細胞分化を抑制し破骨細胞文化を誘導する, 第17回徳島骨代謝研究会, 2010年11月.
8.	倉橋清衛, 中村信元, 吉田守美子, 遠藤逸朗, 粟飯原賢一, 藤中雄一, 松本俊夫, 八木秀介, 岩瀬俊, 赤池雅史, 佐田政隆 : 一酸化炭素中毒を契機に発見された急性心筋梗塞の一例, 第9回徳島総合診療研究会, 2009年7月.

科学研究費補助金 (KAKEN Grants Database @ NII.ac.jp)

ALアミロイドーシスにおける単球に着目した疾患関連遺伝子と新規治療標的の探索 (研究課題/領域番号: 24K11516 )
がん化学療法後の全身性免疫炎症病態へのFusobacteriumの役割の解明 (研究課題/領域番号: 19K08839 )
がん抑制性ニッチの実態とその誘導による新規治療法の開発 (研究課題/領域番号: 16K18420 )
がん酸性環境がもたらすがん細胞の薬剤耐性獲得機序の解明と新規治療薬の開発 (研究課題/領域番号: 26830108 )
骨形成誘導と骨破壊性腫瘍の進展抑制を併せ持つ新たな分子標的薬の開発 (研究課題/領域番号: 25463087 )
研究者番号（10511321）による検索

特任教授 : 中村信元

研究活動

個人のホームページ

専門分野

研究テーマ

著書・論文

著書:

学術論文(審査論文):

学術論文(紀要・その他):

学術レター:

総説・解説:

国際会議:

国内講演発表:

その他・研究会:

科学研究費補助金 (KAKEN Grants Database @ NII.ac.jp)

特任教授 : 中村 信元

研究活動

個人のホームページ

専門分野

研究テーマ

著書・論文

著書:

学術論文(審査論文):

学術論文(紀要・その他):

学術レター:

総説・解説:

国際会議:

国内講演発表:

その他・研究会:

科学研究費補助金 (KAKEN Grants Database @ NII.ac.jp)

特任教授 : 中村信元